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ABSTRACT 
Christina M. Marvin: Spatial and Temporal Delivery of Small Molecules from Long Wavelength 
Sensitive Phototherapeutics using Erythrocytes as Biological Carriers 
(Under the direction of David S. Lawrence) 
 
  
  The need for safe and potent therapeutics has prompted designs of site-targeting drugs 
and the development of delivery systems that spatially and temporally deposit active agents 
directly at disease sites. The work in this dissertation presents the design and implementation of 
a two-part drug delivery system in which light-activated B12 drug conjugates, loaded on 
erythrocyte drug carriers, photo-release bioactive moieties both in vitro and in vivo.  
Historically, light-activated “caged compounds” have been developed to trigger biological 
responses on command with light. Light provides exquisite control that allows for more precise 
study into the dynamics of biological systems, mainly in vitro. Unfortunately, most caged 
compounds have been limited to light below the optimal window of tissue penetration (long 
wavelengths, 600 - 1000 nm), severely limiting their utility in biological systems beyond imaging. 
Common drug carriers in clinical practice include liposomes and nanoparticles. However, both 
systems exhibit fast clearance from the body, prompting attention towards naturally derived drug 
carriers, such as human cells.  
This dissertation describes three generations of B12-loaded RBCs extended into the 
optimal window of tissue penetration and demonstrates the evolution of light-induced drug 
delivery from B12 scaffolds. Modification with fluorophore antennas alters the B12 
photochemistry so that single photon illumination results in bond scission reactions and release 
of modified cargo. Both the RBC membrane and internal cavity can be utilized for drug delivery 
purposes, both having advantages and disadvantages.
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 In this work, the development and characterization of long wavelength sensitive B12-
drug conjugates will be discussed. I will focus on the following three generations of RBC 
loading: external conjugation on human RBCs, internal encapsulation in human RBCs, and 
internal encapsulation in mouse RBCs. Furthermore, I will demonstrate application of a B12 
chemotherapeutic in in vivo models. Finally, I present a chapter which details my dissertation 
research to non-science audiences.
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This work is dedicated to my mother and my father, whose unending support and sacrifices 
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CHAPTER 1: COBLAMIN DRUG DELIVERY IN THE OPTICAL WINDOW OF TISSUE WITH 
ERYTHROCYTES AS BIOLOGICAL CARRIERS 
 
1.1. Overview  
 A concern of many current drugs is their tendency to cause serious, often life threatening 
side effects when administered systemically. This challenge in the pharmaceutical community 
has prompted interest in the design of drug delivery systems (DDS) that finely tune delivery and 
deposit active therapeutics at disease sites under spatial and temporal control.  
In this chapter, I will introduce the design of light-sensitive chemical scaffolds for drug 
delivery and the use of erythrocytes as drug carriers. Both are essential for development of a 
finely tuned drug delivery system. The chemical scaffold permits investigator-controlled delivery, 
while erythrocytes instill extended circulation lifetime and biocompatibility on the system. 
First, I will provide background on the current state of light activated release of biological 
entities and specifically discuss improvements in using light activation as a non-invasive 
stimulus. Next, I will discuss the development of cobalamin (Cbl)-based phototherapeutics, 
which provide a biocompatible, light-sensitive launching pad for a wide array of small molecules. 
Finally, I will transition into the mechanism behind erythrocytes as drug carriers, and highlight 
the advantages and limitations of erythrocytes as biological vesicles for drug delivery. 
Spatiotemporal drug delivery is essential for medication that mitigates side effects and 
enhances efficacy of an administered dose. A bulk of this dissertation focuses on the ability of 
Cbl to act as a light sensitive phototherapeutic. We believe Cbl is an ideal moderator for on-
demand drug release. Advantages such as non-invasiveness, safe administration to human 
tissue, tunable control in an orthogonal manner, and remote spatiotemporal precision, make 
light a particularly attractive approach to implement in the drug delivery field.1,2 
2 
  
1.2. The Dawn of Photoresponsive Biological Agents  
 The first light-responsive agents designed to control biological entities were synthesized 
in the late 1970s through modification of essential residues on biologically active substrates with 
photolabile protecting groups (PPGs).  Absorbed light energy photocleaves the PPG and 
produces an active agent. Pilot approaches with light-activated cyclic adenosine 
monophosphate (cAMP) and adenosine triphosphate (ATP) were undertaken one year apart by 
Engels et al.3 and Hoffman et al.4 in 1977 and 1978, respectively. Even though his work was 
published a year later, Hoffman’s group is often credited with designing the first light-activated 
biological construct with future biochemical implications. Hoffman is also famous for coining the 
word “caging” to describe biological moieties inactivated with PPGs. While this term is still used, 
it is acknowledged that it is often problematic due to its ambiguity in the biochemical field.5  
Hoffman’s group demonstrated successful blocking of ATP hydrolysis by modification of 
the γ-phosphate with an ultraviolet (UV) sensitive ortho-nitrobenzyl (ONB). Upon irradiation with 
340 nm light, the ONB group undergoes photolysis to produce bioactive ATP (Scheme 1.1). The 
group found that the uncaged entity was acted upon by the ATPase function of Na:K ion pumps, 
demonstrating its ability to function as a native biological substrate on demand. Further work 
with caged ATP revealed that individual transports across the Na pump could be observed in 
membrane vesicles.1 While light activated molecules for synthetic purposes were already widely 
in use,2 these initial ATP studies laid the foundation for a new field in biology where 
investigators yield the power to study dynamic biochemical systems with unprecedented spatial 













Scheme 1.1. The first photocleavable biological agents. (a) Hoffman synthesized what he 
termed “caged” ATP. An ONB caging group is appended to the γ phosphate, inactivating the 
substrate. Upon UV illumination, the caging group is photolyzed and liberates functional ATP by 
revealing a phosphate available for cleavage by ATPase. (b) Engle demonstrated a similar 




Since the pilot ATP experiments, various PPGs (the most common of which are ONB 
derivatives), have been used to synthesize a wide range of caged small molecules, peptides, 
proteins, and nucleic acids.3–7 These constructs continue to provide novel insights into the 
understanding of basic biological processes. A few examples are provided below to 
demonstrate the utility and diversity of the field.   
Caged neurotransmitters are used widely in neuroscience to study dynamic properties. 
The amino acid glutamate is the most widely implemented photoactivatable neurotransmitter 
due to its relevance in the study of neuronal signaling kinetics (Figure 1.1).12 Matsuzaki et al. 
used caged 4-methyoxy-7-nitroindolinyl-glutamate (MNI-glutamate) on CA1 pyramidal neurons 
to map functional glutamate receptors at single synapses in an effort to determine structure-
function relationships of dendritic spines. The results revealed that the distribution of functional 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors is dependent on spine 























Figure 1.1. Common glutamate caging constructs. MNI8,9, RuBi10,11, and CDNI9,12 act as the 
PPG, inactivating glutamate activity until photolyzed. Glutamate is one of the most frequently 
used caged neurotransmitters. By finely tuning the activation of this compound, intricate details 
of neuron signaling pathways can be disseminated. More recent constructs use two-photon 




 In 2004, Yaffe and coauthors18 demonstrated that caged peptides could probe biological 
questions that were unable to be answered with standard methodology at the time. The group 
prepared a caged peptide-based ligand for 14-3-3 protein in order to investigate the protein’s 
role in cell cycle control. Because the protein of interest is redundant with other protein family 
members, traditional genetic knock out approaches would be insufficient to demolish activity. 
Using solid-phase peptide synthesis (SPPS), a caged phosphoserine residue was introduced 
into the consensus sequence, effectively inactivating all phosphoserine/phosphothreonine-
binding domain family members (Figure 1.2). Light activation of the phosphoserine revealed a 
temporal role of 14-3-3 in the cell cycle, with activation resulting in G1 arrest and loss of S-




















Figure 1.2. Caged phosphopeptide that targets 14-3-3. Solid phase SPPS is now a common 
method to incorporate PPGs into peptides, allowing temporal protein activity to be studied. In 
this example, Fmoc-(2-nitrophenyl)ethyl-caged phosphoserine is incorporated into a 14-3-3-
binding peptide using SPPS. The core sequence RRLYRSLP is recognized by all 14-3-3 family 





Research continues to improve classical PPGs for enhanced temporal and spatial 
accuracy in cellular biology.9,13–15 However, there is still the question as to whether PPGs have 
utility in biomedical applications. Recently, a number of studies have designed PPG-modified 
nanocarriers.16 In one example, the anti-cancer agent 5-fluorouracil was attached to the outside 
of gold nanoparticles through a photocleavable nitrobenzyl linker. These “smart” carriers 
demonstrated light-controlled cytotoxic efficacy against a MCF-7 breast cancer cell line.17 As an 
alternative strategy, PPGs can be used as light sensitive “caps” on porous nanocarriers. Drugs 
are encapsulated on the inside of these carriers and cargo is released upon illumination and 
subsequent dissociation of the caps. Vivero-Escoto et al. demonstrated the utility of this system 
through attachment of 5 nm gold nanoparticle caps to mesoporous silica nanoparticles via a 
photocleavable linker and reported controlled release of paclitaxel inside of human fibroblast 
and liver cells.18  
1.3. Advancing Photoresponsive Agents into the Optical Window of Tissue 
While researchers have used traditional PPGs to enhance understanding of cell 
signaling and create finely tuned biochemical investigations, application of PPGs as drug 
release agents, even with nanocarriers, has been limited. The largest challenge associated with 
ONB and other traditional PPGs (Figure 1.3) is their activation with UV and short wavelength 
visible light. First, light within this range encompasses only a narrow portion of the potential 
visible and near infrared (NIR) spectrum, limiting the types and diversity of PPGs available. 
Secondly, UV light inflicts biochemical damage on cellular components in the body through the 
production of radicals, making its use for clinical application questionable.19 Finally, UV and 
short visible light have very short penetration depths through mammalian tissue. Cells and 
organisms such as zebrafish are transparent to short wavelength light and thus PPGs have 
found broad application with these systems.4 However, when applied to thick-skinned mammals, 
short wavelength light is strongly absorbed and scattered by melanin and hemoglobin,20,21 


























Figure 1.3. Common PPGs and their wavelength of maximum excitation. These caging groups 






              



































In order to overcome these challenges with short wavelength light, efforts are being 
made to take advantage of the “optical window of tissue penetration” between 600 - 1000 nm, 
where light can penetrate to clinically relevant depths and is free of UV cytotoxic effects. Most of 
the absorption below 600 nm in tissue is caused by hemoglobin and melanin. However, in the 
optical window of tissue penetration, the extinction coefficients (ε), or probability of photon 































Figure 1.4. Optical window of tissue penetration. (a) Most traditional PPGs respond to light 
between the UV and short visible wavelength region (< 600 nm). Unfortunately, light in this 
region is strongly absorbed by biological components such as melanin and hemoglobin, limiting 
their use in biological systems. This absorption is minimized in the “optical window” of tissue 
penetration between 600 - 1000 nm. (b) Light within the optical window can penetrate up to 5 
cm under the skin. Through design of photoresponsive conjugates in this window, light 
controlled biological applications in imaging and medicine can be achieved.  
Figure 1.4a Reprinted with permission from Quek, C.; Leong, K. Near-Infrared Fluorescent 






Several strategies have been investigated to extend PPGs into the optical window of 
tissue penetration and create clinically relevant phototherapeutic systems. Two photon 
activation is one widely used example. With this method, a caged molecule is illuminated with 
long wavelength light so intense (often up to 1000 W) that the molecule has the chance to 
absorb two photons nearly simultaneously, instead of one. Because there is a higher chance of 
two photon absorption where the laser is tightly focused, the high intensity light is extremely 
concentrated in a small three dimensional cross-section where two photon photolysis can 
occur.28 If two photons of a lower energy arrive at a PPG simultaneously, the combined effect is 
the absorption of one photon at a higher energy (Figure 1.5). For example, ONB that normally 
absorbs maximally at 350 nm could be uncaged with 700 nm during two photon activation. This 
strategy is useful for very targeted reactions and has been successfully implemented to uncage 
multiple neurotransmitters in brain slices and for imaging purposes.5,11 Unfortunately, both 
chemical and biological limitations to drug delivery application exist.29 First, not every PPG has 
a usable two photon cross section, prompting the need for new PPG designs. Secondly, the 
kinetics of this process are difficult to predict because of the non-linear relationship between 
illumination and photolysis and illumination may cause excessive heating of the system.4,7 
Finally, while there have been useful advances in two photon strategies for bioimaging30–32 and 
some therapeutic nanocarriers,33,34 the small cross-section inhibits acceptable efficiency and 












Figure 1.5. Two photon absorption. A PPG that normally undergoes photolysis at short 
wavelengths can be activated with long wavelength light when exposed to extremely 
concentrated light pulses. Low energy light is applied at a high enough intensity that the PPG 
absorbs two photons of light nearly simultaneously. Unfortunately, the chances of two photon 
















In terms of clinical application, it would be beneficial to overcome these limitations 
through the design of a therapeutic system that responds to one photon activation energy. Since 
the dawn of UV-responsive ONB groups, one photon responsive dyes have steadily been 
extended into the red region of the visible spectrum with coumarin (400 - 450 nm),23 bodipy 
(~500 nm),24,25 and cyanine (650 - 690 nm)26 derivatives. Other single photon NIR responsive 
(700 - 980 nm)27–29 systems have been recently realized in the form of upconverting 
nanoparticles (UNP). UNPs are nanoparticles doped with lanthanides, or similar transition metal 
groups that contain multiple f orbitals. When illuminated with NIR light, electrons fill multiple 
excited states in these orbitals before emitting at shorter, higher energy, wavelengths roughly 
equal to the sum of their absorptions. These emissions then activate nearby PPGs responsive 
to short wavelength light.30 While UNPs circumvent the illumination challenges of two photon 
absorption, and allow for effective in vivo studies with light in the optical window, the cost and 
















1.3.1. Current Application of Long Wavelength Light Therapy 
Despite the challenges associated with extending light sensitive molecules into the 
optical wavelength of tissue penetration, several industries utilize long wavelength light for 
therapeutic application. The most advanced clinical application to date is photodynamic therapy 
(PDT) (Figure 1.6). The first stage of PDT is the intravenous injection of a molecular 
photosensitizer (PS). PS conjugates, often based on porphyrin structures, are retained for 
prolonged periods of time in cancer cells compared with normal cells. After 2-3 days, enough 
time for the body to clear the PS from healthy cells, the second stage of PDT is initiated through 
treatment of the diseased area with the appropriate long wavelength light. Light dose is 
determined by laser power, treatment time, and treatment area or cable length (in the case of 
delivery via fiber optic cable). Conjugates retained in the tumor strongly absorb the administered 
light. Excited electrons produced from illumination interact with environmental oxygen to create 
















Figure 1.6. Photodynamic therapy for cancer treatment.  The concept of PDT is routed in the 
site directed accumulation and light induced cytotoxicity of a PS. The PS is injected 
systemically, but is retained longer in cancer cells. Upon long wavelength illumination, the PS 




As of 2015, the US Food and Drug Administration (FDA) has approved the PS porfimer 
sodium, or Photofrin ®, to treat esophageal, microinvasive endobronchial non-small cell lung 
cancer, and high grade dysplasia in Barrett’s esophageal cancer. Various other PS molecules 
are also approved for PDT clinical trials in various solid tumors including head and neck, skin, 
perianal, and metastatic breast cancer. While PDT represents a huge advancement for light 
induced therapy, there are several areas for improvement. Major limitations include the need for 
sufficient environmental oxygen at the tumor site and the sole creation of ROS, which is a 
nonspecific cytotoxic agent. The following sections will demonstrate how I aim to broaden the 
concept of long wavelength therapy to the release of a wide range of therapeutic agents, 
including anti-inflammatories and a variety of cytotoxic agents.    
1.4. A Brief History of Cobalamin  
The discovery of Cbl harkens back to the early twentieth century, when Dr. George 
Whipple discovered that raw liver alleviated the lethargic symptoms of anemic dogs.31 Minot and 
Murphy32 went on to cure 45 patients suffering from pernicious anemia through a diet of lightly 
cooked liver. Whipple, Minot, and Murphy shared the 1934 Noble Prize in Medicine for the 
treatment of what was until that time a fatal disease. In 1948, Karl Folkers and Alexander Todd 





1.5. Cobalamin’s Structure and Function 
Cobalamin, and a multitude of its natural and synthetic derivatives, is one of the most 
widely studied organometallic cofactors. Its native photochemistry, discussed further in Section 
1.7, imparts its ability to function as a novel phototherapeutic. Most vitamin B12 derivatives 
contain the same core structure of a cobalt (Co) corrinoid with pseudo-octahedral 
geometry.31,33,34 Corrinoids are structures based on the skeleton of corrin, a cyclic system 
containing four pyrrole rings similar, but not identical, to porphyrins (Scheme 1.2). A true 
porphyrin ring is composed of 20 aromatic carbons. In contrast, the metal center of Cbl is 
surrounded by a negatively charged, nineteen-membered, nonaromatic carbon ring with four 


























Scheme 1.2. Cbl Structure. Left: The full chemical structure of Cbl. Cbl is composed of a 
nineteen membered cobalt corrinoid ring with pseudo-octahedral geometry. The Co normally 
exists in the (+3) oxidation state, but can undergo reduction to (+2) or (+1). The R group at the 
β-axial position can be substituted with a number of various functional groups, including 
bioactive methylCbl (MeCbl) and adenosinylCbl (AdoCbl). Synthetic methods also allow 
alkylated fluorescent reporters and drug constructs to be appended to this position. The α-axial 
position contains a dimethyl benzimidazole (DMBI) ring, where the 5’-OH position is readily 
available for medication and can hold photostable functional groups. Right: An abbreviated Cbl 












The Co metal coordinated in the center normally exists in a stable (+3) oxidation state 
with a d6-low spin configuration. Both biological37 and chemical38 entities can reduce Co (+3) to 
either its (+2) or (+1) oxidation states. Of particular interest to our studies is the conversion from 
(+3) to (+2) which results in the loss of the upper β-axial ligand and the retention of the unpaired 
electron in the dz2 orbital as a radical. The bond at this position is relatively weak (< 44 
kcal/mol), making it particularly susceptible to photolysis when exposed to energy of light at 
which the Cbl can absorb. Photoirradiation results in homolytic scission that generates Co+2 and 
an alkyl radical (Scheme 1.3). This photo-labile bond will be the site of controlled release of 
















Scheme 1.3. Cbl Photolysis. The β-axial ligand undergoes homolytic cleavage when exposed to 




















The β-axial ligand is flexible and varies between cobalamin cofactors, differing in 
identity, bonding interactions, and strength.31,34 The two bioactive vitamin B12 molecules are 
MeCbl AdoCbl, which are found in the cytoplasm and mitochondria, respectively. CyanoCbl 
(CNCbl) in the United States and hydroxocobalmin (HO-Cbl) elsewhere are synthetic derivatives 
commonly used as supplements for vitamin B12 deficiency, due to their ability to be converted 




Cobalamin participates in carbon skeletal rearrangements, acting as a controlled source 
of carbon centered radicals.39 In the cytoplasm, MeCbl is associated with methyltransferase 
activity, undergoing heterolytic cleavage by methionine synthase in the methionine cycle. This 
process transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, which 
generates tetrahydrofolate and methionine. These products are used to make S-adenosyl 
methionine (SAMe), a universal methyl donor important for proper DNA methylation, 
phospholipid membrane formation, and other biological processes. In the mitochondria, AdoCbl 
is associated with isomerase activity, undergoing homolytic cleavage. It acts as a cofactor for 
methylmalonyl-CoA mutase, which converts methylmalonyl-CoA into succinyl Co-A. Succinyl 
Co-A is a necessary intermediate for porphyrin and heme production in mitochondria, which is 
eventually required for hemoglobin construction in red blood cells.  
Many other alkylCbls can be synthesized via standardized protocols such as -CH2CH3 
(ethyl), -(CH2)2CH3 (propyl), (CH2)17CH3 (stearyl), -(CH2)3NH2 (propylamine), and –(CH2)3CO2H 
(butyrate).40,41 More substituted alkyl groups (2° and 3°) are typically not applied to Cbl due to 
instability caused by steric interactions. To offset steric hindrance, highly substituted ligands will 
quickly undergo elimination reactions to yield alkenes and Cbl hydride species.42 For our work, 
this means that we use a non-substituted alkyl chain as a linker to highly substituted 
therapeutics.  
On the other side of Cbl, an α-axial bond coordinates a DMBI that is also attached to the 
corrin ring as a ribonucleotide via a phosphodiester bond. As this portion of the molecule is 
stable to light induced photolysis, it was theorized that non-photocleavable modifications could 
be made at this site. These modifications will be important for anchoring (Chapter 2) and 




1.6. Cobalamin Photochemistry 
Careful examination of the Cbl absorbance spectrum reveals multiple bands that vary 
based on the β-axial ligand (Figure 1.7). This discussion will mainly focus on alkyl-Cbl, as they 
will be the focus of phototherapeutic design. The most intense band, the γ band, is found in the 
UV region (300 - 400 nm) with ε ranging from 10,000 - 30,000 M-1cm-1. With alkyl ligands at the 
β-axial position, this band arises from the multiple π  π* corrin transitions.36,43,44 The strong 
electron donating alkyl groups split the band into an “atypical” spectrum with two maxima 
between 300 and 400 nm. In comparison, β axial ligands that are strong electron withdrawing 
groups, such as –OH and –CN produce a “typical” spectrum with a single strong peak at 350 
nm. The α/β absorption bands between 450 and 600 nm produce a smaller ε with values less 
than 10,000 M-1cm-1.31 When the β-axial ligand dissociates to form Co+2, the α/β band will shift to 
~480 - 490 nm. Although there is some evidence to suggest otherwise, it is most widely 
accepted that the electron transition occurring at these wavelengths arises from a d/ π  π* 
metal-to-ligand charge transfer (MLCT) state.45,46 Additional low intensity (ε < 100 M-1cm-1) d-d 












Figure 1.7. Absorption spectrum of ethylCbl. The γ band is most likely the result of π  
π* transitions in the corrin ring while the α/β band arises from MLCT. Low intensity d-d 


















1.7. Extending Cobalamin into the Optical Window of Tissue Penetration  
In the following chapters, I will demonstrate the utility of Cbl photochemistry in light-
controlled drug release and highlight its advantages over PPGs. Our group previously reported 
that the β-axial ligand could indeed be substituted with an alkyl-modified fluorescent reporter, 5-
carboxytetramethylrhodamine (TAMRA), which is quenched when attached to Cbl. It was 
demonstrated that TAMRA could be released with 560 nm light and quantified via fluorescent 
readout as a result of TAMRA un-quenching upon photolysis from Cbl (Figure 1.8). While 
alkylCbl derivatives naturally absorb light as long as 560 nm, already extending the system past 











Figure 1.8.47 Light activated release of a fluorescent reporter. (a) Structure of Cbl-TAMRA. We 
demonstrated that Cbl’s β-axial ligand could be substituted with an alkylated TAMRA molecule 
and could be released on command with 560 nm light. (b) Kinetics of TAMRA photolysis as 
observed by fluorescent unquenching.  
Reprinted with permission from Priestman, M. A.; Shell, T; Sun, L.; Lee, H.M.; Lawrence, D. S. 
Merging of Confocal and Caging Technologies: Selective Three-Color Communication with 
Profluorescent Reporters. Angew. Chemie - Int. Ed. 2012, 7804 - 7807. © 2014 WILEY-VCH 
















A key observation was made that suggested a relationship between the TAMRA 
fluorophore and photolysis, which would eventually allow for the extension of the wavelength 
response. Compounds with TAMRA at the β-axial position underwent photolysis at a faster rate 
than unsubstituted conjugates when illuminated with 560 nm. It occurred to our group that the 
weak state of the Co-C bond represented an opportunity to extend photolysis into longer 
wavelengths by using long wavelength fluorophores as light-capturing “antennas”. The 
antennas, fluorophores that absorb light at wavelengths greater than 560 nm, should be able to 








Modification of the β-axial ligand is easily carried out by using zinc to reduce Co (+3) into 
a nucleophilic Co (+1) species that reacts with alkyl halides. The antenna hypothesis was 
confirmed with the synthesis and photolysis studies of four unique Cbl-fluorophore conjugates: 
Cbl-TAMRA (λex = 546 nm), Cbl-SulfoCy5 (λex = 650 nm), Cbl-Alexa 700 (λex = 696 nm), and Cbl-
DyLight800 (λex = 775 nm). (Figure 1.9). This study demonstrated that fluorophores can act as 
long wavelength antennas by inducing photolysis at their respective excitation wavelengths, 
even those beyond the Cbl excitation spectrum. Even more importantly, exposure of conjugates 
to wavelengths outside of the appended fluorophore’s absorption had no photolysis effect. While 
this study focused on fluorescent reporters, this observation paved the way for orthogonal 
release of drugs, in which one can image delivering certain drugs in a sequential order under 
exquisite spatiotemporal and orthogonal control. The potential of orthogonal release with Cbl will 

































Figure 1.9.48 Demonstration of orthogonal release using long wavelength antennas. (a) 
Structures of Cbl-based, long wavelength sensitive release agents. Various long wavelength 
functionalized Cbl constructs demonstrated photolysis upon illumination with the attached 
fluorophore’s maximum excitation wavelength. Note that the structures of Alexa700 and 
Dylight800 have not been reported. (b) Illumination at 546 nm, near the excitation maximum of 
the corrin ring, photolyzed all conjugates prepared. The longer wavelengths of light were only 
able to photolyze conjugates with their respective fluorophore antenna, suggesting the potential 
for orthogonal control. 
Reprinted with permission from Shell, T.; Shell, J.; Rodgers Z.; Lawrence, D. Tunable Visible 
and Near-IR Photoactivation of Light-Responsive Compounds by Using Fluorophores as Light-
Capturing Antennas. Angew Chem - Int Ed Engl. 2014, 875 - 878. © 2014 WILEY-VCH Verlag 




My lab also investigated a second area on Cbl for functionalization: photostable 5’-OH of 
the ribose. At the ribose, activation by carbonyl ditriazole permits linkage of amines to form a 
carbamate bond. Anything attached via the 5’-OH is stable under light absorbed by Cbl, or an 
additional antenna, and remains attached, even under wavelengths of maximum absorbance of 
the structure.  In a similar manner to the first long wavelength antennas, it was shown that 
fluorophores appended to the 5’-OH position had the ability to photocleave an adenosyl group 
















Figure 1.10. Adenosyl Cbl derivatives. Fluorophores appended to the 5’-OH position 
demonstrate the utility of the “antenna” principle whereby attached fluorophores promote 
photocleavage of the Co-C bond at the fluorophore’s excitation wavelength. Ado release was 
monitored via LC-MS.   
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With the ability to functionalize a biologically relevant light-stimulated release system, the 
tools necessary to design a finely tuned drug delivery system were available. In the next 
chapters, two approaches will be discussed: photolysis via an adjacent fluorophore (Chapter 2) 
and photolysis via a fluorophore attached at the 5’-OH position on Cbl (Chapter 3). Before 
describing these systems in details, we must transition to a discussion of drug carriers. We 
believed we could increase circulation time and efficacy of our Cbl phototherapeutics with the 
right carrier. While there are a number of widely implemented synthetic carriers in investigation, 
including liposomes, hydrogels, and nanocarriers, we chose to focus on a natural carrier with a 
number of unique advantages in vivo. 
1.8. Erythrocytes: Natural Carriers with a Long History 
 Erythrocytes, also called red blood cells (RBCs), were first observed by early microscopy 
leaders in the 17th century. Both Marcello Malpighi and Jan Swammerdam are credited with 
making preliminary observations on the “red particles” in blood, while Antoni van Leeuwenhoek 
is known for recording the first detailed notes and illustrations of the cells.49,50 Since then, 
erythrocytes have been widely studied, from their role in hematological malignancies to 
biomedical applications stemming from their unique structure and function. As oxygen 
transporters in circulation, erythrocytes serve the immensely important role of delivering oxygen 
to tissue and shuttling carbon dioxide to the lungs for removal. Oxygen transport is mediated by 
hemoglobin, a protein composed of 4 globulin subunits. Each subunit contains a porphyrin 
molecule (heme) and iron that binds oxygen, allowing each hemoglobin molecule to carry a 
maximum of 4 oxygen molecules. In addition, erythrocytes possess a number of interesting 




Erythrocytes have many advantages as natural, versatile drug carriers that can be 
loaded via either membrane binding or internal encapsulation. In their native state, human 
erythrocytes are biconcave discs, 7 to 8 µm in diameter, with an average volume of 90 fL, and 
an average surface area of 140 µm2.51  They are biocompatible, biodegradable, easy to handle, 
and non-immunogenic. If drugs are loaded in the interior, the cells can protect the organism 
from toxic effects of the drug and the drug from clearance mechanisms in the body. In 
comparison to synthetic carriers, erythrocytes survive longer in the blood (days or months vs 
minutes or hours) and have a larger payload capacity (μm vs nm) than synthetic carriers. 
Compared to other cellular carriers they possess the largest surface-to-volume ratio of any cell 
(1.9 x 104 cm/g), abundance (4-6 million cells/μL of whole blood and almost 30 trillion 
cells/human body), and affordability. While these properties provide great potential for 
erythrocyte drug carriers over other systems (liposomes, nanoparticles, stem cells etc.), 
limitations to their use include reticuloendothelial system (RES) removal, reduced 
biocompatibility as a result of ex vivo modification, variations in loading and physiological 
characteristics, difficulty in the identification of appropriate storage conditions, possible 
exposure to contamination due to the origin of blood, and lack of a universal validated industrial 
procedure for preparation.52,53 Many of these challenges can be addressed by fully optimizing a 










Erythrocytes express a functionally rich surface containing multiple sites for covalent and 
non-covalent attachment of chemical entities. These potential handles resulted in intense 
interest in the design of “hitchhiker” chemical entities in circulation.  The erythrocyte membrane 
is composed of a lipid bilayer and membrane cytoskeleton, together containing over 300 unique 
proteins.54 The lipid bilayer, composed of phospholipids, cholesterol, and integral 
transmembrane proteins, contains excess surface area that allows the cell to deform. The 
integral transmembrane proteins in this layer anchor it to the cytoskeleton via horizontal ankyrin 
and junctional protein complexes. The spectrin-based cytoskeleton, held together by horizontal 
interactions with spectrin tetramers and the protein 4.1R, provides strength and flexibility, 
allowing the erythrocyte to maintain its biconcave shape and overcome the stress of 





























Figure 1.11. Erythrocyte membrane structure. The lipid bilayer is physically connected to the 
cytoskeleton via integral membrane proteins and horizontal spectrin interactions. The 
cytoskeleton is an important feature that imparts strength and flexibility to the membrane, 













Over the course of an erythrocyte’s 120-day lifespan, cells undergo chemical alterations 
that eventually signal them for clearance by the spleen. Autologous immunoglobulin binding, 
complement deposition, and macrophage recognition are all signals of old cells. Metabolic 
pathway inactivation, changes in size and shape, and reduction of membrane surface area due 
to spleen-induced vesiculation57 cause the cell membrane to lose its integrity and flexibility, 
which acts as a signal it for clearance by the spleen. Alternatively, aging erythrocytes simply 
undergo surface alterations, most commonly band 3 clustering and externalization of membrane 
phosphatidyl serine on the outer leaflet of the lipid bilayer. In this case, system wide 
macrophages recognize the changes and clear the erythrocytes, predominantly through either 
the spleen or the liver. It is important to understand the signs of erythrocyte senescence when 
developing drug loading methods as ex vivo modification can lead to features that mimic 
erythrocyte senescence states, resulting in quick removal from circulation and loss of the 
erythrocytes’ advantageous circulation lifetime.  
Compared to the membrane, the erythrocyte interior is less complex, a feature that 
makes it ideal for internal encapsulation of biological and therapeutic material. Unlike other 
mammalian cells, erythrocytes lose their nucleus and other intracellular organelles early during 
the differentiation process. In lieu of organelles, the volume of mature erythrocytes is composed 
of water and the oxygen-carrying heme protein, hemoglobin, which constitutes 90% of the 
erythrocyte’s dry weight.56 The erythrocyte’s unique internal makeup is key to its role in 
transporting oxygen and carbon dioxide. Early on, scientists realized that they could take 
advantage of the erythrocyte’s relatively large and simple interior to repurpose erythrocytes as 




Since internal loading will play a large role in Chapters 3-4, the history of this method will 
be briefly discussed. The first chemical entities to be successfully loaded into erythrocyte 
interiors were ATP by Gardos in 195358 and 10-250 kDa dextrans by Marsden and Ostling in 
1959.59 The first reports which describe therapeutic loading of erythrocytes were independently 
published by Ihler et al.60 and Zimmerman61 fourteen years later in the 1970s. Several key 
features of erythrocyte physiology caught the attention of these early scientists. The first aspect 
was the erythrocyte’s flexibility, a property of its unique spectrin-based membrane skeleton that 
allows it to swell to a sphere of 150 µL without breaking or to shrink below its starting volume in 
order to squeeze through 3-4 µm capillary beds. Deformability is key to using osmotic methods 
to load materials into the erythrocyte interior (Section 1.13). As mentioned above, human 
erythrocytes circulate for an average of 120 days, traveling about 250 km through the entire 
bloodstream. This survival time far surpasses that of most synthetic carriers, making 
erythrocytes an attractive carrier for drugs requiring slow release over an extended period of 
time. Chapters 3-4 of will focus on using osmotic methods of loading phototherapeutics into 
erythrocytes, creating light-sensitive vesicles capable of spatial and temporal drug release. 
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1.9. Important Variations among Species 
This section will highlight the importance of accounting for species-specific variations in 
cellular physiology, morphology and membrane deformability of modified cells. Loading was 
initially performed on human erythrocytes in Chapters 2 and 3 since human cells are the most 
relevant to future clinical trials. Chapter 4 highlights the adaption of the loading procedure to 
rodent cells in order to conduct pre-clinical investigations. Before discussing each loading 
strategy in detail, I wish to highlight the challenges and considerations needed when working 
between erythrocytes of multiple species.   
We chose human erythrocytes for in vitro proof of concept studies with various Cbl-
based phototherapeutics, as they are the most relevant for human clinical application. To extend 
our work to pre-clinical models, we adapted our erythrocyte loading system on the basis of the 
biological characteristics of the erythrocytes of small mammals. The most common pre-clinical 
models are the common laboratory mouse (Mus musculus) and the Wistar rat (Rattus 
norvegicus). Table 1.1 compares and contrasts some of the main features in morphology, 














Table 1.1. Comparison and contrast of erythrocytes from humans, mice, and rats.63–66 
 Human Mouse Rat 
Diameter (µm) 7-8 6 6.5 
Surface Area (µm2) 140 91 100 
Mean Corpuscular Volume (fL) 90 52 58 





At first, rat erythrocytes appeared to be the superior model for in vivo preclinical studies, 
as they are slightly larger than mouse erythrocytes and have a longer circulation time. 
Additionally, tail vein injections are easier to perform on rats than mice and are typically more 
accurate than with mice species. However, a fundamental aspect of rat erythrocytes was found 
to greatly limit their use as a model for erythrocyte drug carriers. In order to internally load 
erythrocytes, it is necessary to remove hemoglobin to make room for the new payload. 
Released hemoglobin accumulates in the extracellular environment until it is washed away post-
loading. While I attempted to develop an internal loading procedure for rat erythrocytes, I found 
cell recovery, cell stability, and loading efficiency to be very poor. Crystals were clearly visible 
under widefield microscopy after the internal loading procedure (Figure 1.12). Unlike other 
species, abundant rat hemoglobin displays a remarkably low solubility and readily precipitates 
into an insoluble, irreversible form. Some studies suggest that micro-crystals may even exist in 
the erythrocytes in vivo.67,68 It is suspected that creation of large crystals in solution caused a 
catalytic effect with hemoglobin release and crystal formation. Given this unique feature of rat 









Figure 1.12. Hemoglobin crystals produced by rat erythrocytes. Hemoglobin crystals produced 

































While mouse erythrocytes do not have crystallizing hemoglobin, it is known that they are 
grossly less stable ex vivo than human erythrocytes. We confirmed that mouse erythrocytes 
survive for a shorter amount of time in storage69 and lyse more readily during ex vivo 
manipulation70 when compared to human erythrocytes. In a detailed paper, Muzykantov et al. 
demonstrated that human erythrocytes showed greater resistance to every environmental 
challenge tested, (osmotic, mechanical, and oxidative stress) as well as higher resistance to 
biological injury, than their mouse conterparts.70 Given these challenges, it is important to 
ensure that mouse erythrocytes are used within 24 h of blood draw and that stress of the 
loading procedure is minimized. By reducing handling stress, a maximum cell recovery can be 
achieved and the recovered cells can better maintain their native characteristics. Still, caution 
should also be taken when correlating potential human utility with mouse models – results 
obtained with mouse models often overestimate erythrocyte fragility that is ultimately mitigated 
in sturdier human cells.  
1.10. The Loading Process: External Conjugation vs Internal Encapsulation 
Because of their unique structure, erythrocytes can be loaded by either attaching a 
payload to the membrane through covalent or non-covalent bonds, or by entrapping payloads 
inside erythrocytes through reversible, pore-forming methods. For the sake of clarity, future 
reference in this chapter to external and internal loading will be referred to as “coupling” and 




External coupling is less damaging to the structural integrity of the erythrocytes since 
their membrane remains intact during the procedure. Because of this feature, native erythrocyte 
morphology and circulation times are typically better preserved than with internal encapsulation. 
However, challenges also exist when instilling drugs and materials on the cell’s exterior. Strong 
covalent bonds can weaken membrane integrity while weak non-covalent interactions can lead 
to “membrane hopping” where the attached material hops to adjacent mammalian membranes. 
Other environmental factors such as extracellular proteins, shear stress in circulation, and 
interactions with the vascular wall may also pull off loaded material.71 Finally, natural reduction 
of the membrane through interactions with the spleen may lead to premature shedding of the 
embedded material, and thus become a risk factor in off target effects.  
On the other hand, cargo encapsulated in the erythrocyte interior has a greater chance of 
surviving circulation since the cell acts as a shield between the cargo and the surrounding 
environment. Among other advantages, the two most favorable aspects of “carrier erythrocytes” 
are protection from immunogenic clearance and a large payload capacity.  Natural human 
erythrocytes circulate for up to 120 days,72 protected from immune responses by natural 
markers including CD47, proteins, sialic acid, and glycan.73–75 By sequestering biological or 
chemical moieties on the inside of this shield, carrier erythrocytes have the potential to extend 
an agent’s circulation lifetime and protect surrounding tissue from unintended side effects. The 
high payload is due to the large available interior space (90 fL in human erythrocytes) compared 
with synthetic vesicles such as nanoparticles. Erythrocytes lack a nucleus and other organelles, 
providing opportunities to take full advantage of the interior for drug encapsulation without 
disrupting viability. The greatest challenge of encapsulating drugs into erythrocytes, especially 
true for the more fragile murine cells, is in preserving native physiology and structural integrity 





1.10.1. External Loading: Coupling to Erythrocyte Membranes  
Many chemical agents have been coupled to erythrocyte membranes including proteins, 
antibodies, peptides, and nanoparticles76,77 by either covalent or non-covalent bonds (Figure 
1.13). This coupling can occur either in vivo, or more commonly, ex vivo. Non-covalent coupling 































Figure 1.13. Coupling material to the erythrocyte membrane. Drugs and other chemical 
moieties are coupled to erythrocyte membranes by either non-covalent or covalent coupling 


















Non-covalent coupling on the erythrocyte membrane is described as “hitchhiking” 
because by attaching themselves to cellular carriers, moieties that are normally cleared rapidly 
can maintain circulation for longer time spans. Nonspecific physical interactions are largely 
responsible for the “hitchhiking” effect. Specifically, the two main approaches are electrostatic 
interactions and passive diffusion.  
Positively charged materials in particular can be easily coupled to the membrane through 
electrostatic interactions since the high concentration of sialic acid residues results in an overall 
negatively charged membrane. However, this approach is not often employed as strong 
electrostatic interactions at the membrane have been shown to create erythrocyte aggregates, 
possibly due to collapse of the fluidic lipid bilayer and blockage of the local arrangement 
necessary for lipid coverage.78,79  
On the other hand, passive adsorption coupling, a less detrimental non-covalent strategy 
achieved through hydrogen bonding, van der Waals interactions, and hydrophobic forces, 
removes the need for positively charged particles.80 Circulating pathogens inspired initial studies 
on this coupling approach when scientists observed the bacteria Mycoplasma hemofelis 
adheres to mammalian (mainly feline) erythrocyte membranes and circulates for multiple 
weeks.81 A host of drugs have been non-covalently coupled to erythrocyte membranes, the 
most widely used of which have been agents to increase efficiency of clot dissolutions.82–85 In 
recent years, non-covalent attachment of nanoparticles to erythrocyte membranes has been 
used in an effort to increase the circulation lifetime of the particles. This strategy highlights the 








Nanoparticles have a multitude of advantageous features that make them a promising 
drug carrier including the ability to encapsulate and protect the drug, improve targeting with 
tissue-specific targeting ligands, tighten control on drug release by composition alterations (i.e. 
biodegradable poly(lactic-co-glycolic acid) (PLGA)), and be reproducibly mass produced.80 
However, freely injected nanoparticles typically survive for only a few minutes in circulation86–88 
and this rapid clearance by the RES limits clinical application. By non-covalently attaching 
polymeric nanoparticles to long circulating erythrocytes, the particle lifetime in circulation could 
be extended into multiple days. It has been described that at a particle/RBC ratio of 100:1, 
mouse erythrocytes can carry approximately 24 particles (200 nm) per cell with a nanoparticle 
circulation time of 24 h, although cells with higher payloads were cleared from circulation within 
the first 30 min.70,89  
Another advantage of hitchhiking nanoparticles is the ability to increase particle size and 
thus increase payload. Relatively small (< 150 nm) particles are typically used for extending 
drug delivery because larger ones are readily cleared by the liver and spleen. Chambers et al. 
demonstrated that by non-covalently binding nanoparticles to erythrocytes, polymeric particles 
as large as 450 nm can circulate for up to 12 h, compared to the 2 min circulation of their free 
counterparts.90 Unfortunately, particle detachment appeared to occur at a faster rate than 
erythrocyte clearance in multiple polymeric nanoparticle-erythrocyte coupling studies and those 
groups demonstrated that physical shear stress in circulation and cell-cell interactions with the 
vessel endothelium in small capillaries were strong enough to detach particles.71,89,90 While 
particle detachment is a concern for future work with our phototherapeutic system in vivo, the 
work in Chapter 2 will present a proof of concept study and build a foundation for future work 





As an alternative approach, we note the work conducted to improve stability of moiety 
attachment to the erythrocyte membrane with stronger covalent modifications. The erythrocyte 
membrane is rich in proteins and carbohydrates that provide ample sites  for covalent 
modification.80 The most successful covalent modification to erythrocyte membranes has been 
pioneered by Muzykantov and his collaborators and involves connections with avidin-biotin 
interactions.91–94 However, their studies also revealed an important limitation of this strategy. 
Namely, that polyvalent streptavidin binding induces erythrocyte lysis due to activation of the 
alternative complement pathway. 
Specifically, binding inactivates the membrane regulators of complement, decay-
accelerating factor (DAF) and CD59, which are cross-linked by streptavidin when it attaches to 
biotin.95 While successful binding yielded attachment efficiencies as high as 105 molecules per 
RBC, it should be noted that the concentration of biotin attachment to erythrocytes needs to be 
controlled so that the input of the biotinylating agent is ≤ 100 μM, which has been shown to keep 
the biotin per cell under the threshold for complement activation.83,96 Muzykantov’s optimized 
loading procedure yields a cell recovery of > 90% with approximately 1000 biotin molecules per 
mouse erythrocyte and unaffected in vivo circulation survival for 24 h.96 More recently, modified 
nanoparticles have been conjugated onto erythrocytes via biotin-avidin bridges in efforts to 
increase particle lifetime in circulation and avoid detachment due to shear stress observed with 




1.10.2. Internal Encapsulation: Encapsulating in Erythrocyte Interior  
The second erythrocyte loading strategy is to sequester chemical and biological moieties 
into the cell interior. As noted in Section 1.10, the greatest advantages of this approach are 
mitigation of immunogenic clearance and enhanced payload capacity. The most common 
strategies to encapsulate material into erythrocytes are osmosis, electroporation,99 conjugation 
to cell penetrating peptides,100 and endocytosis-based101 methods. Of these strategies, osmosis 
is the most widely utilized approach due in large part to its ability to be industrially scaled-up.102 
Internal encapsulation via osmosis is based on the ability of erythrocytes to reversibly 
swell in hypotonic conditions, opening pores that allow exchange of material. There is some 
disagreement in the literature as to the exact characteristics of the pores that form during 
osmosis. Many current papers,60 reviews,103,104 and book chapters105 cite studies conducted by 
Seeman et al. in 1973 in which thin section electron micrographs demonstrate the formation of 
multiple pores between 200 – 500 Å in diameter within 10 s of exposure to hypotonic buffer.106 
However, follow-up studies conducted by Lieber et al. nearly 10 years later found contradicting 
results when they used light microscopy to observe the formation of a single pore per 
erythrocyte, each with an initial 7 – 140 Å radius, although it was expandable to over 10,000 
Å.107,108 While the exact nature of the pore is still under debate, it is clear that under hypotonic 
conditions, the membrane barrier becomes an entry point for the exchange of a wide range of 
material including small molecule drugs, large enzymes, and contrasting agents. Osmosis 
encapsulation can be subdivided into three major strategies: hypotonic dilution, hypotonic 
preswelling, and hypotonic dialysis. I will focus on hypotonic dilution (Chapter 3) and hypotonic 
dialysis (Chapter 4). While the procedures vary, the chemical and physical processes for 





First, erythrocytes are isolated from whole blood through centrifugation techniques in 
which the erythrocytes fall to the bottom as a compact pellet while the other blood components 
(serum, monocytes, etc.) remain suspended. The isolated erythrocytes are then exposed to a 
hypotonic buffer (< 300 mOsm/L) and water rushes inside the cells in an effort to maintain 
osmotic equilibrium. Because membrane surface area is fixed and designed to deform, the cells 
swell into spheres upon water influx and form reversible pores (discussed above). During the 
time in which the pores are open, intracellular and extracellular material can be exchanged. 
Most notably, hemoglobin exits while drugs, enzymes, and other material enters. During 
swelling, the erythrocyte volume can increase up to 50 – 75 % of its initial point.109 The 
membranes are resealed with the encapsulated material inside by raising the salt concentration 
























Figure 1.14. Encapsulating material into erythrocytes through osmotic loading. Erythrocytes are 
swollen in hypotonic buffer in which they swell up to a point just before lysis. When swollen, 
reversible pores form that allow for exchange of material. The erythrocytes are resealed, and 
the drug or other material is encapsulated, by returning the cells to an isotonic solution through 





RES targeting was a natural first step towards targeted application of carrier erythrocytes 
since the RES is the main site for the destruction of aging and abnormal erythrocytes. Carrier 
erythrocytes are loaded with an appropriate drug and modified with either clustering agents (i.e. 
ZnCl2) or crosslinking agents (i.e. Bissulfosuccinimidyl suberate [BS3]), glutaraldehyde) so they 
will be quickly recognized by phagocytic macrophages and targeted to RES organs (the spleen 
and liver). Most work in this field has implemented the hypotonic dilution and dialysis strategies 
and has been designed to treat lysosomal storage disease (β-glucosidase, β-glucuronidase, β-
galactosidase)110, hepatic tumors and metastases (methotrexate, bleomycin, asparaginase, and 
adriamycin), RES parasitic disease (pentamidine, primaquine phosphate, and metronidazole), 
and iron over-accumulation (desferrioxamine) in the RES. Desferrioxamine loaded erythrocytes 
















The first encapsulation procedure investigated to load phototherapeutics described in 
Chapter 3 was the hypotonic dilution method. Hypotonic dilution involves suspending packed 
erythrocytes in 2 - 20 volumes of hypotonic buffer containing the entity to be loaded and then 
resealing the cells by returning the solution to isotonicity. The advantages of this strategy 
include simplicity as well as cost and time effectiveness. Ihler60 and Dale112,113 demonstrated the 
advantages of using the erythrocyte interior for enzyme encapsulation and RES targeting in the 
1970s with the hypotonic dilution strategy.109 Independently, they sought to develop an effective 
vehicle for glucocerebrosidase as means to enhance enzyme replacement therapy to treat 
Gaucher’s disease. It should be noted that this strategy was employed so that loaded 
erythrocytes would be effectively taken up by spleen and liver clearance mechanisms.  
Traditional enzyme replacement therapy is largely ineffective due to immunogenicity (namely, 
the production of antibodies), lack of bioavailability, and fast clearance rate.114 Fast clearance 
presents additional problems as administration frequency must be increased to maintain the 
therapeutic blood index, leading to further immune reactions. It is possible that encapsulating 
enzymes in erythrocytes will improve pharmacodynamics, pharmacokinetics, and safety of the 
treatment by reducing the chances of adverse immune responses. Although erythrocyte-
encapsulated glucocerebrosidase replacement provided only transient and inconclusive results 
in a very small clinical trial,113 more recent enzyme replacement therapy using automated 









Hypotonic dilution encapsulation offers an attractive strategy for proof of concept studies 
and initial investigations. However, it is also clear that it presents limitations. Hypotonic dilution 
is damaging to the cells, often altering physical properties of resealed erythrocytes and leading 
to increased membrane instability, cell fragility, low encapsulation efficiency, poor cell recovery, 
and short life spans when re-injected in vivo.103 RBC damage can become advantageous when 
targeting loaded cells to clearance organs, but the phototherapeutics described here are most 
useful when they are able to circulate for an extended period. Therefore, to ensure proper 
survival and circulation after re-injection, a different procedure that produces carrier erythrocytes 
more closely retain native characteristics was needed.  
A gentler and more effective hypotonic dialysis procedure was pioneered by Deloach and 
Ihler115 and Dale et al.116,117 in 1977 as a way to better preserve native erythrocyte morphology 
and increase natural circulation time of engineered erythrocytes. Hypotonic dialysis is performed 
by exposing erythrocytes at 70% hematocrit and the material to be encapsulated to an 
environment of reduced osmotic pressure (such as a hypotonic solution) in conventional dialysis 
tubing. It is thought that the gradual decrease in ionic strength achieved by separating the cells 
from direct contact with the hypotonic solution and minimizing the extracellular volume, better 
maintains the structural integrity of the cell membrane. This method produces more viable cells 
that preserve biochemical and physiological characteristics of native erythrocytes and results in 
a higher encapsulation efficiency than hypotonic hemolysis (30 - 50% vs 1 - 8%). Other 
advantages include higher cell recovery (70 - 80%), ability to load a high volume of erythrocytes 
in one batch, and the potential to automate the loading procedure. Disadvantages include long 
processing time and the need for specialized equipment.103 The hypotonic dialysis method will 
be the focus of Chapter 4, in which extended in vivo circulation time will be important for 




Erythrocyte carriers are emerging as viable solutions to challenges of drug 
biocompatibility and efficacy in human patients. In recent years progress has been made in 
procedure optimization for human erythrocytes. These advances have led to the emergence of 
two major companies, which have independently developed automated ex vivo medical devices 
to handle and load erythrocytes in an industrial-scaled procedure under blood banking 
conditions. These devices have paved the way for erythrocyte carriers to enter numerous 




1.10.2.1. Clinical Application 
The first company to investigate erythrocytes in clinical trials was ERYTECH Pharma, a 
clinical stage biopharmaceutical company that focuses on innovative treatments for rare 
cancers and orphan diseases. ERYTECH’s instrumentation is their proprietary platform 
ERYcaps, a technology patented by Godfrin in 2006.118 The technique follows the hypotonic 
dialysis method to encapsulate active drugs into erythrocytes. Briefly, 250 - 350 mL of 
transfusion-grade, packed erythrocytes from compatible blood donors are swollen and resealed 
by exposing them to reversible hypotonic and hypertonic stress environments in a sterile unit. 
The entire procedure takes 3 h and the resulting resealed erythrocytes have almost normal 
circulation times when administered to patients, making them ideal for prolonging drug activity 
lifetime. Other advantages include decreased risk of side effects, high reproducibility, and broad 
applicability with the ability to encapsulate biological molecules between 1 to 500 kDa in 
size.119,120 While ERYTECH has applied their platform to various diseases in oncology, immuno-
oncology, and enzymatic disorders, their most progressive work implements erythrocyte loaded 
L-asparaginase to treat Acute Lymphoblastic Leukemia. Phase I and II clinical trials continue to 
demonstrate a notable reduction in percentage and severity of allergic reactions when 











The second company, EryDel SpA, was founded based on their proprietary technology 
coined “The Red Cell Loader,” developed by Magnani et al. in 1998. This instrumentation uses 
the functionality of the hypotonic preswell method, instead of dialysis, to load erythrocytes. The 
fully automated Red Cell Loader combines sterile, portable, disposable kits with a specially 
designed software process. The erythrocytes to be loaded can be taken directly from the 
patient, employing as little as 50 mL of whole blood and alleviating concerns of blood 
compatibility. Packed erythrocytes are swollen through exposure to two sequential steps of 
hypotonic dilutions that open the pores in a slow, controlled manner before resealing them by 
returning the erythrocytes to isotonic conditions. This procedure takes only 90 min and the 
carrier erythrocytes can be rapidly re-infused to the patient, mitigating in vitro leakage. The most 
prominent drug used by the EryDel team is the non-membrane permeable prodrug 
dexamethasone 21-phosphate (DSP). While encapsulated in carrier erythrocytes, DSP 
circulates while slowly being hydrolyzed to form the membrane permeable therapeutic, 
dexamethasone. In this way, active drug is continuously released and maintains a 
therapeutically relevant concentration in the blood stream for an extended period of time. This 
platform is called the EryDex System.  
 
1.11. Conclusion 
In summary, I have described the advancements of a long wavelength sensitive drug 
release system and have discussed the utility of erythrocytes as drug carriers. In the following 
chapters, I will discuss ways in which the delivery of light-activated Cbl phototherapeutics by 
erythrocyte mediated carriers can be achieved. I will demonstrate the spatial and temporal 
release of multiple drug types and investigate two ways of erythrocyte loading (external and 
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CHAPTER 2: LOADING ERYTHROCYTE CARRIERS WITH COBALAMIN 
PHOTOTHERAPEUTICS. GENERATION 1 – MEMBRANE DECORATION 
 
Reproduced with permission from Smith, W. J.; Oien, N. P.; Hughes, R. M.; Marvin, C. M.; 
Rodgers, Z. L.; Lee, J.; Lawrence, D. S. Cell-Mediated Assembly of Phototherapeutics. Angew. 
Chemie - Int. Ed. 2014, 10945–10948. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim 
 
The work in this chapter was a collaboration between the authors Weston J. Smith, Nathan P. 
Oien, Robert M. Hughes, Christina M. Marvin, Zachary L. Rodgers, Junghyun Lee, and David S. 
Lawrence. The first author of the published work, Weston J. Smith, wrote the publication and 
contributed the most experimental effort and scientific ideas. Christina M. Marvin, the author of 
this dissertation, performed the RBC loading and photo-release studies in Sections 2.5, 2.6, 2.7, 
2.9, 2.10, and 2.11. 
 
2.1. Background 
The use of light to activate therapeutic agents at disease sites offers the advantage of 
aggressive treatment with exquisite spatial control, thereby reducing potential deleterious side 
effects at unintended sites. An excellent example of this concept is photodynamic therapy, 
which employs the delivery of a photosensitizer to the tissue of interest.1 Upon excitation with 
the appropriate wavelength of light and, in the presence of oxygen, cytotoxic reactive oxygen 
species are generated, resulting in destruction of the target cells. This minimally invasive 
procedure furnishes control over where and when the reactive oxygen species are produced. 
However, a more general strategy that can control the delivery of any drug could profoundly 
influence the treatment of a variety of disorders, including cancer, diabetes, and autoimmune 
and vascular diseases. A major challenge in this regard is the so‐called “optical window of 




 Wavelengths less than 600 nm are absorbed by hemoglobin in the circulatory system 
and melanin in the skin, whereas water interferes with light penetration for wavelengths greater 
than 900 nm. Unfortunately, nearly all light‐activatable prodrugs described to date respond to 
short‐wavelength irradiation < 450 nm.3,4 This limitation is responsible for the intense interest in 
two‐photon5 and up‐converting6 technologies. However, as discussed in recent reviews,5,6 both 
technologies must overcome daunting challenges before potential therapeutic applications are 
realized. The long‐wavelength (> 600 nm) photolysis of alkylcobalamins (alkyl‐Cbl)7 was 
recently described. Now, the cell‐mediated assembly of lipid‐Cbl‐drug and lipid‐fluorophore 
conjugates in which the latter serve as long‐wavelength‐capturing antennas that promote drug 
release is reported.  
Erythrocytes have been called the “champions of drug delivery” due to their 
biocompatibility, their long lifespan (120 days), and their size, which allows large quantities of 
drug to be conveyed relative to other carriers.8 However, “practically useful controlled release 
from carrier RBC (red blood cells) remains an elusive goal”.8 Our strategy to address this issue 
is depicted in Figure 2.1. Based on a previously demonstrated energy transfer between 
fluorophores and Cbls in covalently appended Cbl‐fluorophore conjugates,7 the premise that the 
cell‐mediated assembly of C18‐Cbl‐drug and C18‐fluorophore conjugates could act in concert as 
a photoresponsive drug‐delivery system was explored. Illumination of the fluorophore antenna 
at its λmax and subsequent energy transfer to the Cbl‐drug moiety should result in cleavage of 


















Figure 2.1. Cbl phototherapeutics decorating the erythrocyte membrane. A wavelength‐
encoded drug‐release strategy. Anti‐inflammatory drugs are covalently appended to Cbl by 
means of a photolabile Co-C bond. Lipidated‐Cbl and fluorophore constructs assemble on the 
plasma membrane of human erythrocytes. The fluorophore serves as an antenna, capturing 
long‐wavelength light and transmitting the energy to the Cbl‐drug conjugate, resulting in drug 













2.2. Design and Synthesis of Anchored Compounds 
A series of lipidated Cbl (C18‐Cbl) and C18‐fluorophore derivatives were prepared 
(Figures 2.2 and 2.3 and Schemes 2.2-2.10). In the case of the Cbl derivatives, the C18 moiety 
was appended to the 5′ ribose hydroxy group of Cbl using ODA and carbonylditriazole (CDT). 
Subsequent alkylation of the Co furnished an amine or carboxylic acid handle, to which drugs 
and fluorescent reporters were covalently attached (Figure 2.2). These species include the anti‐
inflammatories methotrexate (MTX), colchicine (COL), and dexamethasone (DEX), and the 
fluorescent reporters, tetramethylrhodamine (TAMRA) and fluorescein (FAM). The C18‐
fluorophore derivatives were prepared by direct condensation of the activated carboxylate of the 























 Figure 2.2. Structures of lipidated Cbl‐reporters and Cbl-drug conjugates. Top: TAM (C18‐Cbl‐
TAM) and FAM (C18‐Cbl‐FAM). Bottom: lipidated Cbl‐drug conjugates, MTX (C18‐Cbl‐MTX), COL 









Figure 2.3. Structures of C18 conjugated fluorophore antennas. Their λex wavelengths are: C18-




2.3. Light-dependent Release of Drugs and Reporters  
Initial studies sought to explore the premise of the strategy outlined in Figure 2.1 by 
establishing the light‐triggered movement of drugs and reporters from a hydrophobic 
environment to an aqueous one. For these preliminary experiments we directly photolyzed C18‐
Cbl‐drug and C18‐Cbl‐reporter conjugates at the Cbl absorbance wavelength (525 nm). As 
expected, both C18‐Cbl‐TAM and C18‐Cbl‐MTX are soluble in octanol. Illumination at 525 nm 
cleaved the Co-C bond in C18‐Cbl‐TAM and promoted migration of TAM from octanol to water 
as assessed by fluorescence (Figure 2.4). In an analogous fashion, 525 nm illumination of C18‐
Cbl‐MTX triggered the release of MTX into the aqueous phase as demonstrated by LC‐MS 
(Figure 2.5). We subsequently explored the light‐triggered transfer of drug/reporter from the 





















Figure 2.4. Light induced migration of TAM from octanol to water monitored by fluorescence of 
the aqueous layer. C18-Cbl-TAM (primarily soluble in the octanol layer) in a water/octanol 
partition was photolyzed at 525 nm. Fluorescence of TAM in the water layer ʎex: 555 nm ʎem: 
585 nm. Photolysis time: 0 (red), 1 (orange), 2 (yellow), 3 (green), and 10 min (blue). The inset 
shows the emission spectrum of aqueous TAM (570 nm - 600 nm). Data are represented as 

















Figure 2.5. Light induced migration of MTX from octanol to water as quantified by the MTX LC-
MS assay. C18-Cbl-MTX (primarily soluble in the octanol layer) was photolyzed using 525 nm 
light-emitting diodes (LEDs). Migration is represented as the mole percent of total amount of 
MTX found in the aqueous layer. Data are represented as averages with standard errors of 













2.4. Fluorescent Reporter TAM as a Model of Loading and Release from Erythrocyte 
Membranes 
 
First, exposure of erythrocytes to C18‐Cbl‐TAM furnished even and extensive loading as 
assessed by widefield fluorescence microscopy. In addition, given the established photolytic 
sensitivity of the Co-C bond,7,9,13 we were not surprised to find that imaging C18‐Cbl‐TAM on 
erythrocytes results in the rapid migration (<1 s) of TAM fluorescence from erythrocytes into 































Figure 2.6. C18-Cbl-TAM loading and release. Erythrocytes loaded with 10 µM C18-Cbl-TAM and 
visualized at (a) long wavelength (λex = 650 nm, λem = 684 nm) to prevent photo-cleavage of the 
Co-TAM bond. Visualization and photolysis of C18-Cbl-TAM at (b) λex = 570 nm, λem = 590 nm, 
with 20 ms exposure times. Photolysis occurred within the first frame. Images were taken every 
1/3 s. After the first exposure, the fluorophore is nearly completely dissociated from the 
erythrocyte membrane and only present in solution. All images were acquired using an Olympus 











2.5. Photochemistry: Demonstrating Loading and Release of C18-Cbl-drug Constructs 
from Erythrocyte Membranes  
 
C18‐Cbl‐MTX, C18‐Cbl‐COL, and C18‐Cbl‐DEX were loaded onto intact human 
erythrocytes with minimal lysis (ca. 5% at 5 μM C18‐Cbl‐drug, Figure 2.7). Illumination with the 
excitation wavelength of Cbl (525 nm) demonstrates that drug release was linearly proportional 
to the loading concentration (Figure 2.8). While C18-Cbl-MTX and C18-Cbl-COL display similar 
loading capacities, it should be noted that the loading capacity of C18-Cbl-DEX was observed to 
be higher than the other two conjugates. When the cells were exposed to 4 µM C18‐Cbl‐drug 
concentration, the amount of C18‐Cbl‐drug loaded per red blood cell was 0.3 - 1.0 fmol. 
Subsequent photorelease of the drug was quantitative for C18‐Cbl‐COL and C18‐Cbl‐DEX and 
35 % for C18‐Cbl‐MTX (Figure 2.9). We were able to accurately measure the concentrations of 











 Figure 2.7. Structural integrity of erythrocytes exposed to various concentrations of lipidated 
drug conjugates for 14 h. Leaked heme was measured by optical density at 550 nm minus the 
optical density of a dimethyl sulfoxide (DMSO) control (7 ± 1%) and divided by the absorbance 
of a 100% lysed control (0.05% sodium dodecyl sulfate [SDS]). In this way, only hemolysis due 
to compounds was measured. Data are represented as averages with standard errors of three 







Figure 2.8. Drug loading on and release from human erythrocytes. Amount of drug photo-
released from erythrocytes as a function of C18-Cbl-Drug loading concentration. Samples were 
photolyzed to completion using 525 nm LEDs exposure for 2 h. Concentrations were 
determined by LC-MS assays described for each drug. Data are represented as averages with 
standard errors of three independent experiments. C18- Cbl-MTX (blue), C18-Cbl-COL (orange), 









Figure 2.9. Quantification of drug loading and photo-release. Erythrocytes (200 µL, 5% 
hematocrit) were incubated with 4 µM of each Cbl-drug conjugate for 30 min. At the end of this 
time, three washes were performed in which the erythrocytes were spun down at 1000 g and 
the phosphate buffered saline (PBS) buffer was exchanged. Supernatants were collected, 
pooled, photolyzed for 30 min at 525 nm, and then analyzed by the various LC-MS assays 
described for each drug. This provided a measure of unbound C18-Cbl-drug. The erythrocytes 
were resuspended at 200 µL and photolyzed for 1 h at 525 nm [as in (a)] and the supernatant 
analyzed by the drug specific LC-MS assays. Black bars represent the total amount of drug 
loaded onto erythrocytes at 5% hematocrit in 200 µL. Conversion of the y-axis values to fmol of 
C18-Cbl-Drug/RBC was calculated from the experimentally derived value of 2.3 ± 0.1 x 107 
RBC/mL (5% hematocrit): 0.28 ± 0.04 fmol of C18-Cbl-DEX/RBC, 1.03 ± 0.03 fmol of C18-Cbl-
COL/RBC, and 0.57 ± 0.01 fmol of C18-Cbl-MTX/RBC. White bars represent the amount of drug 


















Figure 2.10. Drug standard curves (a) The standard curve used with MTX LC-MS assay was 
generated by titration of known amounts of commercially available MTX and subsequent 
analysis of the area under the curve by UV-Vis (300 nm) via LC-MS; concentrations used were 
1.0 µM, 0.5 µM, 0.1 µM, 0.05 µM, and 0.01 µM. Data are represented as averages of three 
independent experiments. (b) standard curve used with COL LC-MS assay was generated by 
titration of known amounts of commercially available COL and subsequent analysis of the area 
under the curve by UV-Vis (365 nm) via LC-MS. Concentrations used were 5 µM, 1 µM, 0.5 µM, 
0.1 µM. Data are represented as averages of three independent experiments. (c) standard 
curve used with DEX LC-MS assay was generated by titration of known amounts of 
commercially available DEX and subsequent analysis of the area under the curve by UV-Vis 
(239 nm) via LC-MS; concentrations used were 5.0 µM, 2.5 µM, 1 µM, 0.5 µM, and 0.1 µM. 
Data are represented as averages of three independent experiments. 
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LC‐MS analysis revealed that photolysis of erythrocyte‐anchored C18‐Cbl‐MTX primarily 
furnishes N‐propylamide MTX, erythrocyte‐anchored C18‐Cbl‐COL primarily produces the 
photoproduct N‐butanoyl COL, and DEX is the observed product from photolysis of C18‐Cbl‐
DEX‐loaded erythrocytes, instead of one or more of the expected photoproducts (Figure 2.11; 
Scheme 2.1 and Tables 2.1-2.2). With regards to the DEX photoproduct, the 21‐esters of DEX 
are prodrugs that are hydrolyzed to DEX in vivo.14,15 The possible presence of blood 
esterases16 may explain the formation of DEX once the conjugate is freed from the RBC 

























Figure 2.11. Released photoproducts of C18‐Cbl‐MTX, C18‐Cbl‐COL, and C18‐Cbl‐DEX. In the 






















Scheme 2.1. Mechanism and products of alkyl cobalamin photolysis. Photolysis results in the 
homolytic cleavage of the cobalt carbon bond producing a primary carbon centered radical and 
a cobalt II species. In the absence of oxygen, recombination dominates and the parent 
compound is restored. In aerobic environments, the alkyl radical reacts with oxygen to form a 
peroxy radical. This is believed to react with cob(II)alamin to generate the final products of 
photolysis. When this process takes place on a biological membrane, which could act as a 





Table 2.1. Elution times and predicted/detected masses of intact C18-Cbl-MTX, C18-Cbl-COL, 






Products analyzed by their various LC-MS assays using the gradient from Table 2.8.  
Table 2.2. Elution times and detected masses of the photocleavage products for C18-Cbl-MTX, 
C18-Cbl-COL, and C18-Cbl-DEX. 
 Elution Time (min) Yield (mole fraction) 
 
X = H X = OH X = O C18-Cbl X = H 
Other 
Products 
C18-Cbl-MTX 3.3 2.9 3.1 6.8 0.83 0.17 
Mass 494.2 510.2 528 812.8   
C18-Cbl-COL 4.7 4.4 4.4 6.7 0.20 0.80 
Mass 426.1 442 460 812.7   
C18-Cbl-DEX 5.5 5.5 5.5 6.7 n/a n/a 
Mass 514.3 533 532 812.7   
 
Products measured after illumination at 525 nm light for 20 min in PBS buffer, pH 7.4. 
These products are described in detail in Scheme 2.1. Detection was performed using the MTX, 
COL, and DEX LC-MS assays. The solvent gradient is described in Table 2.8. Note that the 













(M + 2H+) z=2 
m/z 
C18-Cbl-MTX 6.8 1060.0 1060.3 
C18-Cbl-COL 7.3 1026.0 1026.5 
C18-Cbl-DEX 7.5 1079.1 1079.3 
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Consistent with the established structure–activity relationship of MTX derivatives,17,18 the 
photolyzed product of C18‐Cbl‐MTX serves as an effective inhibitor of dihydrofolate reductase 





























Figure 2.12. C18‐Cbl‐MTX as an effective inhibitor of DHFR. Inhibition of DHFR by MTX (circles) 


















2.6. Delivery of Active Photoproducts from Erythrocyte Membranes to Mammalian Cells 
 Erythrocytes decorated with C18-Cbl-Drug conjugates were incubated with HeLa cells 
and illuminated at the appropriate wavelength to induce the production of active photoproducts. 
Photoreleased MTX from erythrocyte‐anchored C18‐Cbl‐MTX binds to DHFR in HeLa cells 
(Figure 2.13), photolyzed C18‐Cbl‐COL disrupts microtubules in HeLa cells as effectively as COL 
itself (Figures 2.14 and 2.15), and photorelease of DEX from C18‐Cbl‐DEX‐loaded erythrocytes 
cocultured with HeLa cells results in the migration of glucocorticoid receptor α (GRα) from the 
cytosol to the nucleus in HeLa cells (Figures 2.16 and 2.17). It was noted that, in the absence of 
illumination, C18‐Cbl‐MTX‐, C18‐Cbl‐COL‐, and C18‐Cbl‐DEX‐loaded erythrocytes do not release 




















Figure 2.13. Assessment of MTX photo-release from C18-Cbl-MTX-loaded erythrocytes. 
Assessment via the cellular thermal shift assay (CETSA). In the absence of MTX (“Dark”, “No 
Treatment”, and “‘-‘MTX“) no DHFR is detected from HeLa cells following incubation of HeLa 
cells at 52 °C. By contrast, exposure of HeLa cells to C18-Cbl-MTX-loaded erythrocytes with 
increasing illumination times (10, 20, and 30 min) leads to increasing amounts of DHFR stable 










Figure 2.14. Effect of COL on microtubules in HeLa cells. COL was added to HeLa cell culture 
and allowed to incubate for 1 h before the cells were fixed and stained for tubulin to visualize 
microtubule networks. (a) DMSO only (b) 250 nM (c) 500 nM (d) 1 µM (e) 2 µM (f) 4 µM. At 2 
µM COL well-structured microtubules disappear and pools of depolymerized tubulin are visible 
at the cell periphery. 
 
a) b) c) 





















Figure 2.15. Effect of photo-released COL from erythrocyte-bound C18-Cbl-COL on 
microtubules in HeLa cells. Human erythrocytes were loaded with C18-Cbl-COL (5% hematocrit, 
6 µM). (a) 20 min photolysis at 525 nm, (b) dark, (c) no erythrocytes and dark, (d) no 
erythrocytes and 20 min photolysis at 525 nm. Disruption of microtubule networks from 
























Figure 2.16. Effect of DEX on the subcellular location of GRα in HeLa cells. HeLa cells were 
stained with Alexa488 antiRabbit/anti-GRα (green) and HOESCHT 33342 (blue). (a) In HeLa 
cells treated with DMSO, GRα is largely cytosolic and does not co-localize with (b) nuclear 
HOESCHT 33342 stain. (c) In HeLa cells treated with 250 nM DEX, GRα migrates to the 



















Figure 2.17. Effect of photo-released DEX from erythrocyte-bound C18-Cbl-DEX on the 
subcellular location of GRα in HeLa cells. (a) HeLa cells were treated with erythrocytes loaded 
with 1 µM C18-Cbl-DEX without photolysis. (b) HeLa cells were treated with erythrocytes loaded 
with 1 µM C18-Cbl-DEX with 10 min photolysis at 525 nm. HeLa cells were stained with 



















2.7. Demonstration of C18-Cbl-Drug Stability on Erythrocytes 
Whether C18‐Cbl‐drug conjugates transfer from erythrocytes to HeLa cells in the 
absence of light was also examined. HeLa cells were incubated with C18‐Cbl‐DEX‐loaded 
erythrocytes and, subsequently, the adherent HeLa cells were washed to remove the red blood 
cells. If C18‐Cbl‐DEX had migrated to HeLa membranes during the incubation process, 
illumination at 525 nm should result in DEX release, uptake, and GRα migration. Receptor 
relocation to the nucleus was not observed, suggesting that C18‐Cbl‐DEX is retained by 




















Figure 2.18. Assessment of C18-Cbl-DEX transfer between the erythrocyte and HeLa cell 
membranes. Erythrocytes were loaded with C18-Cbl-DEX (1 µM at 5% hematocrit). A 525 nm 
LED light source was used for all illumination experiments. (a) HeLa cells were exposed to C18-
Cbl-DEX loaded erythrocytes in the dark for 1 h followed by removal of the erythrocytes via 
washing prior to photolysis and then fixed and stained for GRα. (b) HeLa cells were exposed to 
C18-Cbl-DEX loaded erythrocytes in the dark for 1 h followed by removal of the erythrocytes via 
washing; without photolysis; fixed and stained for GRα. (c) HeLa cells were not exposed to 
erythrocytes but were washed and illuminated; and then fixed and stained for GRα. In all 











2.8. Extending the Photoresponsive Platform to Biologically Relevant Wavelengths in the 
Optical Window of Tissue Penetration 
 
With the biological efficacy of the light‐triggered release of drugs from erythrocytes 
established, attention was turned to the assembly of photoresponsive constructs that 1) operate 
within the optical window of tissue and 2) are encoded to respond to specific wavelengths. Our 
choice of anti‐inflammatory drugs is based upon their role in the treatment of rheumatoid 
arthritis (RA). The long‐term administration of anti‐inflammatory agents produces moderate to 
severe side effects, such as weight gain, osteoporosis, diabetes mellitus, hypertension, skin 
fragility, and infections arising from the systemic immunocompromised state.19,20 Not 
surprisingly, there is significant interest in the development of therapeutics that can be 
selectively delivered to RA joints.21–23 With this in mind, we prepared C18 derivatives of Cy5 (C18‐
Cy5; λex = 646 nm), AlexaFluor 700 (C18‐AF700; λex  = 700 nm), Cy7 (C18‐Cy7; λex = 747 nm), 
and a DyLight 800 analogue (C18‐DY800; λex = 784 nm) and examined whether they are capable 
of serving as long‐wavelength antennas for drug release. Photolysis experiments employed in‐
house‐constructed LED circuit boards centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 



















Figure 2.19. LED boards. All boards were powered with a 12V DC power supply. LEDs were 
wired in units of 4 LEDs in series with a 100 Ω resistor in parallel. 







525 1.50 ± 0.03 66 ± 1 
660 3.30 ± 0.02 183 ± 1 
725 6.00 ± 0.05 365 ± 3 






LEDs are from Figure 2.20 after filters were applied to cut off wavelengths shorter than 
those specified. MacNan colored film gels (Aqua, Blue, Green, Magenta, and Red) were used in 
combination as filters for the following LEDs: 525 nm (Green), 660 nm (Red and Magenta), 725 
nm (Red and Magenta), and 780 nm (Blue, Green, and Aqua). 
2.9. Long Wavelength Fluorophore Antennas Release Fluorescent Reporters via Energy 
Transfer 
Initial studies employed C18‐Cbl‐TAM in the presence of the C18‐fluorophores, since the 
photorelease of TAM from C18‐Cbl‐TAM‐labeled erythrocytes is readily monitored by 
fluorescence. In order to identify optimal energy transfer conditions, erythrocytes were first 
exposed to various relative concentrations of C18‐Cbl‐TAM and C18‐Cy5. After the erythrocytes 
had been washed to remove any unbound C18‐Cbl‐TAM and C18‐Cy5, the loaded red blood cells 
were illuminated at 660 nm. The carrier erythrocytes were subsequently pelleted by 
centrifugation and TAM fluorescence in the supernatant was measured. Although the most 
efficient TAM release was observed with erythrocytes exposed to a 1 μM:10 μM ratio of C18‐Cbl‐
TAM:C18‐Cy5 (Figure 2.20), we employed a 1 μM:5 μM ratio to keep disruption of the 
erythrocyte’s structural integrity at an absolute minimum. In addition to the C18‐Cy5 @ 660 nm 
antenna, the photorelease of TAM from C18‐Cbl‐TAM‐loaded erythrocytes can be triggered at 
longer wavelengths in the presence of other antennas [C18‐Cy7 @ 725 nm, C18‐Cy7 @ 725 nm, 
C18‐DY800 @ 780 nm]. Figure 2.21 compares the fraction of TAM released as a function of 
antenna wavelength, power of the different LEDs, and photon density. An analogous set of 
experiments with similar results was performed with C18‐Cbl‐FAM/ C18‐fluorophores (Figure 
2.22). Erythrocytes in the dark do not release TAM or FAM and, erythrocytes lacking a 
fluorophore antenna do not release FAM or TAM at wavelengths longer than those absorbed by 
Cbl (Figures 2.23, 2.24, 2.25). Finally, confocal microscopy revealed that the structural integrity 



















Figure 2.20. Heat map of TAM release from erythrocytes. Heat map when erythrocytes (5% 
hematocrit) exposed to variable concentrations of C18-Cbl-TAM and C18-Cy5 followed by 
photolysis (30 min with 660 nm). The most efficient release (yellow/orange/red) is observed at 
low C18-Cbl-TAM:C18-Cy5 ratios. Given that lipid concentrations >10 µM begin to compromise 
erythrocyte structural integrity according to the Hemolysis Assay, we chose to employ 1 µM:5 
















Figure 2.21. Photo-release of TAM from C18-Cbl-TAM/C18-fluorophore-loaded erythrocytes. LED 
arrays centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800) were 
employed as the light sources. TAM release is displayed as the fraction liberated from 
erythrocytes. Total erythrocyte bound C18-Cbl-TAM was determined via a time study where 3 h 
of illumination generated maximal TAM release. Unfilled bars: fraction of TAM release; Black 
bars: fraction of TAM release normalized by the power of the different light sources; Grey bars: 
fraction of TAM release normalized by photon density produced by the light sources; n = 3 for all 
experiments. Power was normalized to C18-Cy5 by multiplying the fraction released (white bar) 
by a ratio of the power output of the LED board used to the output of the 660 board used for 
C18-Cy5 (Table 2.3). Photon density normalization was carried out in a similar fashion with 
photon flux values reported in Table 2.3. Data are represented as averages with standard errors 
















Figure 2.22. Photo-release of FAM from C18-Cbl-FAM/C18-fluorophores-loaded erythrocytes 
Release of FAM from erythrocytes loaded with C18-Cbl-FAM/C18-fluorophores (1 µM/5 µM) after 
30 min illumination. Release is displayed as the fraction of FAM liberated out of the total amount 
of FAM bound. Total FAM bound was determined by measuring the concentration of FAM in the 
supernatant after 3 h of photolysis (@ 525 nm). The light sources employed were arrays of 
LEDs (shown in Figure 2.19) centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm 
(DY800). The fraction of FAM released (white), the fraction of FAM release normalized by the 
power of the different light sources (black), and the fraction of FAM released normalized by 
photon density produced by the various light sources (grey). Power was normalized to C18-Cy5 
by multiplying the fraction released (white bar) by a ratio of the power output of the LED board 
used to the output of the 660 board used for C18-Cy5 (Table 2.3). Photon density normalization 
was carried out in a similar fashion with photon flux values reported in Table 2.3. Data are 















Figure 2.23. Photo-release of TAM from C18-Cbl-TAM/C18-fluorophores-loaded erythrocytes 
after 30 min illumination. Release of TAM from erythrocytes loaded with C18-Cbl-TAM/C18-
fluorophores (1 µM/5 µM) after 30 min of illumination. Release is displayed as the fraction of 
TAM liberated. The light sources employed are the LED arrays shown in Figure 2.19. In the 
absence of a long wavelength fluorescent antenna, illumination at 660, 725, or 780 nm fails to 
release membrane-tethered TAM. Data are represented as averages with standard errors of 








Figure 2.24. Release of TAM from erythrocytes loaded with C18-Cbl-TAM. Release (1 µM) as a 
function of photolysis time. Release is displayed as the fraction of TAM liberated. All samples 
were analyzed at 1 h. The light sources employed are the LED arrays (shown in Figure 2.19) 
centered at 525 nm (circles) and 660 nm (triangles). Data are represented as averages with 











Figure 2.25. Release of FAM from erythrocytes loaded with C18-Cbl-FAM (1 µM) as a function 
of photolysis time. Release is displayed as the fraction of FAM liberated. All samples were 
analyzed at 1 h. The light sources employed were arrays of LEDs (shown in Figure 2.19) 
centered at 525 nm (circle) and 660 nm (triangle). Data are represented as averages with 








Figure 2.26. Confocal images of erythrocytes loaded with C18-Cy5. C18-Cy5 (5 µM) was added 
to 10% hematocrit erythrocytes. Following incubation, erythrocytes were washed, plated at 0.1% 
hematocrit, and imaged by confocal microscopy. Left: DIC, Middle: Cy-5 fluorescence, and 




2.10. Long Wavelength Fluorophore Antennas Release Drugs  on Command 
 Drug photorelease from the erythrocyte‐assembled drug/antenna array was 
subsequently examined. C18‐Cbl‐MTX, C18‐Cbl‐COL, and C18‐Cbl‐DEX were each paired with 
C18‐fluorophores and illuminated. LC‐MS confirmed the release of MTX, COL, and DEX at the 






























Figure 2.27. Release of MTX from C18-Cbl-MTX/C18-fluorophore-loaded erythrocytes. (a) MTX 
release was measured by the LC-MS MTX Assay following photolysis at the λex of each 
fluorophore. LED arrays (Figure 2.19) were centered at 660 nm (Cy5), 725 nm (AF700 and 
Cy7), and 780 nm (DY800). Data are represented as averages with standard errors of three 
independent experiments. In the presence (white column) and absence of illumination (black 
columns). (b) The relative efficiency of MTX release. The total nmols of MTX released from 
photolyzed RBC MTX mixtures in (a) was divided by the total number of photons that 
accumulated in the cross-sectional surface area of those mixtures during 30 min of illumination 
time. The relative efficiency of the release of MTX for each of the various fluorescent antennae 
is given in nmol MTX released/µmol photons-cm2. LED arrays (Figure 2.19) were centered at 





















Figure 2.28. Release of COL and DEX from erythrocytes. (a) Release of COL and (b) DEX from 
C18-Cbl-COL/ C18-fluorophore-loaded erythrocytes and C18-Cbl-DEX/C18-fluorophore-loaded 
erythrocytes, respectively. Drug release was measured by the LC-MS COL or DEX Assays 
(white columns) following illumination at 660 nm (C18-Cy5) or 780 nm (C18-DY800). Control 
experiments in the dark were performed in parallel (black columns). Data are represented as 
averages with standard errors of three independent experiments. (c) The relative efficiency of 
drug release. The total nmols of drug released from photolyzed RBC drug mixtures in (a) and 
(b) was divided by the total number of photons that accumulated in the cross-sectional surface 
area of those mixtures during 30 min of illumination time. The relative efficiency of drug release 
for each of the various fluorescent antennae is given in nmol drug released/µmol photons-cm2. 
LED arrays (Figure 2.19) were centered at 660 nm (C18-Cy5). 
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Table 2.4. Elution times for the products of C18-Cbl-MTX and C18-Cbl-COL after fluorophore 
assisted, photocleavage from erythrocytes. 
 Elution Times (min) Yield 
(mole fraction) 
 X = H X = OH X = O C18-Cbl X = H Other 
Products 
C18-Cbl-MTX       
525 nm 3.4 2.9 3 n/a 0.76 0.24 
660 nm (Cy5) 3.4 2.9 3 n/a 0.80 0.20 
725 nm (AF700) 3.3 2.9 3 n/a 0.80 0.20 
725 nm (Cy7) 3.4 n/a 3 n/a 0.80 0.20 
725 nm (DY800) 3.4 2.9 n/a n/a 0.80 0.20 
       
C18-Cbl-COL       
525 nm 4.6 4.3 4.3 n/a 0.91 0.09 
660 nm (Cy5) 4.5 n/a n/a n/a <0.94  
780 nm (DY800) 4.5 n/a n/a n/a <0.90  
 
C18-Cbl-MTX was loaded with a 1:5 C18-Cbl-Drug: C18-fluorophore ratio. C18-Cbl-COL 
and C18-Cbl-DEX were loaded with a 1:1 C18-Cbl-Drug: C18-fluorophore. C18-Cbl-DEX is not 
listed in the table as the ester of the cleaved product is hydrolyzed upon photo-release (possibly 
due to the presence of esterases) and only DEX was recovered. Photolysis times were all 30 
min at the wavelengths indicated. These products are described in detail in Scheme 2.1. 
Detection was performed using the MTX, COL, and DEX LC-MS assays. The solvent gradient is 












2.11. Delivery of Active Photoproducts from Erythrocyte Membranes to Mammalian Cells 
using Long Wavelength Light 
Erythrocytes were decorated with C18‐Cbl‐DEX/C18‐Cy5. DEX is released from C18‐Cbl‐
DEX/C18‐Cy5‐loaded erythrocytes cultured with HeLa cells upon 660 nm illumination. As a 
consequence, GRα in HeLa cells migrates from the cytoplasm to the nucleus (Figure 2.29). By 
contrast, C18‐Cbl‐DEX‐loaded erythrocytes lacking a long‐wavelength‐absorbing antenna fail to 
trigger GRα migration when exposed to long wavelengths (e.g. 780 nm; Figures 2.30 - 2.31). A 
second set of erythrocytes were decorated with C18‐Cbl‐COL/C18‐DY800. Irradiation at 780 nm 
elicits COL release from erythrocyte‐anchored C18‐Cbl‐COL/C18‐DY800, which induces 
microtubule depolymerization in the plated HeLa cells (Figures 2.32 - 2.33). A third set of 
erythrocytes were decorated with C18‐Cbl‐MTX/C18‐Cy7. MTX is released from C18‐Cbl‐
MTX/C18‐Cy7‐loaded erythrocytes upon 725 nm illumination. The MTX photoproduct associates 
with endogenous DHFR in the cocultured HeLa cells, as assessed by the cellular thermal shift 

















Figure 2.29. DEX release from C18-Cbl-DEX/C18-Cy5-loaded erythrocytes. Release at 660 nm 
triggers HeLa cell GRα nuclear localization, where (a) is dark and (b) 660 nm. HeLa GRα 








Figure 2.30. Wavelength selective release of DEX from erythrocyte-bound C18-Cbl-DEX and the 
effect on GRα subcellular location. (a) HeLa cells treated with DMSO. (b) HeLa cells treated 
with erythrocyte-bound C18-Cbl-DEX in the dark. (c) HeLa cells treated with erythrocyte-bound 
C18-Cbl-DEX and illuminated at 780 nm. (d) HeLa cells treated with erythrocyte-bound C18-Cbl-























Figure 2.31. Quantitation of the effect of DEX release from C18-Cbl-DEX/C18-Cy5-loaded 
erythrocytes on GRα subcellular location in HeLa cells. Analysis of data from Figure 2.29. GRα 
is shown in green and HOESCHT 33342 nuclear staining in blue. (a) HeLa cells treated with 
C18-Cbl-DEX/C18-Cy5-loaded erythrocytes and illuminated at 660 nm. (b) HeLa cells treated with 
C18-Cbl-DEX/C18-Cy5-loaded erythrocytes in the dark. Lines indicate where cross-sectional 
fluorescent intensity is measured. A plot of two of these cross sections showing fluorescent 
intensities of GRα (green) and Hoescht (blue) is shown in (c, light) and (d, dark). (e) The 
correlation between HOESCHT and FITC fluorescence from (c). (f) The absence of correlation 
between HOESCHT and FITC fluorescence from (d). R2 values for HOESCHT/FITC correlations 













Figure 2.32. COL release from Cbl-COL/C18-DY800 erythrocytes at 780 nm. Release initiates 
HeLa microtubule depolymerization, where (a) is dark and (b) 780 nm. HeLa microtubules 












































Figure 2.33. Long wavelength release of COL from erythrocytes. (a) Untreated HeLa cells, (b) 
HeLa cells treated with C18-Cbl-COL/C18-Cy5-loaded erythrocytes in the dark, (c) HeLa cells 
















Figure 2.34. MTX release from C18-Cbl-MTX/C18-Cy7-loaded erythrocytes at 725 nm. Release 
shifts the thermal stability of DHFR where left 3 lanes (dark) and right 3 lanes (725 nm). GAPDH 
used as loading control. MTX release from C18-Cbl-MTX/C18-Cy7 loaded erythrocytes at 725 nm 
shifts the thermal stability of DHFR. (a) Western blot staining (anti-DHFR and anti-GAPDH 
antibodies) of HeLa cell extracts created from cultures exposed to loaded erythrocytes with and 














In summary, the cell‐mediated assembly of photoresponsive drug‐release constructs has 
been described. Release is triggered upon exposure to far‐red and near‐IR light that falls well 
within the optical window of tissue. Furthermore, drug release is wavelength‐encodable, such 
that the action wavelength can be chosen in advance based upon the known excitation 
properties of a given fluorophore. Finally, although this study focused on erythrocytes as drug 




2.13 Materials and Methods 
Cyanocobalamin was purchased from Lalilab Inc. Alexa Fluor 700 carboxylic acid 
sccunimidyl ester was purchased from Life Technologies. All other chemical reagents were 
purchased from Sigma Aldrich. 8 x 10 Color Film Gels were manufactured by MacNan and 
supplied by Amazon. 525 nm and 660 nm LEDs were purchased from LED Supply. 725 nm and 
780 nm LEDs were purchased from Techmark. Erythrocytes were purchased from Allcells. 
HRMS data was acquired on a Thermo Scientific electrospray linear trap quadrupole fourier 























Scheme 2.2. The structure and synthesis of C18-modified Cbls 2a, 2b, and 2c.  
 
C18-Cbl (2a). Cyanocobalamin (CN-Cbl, 200 mg, 148 µmol) was dissolved in 10 mL 
anhydrous dimethylsulfoxide (DMSO) and carbonylditriazole (CDT, 121 mg, 740 µmol) was 
added. The solution was rapidly stirred for 45 min. To this solution octadecylamine (ODA, 398 
mg, 1.48 mmol) was added. The resulting mixture was stirred for 1 h before being added to 90 
mL ether/chloroform. The resulting precipitate was collected by centrifugation and decantation. 
The pellet was dried under vacuum and 10 mL ethanol (EtOH) was added. A CDT-mediated 
ODA dimer formed as a white precipitate and was removed by centrifugation. The Cbl product 
was precipitated in 40 mL ether/chloroform (1:1) and collected by centrifugation and 
decantation. The pellet was dissolved in EtOH and purified on a 100 g Biotage KP-C18-HS flash 
column with a linear gradient of H2O:MeOH from 100% H2O to 100% MeOH in eight column 




Electrospray ionization mass spectrometry (ESI MS) calculated for C82H125CoN15O15P + 
H+ (M1+): m/z = 1650.8627, found 1650.7273; C82H125CoN15O15P + 2H+ (M2+): m/z = 825.9353, 
found 825.9091. 
1 H nuclear magnetic resonance (NMR) (DMSO-d6,400 MHz): δ = 7.50 - 7.75 (m, 4 H), 
7.35 (br. s., 1 H), 7.27 (br. s., 1 H), 7.17 (d, J = 17.6 Hz, 2 H), 7.04 (d, J = 10.6 Hz, 2 H), 6.77 
(br. s., 1 H), 6.71 (br. s., 1 H), 6.51 (br. s., 1 H), 6.46 (s, 1 H), 6.24 (br. s., 2 H), 5.92 (s, 1 H), 
4.62 - 4.80 (m, 2 H), 4.33 - 4.42 (m, 1 H), 4.18 - 4.30 (m, 1 H), 3.90 - 4.15 (m, 4 H), 3.67 - 3.76 
(m, 2 H), 3.08 (d, J = 11.0 Hz, 1 H), 2.95 (d, J = 6.3 Hz, 2 H), 2.72 - 2.86 (m, 2 H), 2.54 (s, 2 H), 
2.48 (br. s., 2 H), 2.42 (s, 2 H), 2.25 (d, J = 5.5 Hz, 2 H), 2.17 (br. s., 4 H), 2.07 (br. s., 3 H), 1.58 
- 1.84 (m, 6 H), 1.46 - 1.57 (m, 2 H), 1.38 (d, J = 5.9 Hz, 2 H), 1.33 (br. s., 2 H), 1.20 - 1.29 (m, 
27 H), 1.18 (br. s., 1 H), 1.15 (d, J = 5.9 Hz, 2 H), 1.06 (s, 2 H), 0.85 (t, J = 7.3 Hz, 3 H), 0.33 
















C18-Cbl-propylamine (2b). 2a (100 mg, 61 µmol) was dissolved in 10 mL of EtOH under 
N2. NH4Br (500 mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were added and the solution 
stirred for 20 min. To this slurry, 3-chloropropylamine hydrochloride (40 mg, 305 µmol) was 
added. The resulting mixture was stirred for 3 h under continuous N2 flow. A color change from 
red to orange was observed. Zn was removed by centrifugation, and the Cbl product 
recrystallized twice in 50 mL ether/chloroform (1:1). The resulting precipitate was collected by 
centrifugation and decantation. The pellet was S-2 dried under vacuum and 10 mL EtOH was 
added. UV-Vis analysis revealed that alkylation had gone to completion. 2b was purified on a 
100 g Biotage KP-C18-HS flash column with a linear H2O:MeOH (0.1% trifluoroacetic acid [TFA]) 
gradient from 100% H2O - 100% MeOH 8 column volumes. 2b eluted at 100% MeOH and, upon 
removal of MeOH furnished an orange solid in quantitative yield.  
ESI MS calculated for C84H133CoN15O15P + H+ (M1+): m/z = 1682.9253, found 
1682.9276; C84H133CoN15O15P + 2H+ (M2+): m/z = 841.9666, found 841.9669. 
1 H NMR (DMSO-d6, 400 MHz): δ = 7.76 (s, 1H), 7.67 (s, 1H), 7.55 - 7.63 (m, 2 H), 7.51 
(s, 1H), 7.37 - 7.44 (m, 3 H), 7.34 (s, 1H), 7.29 (s, 1H), 7.10 - 7.19 (m, 3 H), 7.00 (s, 1H), 6.93 
(s, 1H), 6.88 (s, 1H), 6.77 (s, 1H), 6.48 - 6.65 (br. m, 2 H), 6.25 (s, 1H), 6.12 (s, 1H), 4.71 (q, 
2H, J = 7.04 Hz), 4.36 (d, J = 8.61 Hz, 2H), 4.15 – 4.33 (br. m, 7H), 3.97 - 4.09 (m, 4H), 3.71 (t, 
J = 6.62 Hz, 2H), 3.51 (br. s, 2H), 3.12 (d, J = 8.61 Hz, 1H), 2.92 - 3.07 (br. m, 3H), 2.75 (br. m, 
1H), 2.44 - 2.48 (br. m, 2H), 2.42 (s, 3H), 2.37 (s, 3H), 2.15 - 2.24 (m, 7H), 1.98 - 2.08 (m, 2H), 
1.69 - 1.95 (br. m, 8H), 1.64 (s, 3H), 1.37 (br. s, 3H), 1.19 - 1.29 (m, 28 H), 1.15 (d, J = 6.26 Hz, 
3H), 1.06 (s, 2H), 0.85 (t, J = 6.65 Hz, 3H), 0.47 (br. m, 3H), 0.32 (br. m, 2H), 0.07 (br. m, 2H),-






C18-Cbl-butyrate (2c). 2a (100 mg, 61 µmol) was dissolved in 10 mL of EtOH under N2. 
NH4Br (500 mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were added and the solution stirred 
for 20 min under N2. To this slurry, 4-chlorobutyric acid (30 µL, 305 µmol, mw = 122, d = 1.24) 
was added. The resulting mixture was stirred for 3 h under continuous N2 flow. A color change 
from red to orange was observed. Zn was removed by centrifugation, and the Cbl was 
recrystallized twice in ether/chloroform (50 mL). The resulting precipitate was collected by 
centrifugation and decantation. The pellet was dried under vacuum and 10 mL EtOH was 
added. 2c was purified on a 100 g Biotage KP-C18-HS flash column with a linear gradient from 
100% H2O – 100% MeOH 8 column volumes. 2c eluted at 100% MeOH and, upon removal of 
MeOH furnished an orange solid in 82% yield. 
ESI MS calculated for C85H132CoN14O17P + H+ (M1+): m/z = 1711.9042, found 
1711.9075; C85H132CoN14O17P + 2H+ (M2+): m/z = 856.4560, found 856.4571.  
1 H NMR (DMSO-d6 ,400M Hz): δ = 7.58 - 7.73 (m, 3 H), 7.47 - 7.57 (m, 2 H), 7.31 - 
7.40 (m, 2 H), 7.13 - 7.26 (m, 3 H), 7.04 - 7.12 (m, 2 H), 6.92 - 7.00 (m, 2 H), 6.74 - 6.88 (m, 3 
H), 6.59 - 6.69 (m, 2 H), 6.04 - 6.43 (m, 5 H), 4.50 - 4.75 (m, 3 H), 4.32 - 4.46 (m, 2 H), 4.14 - 
4.33 (m, 4 H), 3.90 - 4.09 (m, 3 H), 3.72 - 3.87 (m, 2 H), 2.91 - 3.01 (m, 3 H), 2.08 - 2.46 (m, 16 
H), 1.75 - 2.00 (m, 8 H), 1.60 - 1.73 (m, 5 H), 1.32 - 1.52 (m, 7 H), 1.15 - 1.32 (m, 26 H), 1.02 - 
1.14 (m, 4 H), 0.93 - 1.02 (m, 2 H), 0.85 (t, J=7.1 Hz, 1 H), 0.50 - 0.76 (m, 4 H), 0.30 - 0.36 (m, 1 
















Scheme 2.3. Synthesis and purification of C18-Cbl-MTX. MTX (30 mg, 66 µmol), N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 25 mg, 66 µmol), 
and N,N-diisopropylethylamine (DIPEA, 58 µL, 332 µmol) were dissolved in 5 mL of 
dimethylformamide (DMF) and stirred for 5 min. 2b (120 mg, 71 µmol) was added and the 
solution was stirred overnight. 2b was unable to be separated from C18-Cbl-MTX via HPLC and 
thus the mixture was exposed to 4,5,6,7,7-hexachloro-5-norbornene-2,3- dicarboxylic anhydride 
(37 mg, 185 µmol). The solution was stirred for 30 min and then frozen at -80 °C being careful 
not to thaw until just before purification. C18-Cbl-MTX was purified on a 5 µm, 250 x 21.2 mm 
Viva C4 preparative column from Restek, using a H2O:CH3CN, 0.1% TFA gradient (elution time 













ESI MS calculated for C104H153CoN23O19P + 2H+ (M2+): m/z = 1060.0469, found 
1060.0476; C104H153CoN23O19P + 3H+ (M3+): m/z = 707.0339, found 707.0341. 
1 H NMR (DMSO-d6 ,400 MHz): δ = 8.71 (s, 1 H), 8.19 - 8.26 (m, 1 H), 7.82 (d, J = 12.9 
Hz, 2 H), 7.61 - 7.76 (m, 4 H), 7.58 (d, J = 5.1 Hz, 3 H), 7.36 (d, J = 9.8 Hz, 3 H), 7.05 - 7.21 (m, 
3 H), 6.92 (br. s., 2 H), 6.73 - 6.87 (m, 4 H), 6.61 (br. s., 2 H), 6.28 (d, J = 16.4 Hz, 4 H), 4.87 
(br. s., 2 H), 4.71 (d, J = 4.7 Hz, 2 H), 4.21 - 4.41 (m, 8 H), 4.04 (d, J = 9.0 Hz, 3 H), 3.72 (br. s., 
2 H), 3.30 - 3.42 (m, 2 H), 2.88 - 3.18 (m, 5 H), 2.78 (br. s., 2 H), 1.38 (br. s., 4 H), 1.17 - 1.31 
(m, 27 H), 1.14 (d, J = 5.9 Hz, 3 H), 0.96 (d, J = 7.4 Hz, 3 H), 0.85 (t, J = 6.7 Hz, 4 H), 0.56 (br. 







































Scheme 2.4. Synthesis of C18-Cbl-COL. 2e was synthesized as previously reported28 2c (63 
mg, 37 µmol, mw = 1681), HBTU (10 mg, 26 µmol, mw = 379), and DIPEA (15 µL, 86 µmol) 
were dissolved in 2 mL of DMF and stirred for 5 min. 2e (10 mg, 28 µmol, mw = 1386) was 





C18-Cbl-COL was purified on a 5 µm, 250 x 21.2 mm, Viva C4 preparative column using 
a H2O:CH3CN, 0.1% TFA, gradient (elution time 35 min, Table 2.6). Orange solid, 43% yield.  
ESI MS calculated for C105H153CoN15O21P + 2H+ (M2+): m/z = 1026.0295, found 
1026.0299. 
1 H NMR (DMSO-d6 ,400 MHz): δ = 8.23 (d, J = 7.4 Hz, 1 H), 7.78 (br. s., 1 H), 7.49 - 
7.70 (m, 3 H), 7.42 (br. s., 1 H), 7.35 (br. s., 2 H), 7.13 - 7.26 (m, 2 H), 7.02 - 7.13 (m, 3 H), 6.93 
- 7.02 (m, 2 H), 6.88 (d, J = 7.4 Hz, 2 H), 6.77 (s, 2 H), 6.59 (br. s., 1 H), 6.13 - 6.35 (m, 3 H), 
4.71 (dd, J = 11.2, 6.5 Hz, 2 H), 4.23 - 4.41 (m, 6 H), 4.14 (dd, J = 17.8, 6.8 Hz, 3 H), 4.04 (d, J 
= 7.0 Hz, 3 H), 3.88 (d, J = 4.3 Hz, 3 H), 3.79 (s, 2 H), 3.61 (br. s., 1 H), 3.46 - 3.53 (m, 7 H), 
3.30 - 3.43 (m, 2 H), 3.14 - 3.21 (m, 1 H), 3.00 - 3.13 (m, 2 H), 2.96 (d, J = 5.9 Hz, 2 H), 2.75 (s, 
1 H), 2.31 - 2.41 (m, 5 H), 2.20 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.73 - 1.95 (m, 6 H), 1.59 - 1.71 
(m, 5 H), 1.32 - 1.46 (m, 4 H), 1.17 - 1.31 (m, 25 H), 1.05 - 1.16 (m, 6 H), 0.81 - 0.90 (m, 3 H), 
































Scheme 2.5. Synthesis of C18-Cbl-DEX. 2f was synthesized as previously reported29. 2f (6 mg, 
12 µmol), HBTU (5 mg, 12 µmol), and DIPEA (10 µL, 57 µmol) were dissolved in 1 mL of DMF 









C18-Cbl-DEX was purified on a 5 µm 250 x 21.2 mm a Viva C4 preparative column using 
a H2O:CH3CN, 0.1% TFA gradient (elution time 62 min, Table 2.5.). Orange solid, 70% yield.  
ESI MS calculated for C110H164CoFN15O22P + 2H+ (M2+): m/z = 1079.0693, found 
1079.0707. 
1 H NMR (DMSO-d6 ,400 MHz): δ = 8.09 - 8.20 (m, 2 H), 8.02 - 8.07 (m, J = 5.1 Hz, 1 
H), 7.92 (s, 1 H), 7.78 (s, 2 H), 7.60 - 7.69 (m, 2 H), 7.47 - 7.59 (m, 3 H), 7.21 - 7.37 (m, 4 H), 
7.09 - 7.20 (m, 3 H), 6.94 (br. s., 2 H), 6.77 (br. s., 3 H), 6.58 (br. s., 1 H), 6.22 (dd, J = 10.2, 2.0 
Hz, 2 H), 6.08 - 6.16 (m, 2 H), 6.01 (s, 1 H), 5.38 (d, J = 4.3 Hz, 1 H), 5.14 (s, 1 H), 5.04 (br. s., 
1 H), 4.99 (s, 1 H), 4.76 (br. s., 1 H), 4.66 - S-4 4.74 (m, 2 H), 4.20 - 4.34 (m, 4 H), 4.07 - 4.19 
(m, 3 H), 4.03 - 4.07 (m, 1 H), 3.96 - 4.02 (m, 2 H), 3.80 - 3.89 (m, 2 H), 3.64 - 3.71 (m, 2 H), 
3.54 - 3.60 (m, 3 H), 3.05 - 3.21 (m, 6 H), 2.92 - 3.04 (m, 4 H), 2.40 - 2.47 (m, 5 H), 2.38 (br. s., 
2 H), 2.16 - 2.24 (m, 5 H), 1.65 - 1.84 (m, 7 H), 1.48 (s, 5 H), 1.38 (br. s., 4 H), 1.23 (s, 27 H), 
1.15 (d, J = 6.3 Hz, 2 H), 0.97 - 1.11 (m, 4 H), 0.85 (t, J = 7.3 Hz, 3 H), 0.78 (d, J = 7.4 Hz, 2 H), 





















Figure 2.35. LC-MS UV/Vis chromatograms of purified C18-Cbl-drugs. (a) C18-Cbl-MTX 
monitored at 300 nm (b) C18-Cbl-COL monitored at 365 nm and (c) C18-Cbl-DEX monitored at 






























Scheme 2.6. Synthesis of C18-Cbl-TAM. TAM (5 mg, 12 µmol), HBTU (4.5 mg, 12 µmol), and 
DIPEA (8.3 µL, 48 µmol) were dissolved in 5 mL of DMF and stirred for 5 min. 2b (20 mg, 12 
µmol) was added and the solution stirred overnight. C18-Cbl-TAM was purified on a 5 µm 250 x 
21.2 mm a Viva C4 preparative column using a H2O:CH3CN, 0.1% TFA gradient (elution time 46 













ESI MS calculated for C109H154CoN17O19P+ + 1H+ (M2+): m/z = 1048.0377, found 
1048.0386. 
1 H NMR (DMSO-d6,400 MHz): δ = 8.56 - 8.63 (m, 1 H), 8.42 - 8.47 (m, 1 H), 8.01 - 8.06 
(m, 1 H), 7.95 - 8.00 (m, 1 H), 7.74 - 7.81 (m, 1 H), 7.65 - 7.70 (m, 1 H), 7.53 (br. s., 3 H), 7.32 - 
7.36 (m, 1 H), 7.24 - 7.29 (m, 1 H), 7.03 - 7.21 (m, 4 H), 6.96 (br. s., 4 H), 6.73 - 6.81 (m, 2 H), 
6.54 - 6.60 (m, 1 H), 6.19 - 6.26 (m, 1 H), 6.09 - 6.17 (m, 1 H), 4.66 - 4.74 (m, 1 H), 4.13 - 4.39 
(m, 5 H), 3.96 - 4.08 (m, 2 H), 3.51 (s, 4 H), 3.27 (br. s., 5 H), 2.43 (br. s., 2 H), 2.30 - 2.36 (m, 2 
H), 2.16 - 2.27 (m, 5 H), 2.05 - 2.09 (m, 2 H), 1.70 (br. s., 3 H), 1.37 (br. s., 3 H), 1.18 - 1.31 (m, 
28 H), 1.15 (d, J = 6.3 Hz, 2 H), 1.03 (br. s., 1 H), 0.85 (t, J = 6.8 Hz, 3 H), 0.47 (br. s., 3 H), 











Scheme 2.7. Synthesis of C18-Cbl-FAM. 5-carboxyfluorecein (5-FAM, 5 mg, 12 µmol), O-
(Nsuccinimidyl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TSTU, 3.6 mg, 12 µmol), and 
DIPEA (8.3 µL, 48 µmol) were dissolved in 5 mL of DMF and stirred for 5 min. 2b (20 mg, 12 
µmol) was added and the solution stirred overnight. C18-Cbl-FAM was purified on a 5 µm 250 x 
21.2 mm a Viva C4 preparative column using a H2O:CH3CN, 0.1% TFA gradient (elution time 46 
min, Table 2.5.). Orange solid, 90% yield.  
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ESI MS calculated for C105H143CoN15O21P + 2H+ (M2+): m/z = 1020.9905, found 
1021.9900. 
 1 H NMR (DMSO-d6, 400 MHz): δ = 8.53 (br. s., 1 H), 8.18 (s, 1 H), 7.99 (d, J = 7.8 Hz, 
1 H), 7.79 (br. s., 1 H), 7.48 - 7.69 (m, 5 H), 7.28 - 7.46 (m, 5 H), 7.08 - 7.21 (m, 3 H), 6.96 (br. 
s., 2 H), 6.87 (br. s., 2 H), 6.78 (br. s., 2 H), 6.67 - 6.71 (m, 2 H), 6.50 - 6.63 (m, 5 H), 6.31 (br. 
s., 3 H), 4.71 (dd, J = 11.2, 6.5 Hz, 3 H), 4.24 - 4.42 (m, 7 H), 4.00 - 4.16 (m, 4 H), 3.73 (br. s., 2 
H), 3.36 (d, J = 7.0 Hz, 2 H), 3.17 (br. s., 2 H), 3.02 - 3.11 (m, 2 H), 2.91 - 3.01 (m, 3 H), 2.69 - 
2.85 (m, 4 H), 2.32 - 2.41 (m, 7 H), 2.21 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.72 - 1.97 (m, 9 H), 1.69 
(br. s., 3 H), 1.33 - 1.44 (m, 6 H), 1.26 (br. s., 5 H), 1.22 (s, 27 H), 1.14 (d, J = 6.3 Hz, 2 H), 0.94 
(s, 2 H), 0.85 (t, J=6.7 Hz, 3 H), 0.57 (br. s., 3 H), 0.29 - 0.40 (m, 1 H), 0.13 - 0.28 (m, 2 H), -

































C18-Cbl-MTX, C18-Cbl-DEX, C18-Cbl-COL, C18-Cbl-TAM, and C18-Cbl-FAM were purified. 


















0.01 10.00 90.0 10.0 
10.00 10.00 90.0 10.0 
30.00 10.00 45.0 55.0 
45.00 10.00 35.0 65.0 
60.00 10.00 25.0 75.0 
65.00 10.00 0.0 100.0 
75.00 10.00 0.0 100.0 
80.00 10.00 90.0 10.0 
90.00 10.00 90.0 10.0 
91.00 0.00 90.0 10.0 
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Synthesis of C18-AF700. Alexa Fluor 700 N-hydroxysuccinimide (NHS) ester (1 mg, 1 
µmol), DIPEA (5 µL, 29 µmol), and octadecylamine (5 mg, 19 µmol) were dissolved in 500 µL 
DMF and mixed by agitation overnight. The resulting mixture was added to 5 mL H2O:CH2Cl2 
mixture (5:1). The CH2Cl2 layer was washed three times with 4 mL H2O, the CH2Cl2 removed 
under reduced pressure and the product purified by flash chromatography silica column (30 g) 
80 using a binary solvent system (A: CH2Cl2, B: MeOH) with an initial A:B ratio of 100:0, 
gradually increasing to 80:20. The purified lipidated fluorophore was concentrated by rotary 
evaporation. Note: the structure of AF700 has not been released. 



























Scheme 2.8. Synthesis of C18-C5 and C18-Cy7.  
C18-Cy5: Cy5 (6.2 mg, 12.8 µmol) and diisopropylcarbodiimide (DIC, 2.5 mg, 19.2 µmol) 
were dissolved in CH2Cl2 (320 µL) and mixed for 5 min. A solution of ODA (6.9 mg) in 
chloroform (100 µL) was then added and the solution was allowed to react for 1 h. The solution 
was diluted with additional CH2Cl2 (2 mL) and purified via silica gel elution using a binary solvent 
system (A: CH2Cl2, B: MeOH) with an initial A:B ratio of 90:10, gradually increasing to 1:4. 
Removal of solvent by rotary evaporation yielded a blue-viscous oil (74%, calculated from 
absorption, λmax: 646 nm).  
ESI MS calculated for C50H76N3O+ (M1+): m/z = 734.5988, found 734.5983.  
1 H NMR (CD2Cl2, 400 MHz): δ = 7.85 - 7.95 (m, 2 H), 7.37 - 7.46 (m, 4 H), 7.28 (q, J = 
7.3 Hz, 2 H), 7.11 - 7.18 (m, 2 H), 6.63 (t, J = 12.5 Hz, 1 H), 6.12 - 6.25 (m, 2 H), 4.01 (t, J = 7.6 
Hz, 2 H), 3.57 (s, 3 H), 3.12 - 3.21 (m, 2 H), 2.20 (t, J = 7.0 Hz, 2 H), 1.84 (br m, 6 H), 1.70 (s, 







C18-Cy7: Cy7 (5.0 mg, 9.8 µmol) was coupled to ODA as described for C18-Cy5. Silica 
gel chromatography afforded a blue-green oil (95.2%, calculated from absorption, λmax: 760 nm).    
 ESI MS calculated for C52H78N3O+ (M1+): m/z =760.6145, found 760.6324. 
1 H NMR (CD2Cl2, 400 MHz): δ = 7.69 - 7.83 (m, 2 H), 7.35 - 7.45 (m, 4 H), 7.26 (m, 2 
H), 7.14 (d, J = 7.8 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 6.45 - 6.63 (m, 2 H), 6.19 (d, J = 13.7 Hz, 
1 H), 6.08 (br m, 2 H), 3.95 - 4.03 (m, 2 H), 3.52 (s, 2 H), 3.17 (d, J = 6.3 Hz, 2 H), 2.19 (t, J = 
7.2 Hz, 2 H), 1.67 - 1.82 (br m, 21 H), 1.44 - 1.52 (br m, 4 H), 1.22 - 1.34 (m, 26 H), 0.88 (t, J = 



















Figure 2.36. LC-MS UV/Vis chromatogram of purified C18-Cy5. C18-Cy5 was collected using a 






















Figure 2.37. LC-MS UV/Vis chromatogram of purified C18-Cy7. C18-Cy7 was collected using a 




















Scheme 2.9. Synthesis of DY800 fluorophore. 
Cl-DY800: N-(5-carboxypentyl)-2,3,3-trimethyl indolium-5-sulfonate (300 mg, 850 µmol) 
and 3-chloro-2,4-trimethyleneglutacondianil hydrochloride (305 mg, 850 µmol) were refluxed in 
a solution of acetic acid/acetic anhydride (4 mL, 1:1 ratio) for 2 h. The solvent was then 
removed under reduced pressure and the residue re-dissolved in a mixture of pyridine and 
acetic acid (4 mL, 1:1 ratio). N-(3-sulfopropyl)-2,3,3-trimethyl indolium-5-sulfonate (325 mg, 850 
µmol) was added and the solution was heated to 80 °C for 1 h. The product was then 
precipitated and washed 3x with ethyl acetate (100 mL). The blue precipitate was dissolved in 
water and eluted on a Biotage KP-C18-HS column using a binary solvent A:B solvent system 
(A: H2O 0.1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was gradually increased from an 
initial ratio of 19:1 to 2:3. Removal of the solvent by lyophilization yielded a green solid (180 mg, 








ESI MS calculated for C39H45ClN2O11S32- + 3H+ (M1+): m/z = 851.2109, found 851.2115. 
1 H NMR (DMSO-d6, 400 MHz): δ = 8.25 (dd, J = 16.8 Hz, 14.5 Hz, 2 H), 7.79 S-6 (d, J 
= 9.0 Hz, 2 H), 7.64 - 7.69 (m, 2 H), 7.47 (d, J = 8.6 Hz, 1 H), 7.36 (d, J = 8.2 Hz, 1 H), 6.59 (d, J 
= 14.1 Hz, 1 H), 6.30 (d, J = 14.1 Hz, 1 H), 4.39 (br s, 2 H), 4.18 (br s, 2H), 2.67 - 2.79 (m, 4 H), 
2.64 (t, J = 6.6 Hz, 2 H), 2.20 (t, 7.1 Hz, 2 H), 1.98 - 2.09 (br m, 2 H), 1.79 - 1.89 (br m, 2 H), 
1.78 - 1.62 (m, 12 H), 1.61 - 1.48 (m, 3 H), 1.31 - 1.44 (m, 3 H).  
DY800: Chloro-DY800 (100 mg, 120 µmol) was dissolved in anhydrous DMF (18 mL) to 
which a solution of sodium phenoxide (139 mg, 1.2 mmol) in DMF (1mL) was added. The 
solution was stirred for 1 h, and then poured into a vigorously stirring solution of diethyl ether 
(250 mL). The precipitate was collected and then purified with a Biotage KP-C18-HS column 
using a binary solvent A:B solvent system (A: H2O 0.1 v/v% TFA, B: CH3CN .1 v/v% TFA). The 
A:B ratio was gradually increased from an initial ratio of 19:1 to 2:3. Lyophilization provided the 
product as a green solid (86 mg, 79% yield, λmax: 774 nm).  
ESI MS calculated for C45H50N2O12S32- + 3H+ (M1+): m/z = 909.2761, found 909.2764. 
1 H NMR (DMSO-d6,400 MHz): d = 7.74 - 7.88 (m, 3 H), 7.56 - 7.65 (m, 3 H), 7.38 - 7.46 
(m, 3 H), 7.25 (d, J = 8.2 Hz, 1 H), 7.16 (d, J = 8.2 Hz, 2 H), 7.05 (t, J = 7.2 Hz, 1 H), 6.49 (d, J = 
14.5 Hz, 1 H), 6.13 (d, J = 14.1 Hz, 1 H), 4.33 (br s, 2 H), 4.08 (br s, 2 H), 2.68 - 2.80 (m, 4 H), 
2.56 (t, J = 6.5 Hz, 2 H), 2.19 (t, J = 7.2 Hz, 2 H), 1.88 - 2.02 (m, 4 H), 1.61 - 1.73 (m, 3 H), 1.50 

























Figure 2.38. LC-MS UV/Vis chromatograms of purified chloro-DY800. Chloro-DY800 was 
collected with a reverse phase C18 at (a) 300 nm and (b) 600 nm. DY800 is also shown with 
























Scheme 2.10. Synthesis of C18-DY800.  
DY800 (2.0 mg, 2.2 µmol) and HCTU (1.4 mg, 3.3 µmol) were dissolved in anhydrous 
DMF (500 µL) and allowed to react for 5 min. A 500 µL solution of ODA in chloroform (1 mg/mL) 
was added and the solution mixed for 1 h. The product was extracted into aqueous solution by 
washing of the organic solution with water (2 x 1 mL). The aqueous phase was then purified by 
HPLC using a stationary C4 phase with a A:B solvent system (A: H2O 0.1 v/v% TFA, B: CH3CN 
0.1 v/v% TFA). The A:B ratio was gradually increased from 10:1 to 1:19. The solvent was 








ESI MS calculated for C63H87N3O11S32- + 3H+ (M1+): m/z = 1160.5737, found 1160.5738. 
1 H NMR (DMSO-d6,400M Hz): δ = 7.72 - 7.87 (m, 3 H), 7.56 - 7.65 (m, 3 H), 7.37 - 7.45 
(m, 3 H), 7.19 - 7.26 (m, 1 H), 7.12 - 7.18 (m, 2 H), 7.02 - 7.09 (m, 1 H), 6.50 (d, J = 14.2 Hz, 1 
H), 6.12 (d, J = 14.5 Hz, 1 H), 4.29 - 4.37 (m, 2 H), 4.02 - 4.11 (m, 2 H), 2.98 (dd, J = 12.7, 6.8 
Hz, 3 H), 2.74 - 2.80 (m, 2 H), 2.65 - 2.74 (m, 2 H), 2.31 - 2.35 (m, 2 H), 2.02 (t, J = 7.4 Hz, 3 H), 
1.89 - 1.99 (m, 4 H), 1.60 - 1.72 (m, 3 H), 1.47 - 1.58 (m, 3 H), 1.26 - 1.40 (m, 12 H), 1.22 (s, 30 





























Figure 2.39. LC-MS UV/Vis chromatogram of purified C18-DY800. C18-DY800 was collected 
using a reverse phase C18 column and monitored at (a) 300 nm and (b) 600 nm. Water was 
used as the loading solvent. 
 










Gradient was performed using a Viva C4 column (5 µm, 50 mm x 2.1 mm). Product 












0 1 90 10 
1 1 90 10 
7 1 5 95 
8 1 0 100 
10 1 0 100 
11 1 90 10 












Gradient was performed using an Agilent Eclipse Plus C18 column (3.5 µm, 4.6 mm x 

























0 1 97 3 
5 1 97 3 
18 1 3 97 
20 1 3 97 
24 1 97 3 
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MTX LC-MS Assay. The following experiments were analyzed using the MTX LC-MS Assay: 
Octanol/Water Partition MTX, RBC Drug Loading Capacity, and MTX Photolysis from 
Erythrocyte Membranes. Samples of 75 µL were injected onto a 1200 series Agilent HPLC with 
a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 quadrupole mass spectrometer 
from a 384 well plate. The mobile phase consisted of S-7 H2O:CH3CN 0.1% FA (Formic Acid) 
(gradient provided in Table 2.8). The column used was a Viva C4 analytical column 5 µm, 50 x 
21.2 mm from Restek. Concentrations were determined by taking the area under UV 
absorbance trace at 300 nm from 3.1 - 3.7 min where the C18-Cbl-MTX cleavage products were 
shown to elute and this integration was compared to known standards (Figure 2.10). 
Spectrofluorimetry (λex: 365 nm λem: 470 nm) was used to detect the possible presence of MTX 
by-products due to light degradation32 (none were observed), undamaged MTX is non-
fluorescent. 
COL LC-MS Assay. The following experiments were analyzed using the COL LC-MS Assay: 
RBC Drug Loading Capacity Samples and Photo-release of COL and DEX from C18-Cbl-COL- 
and C18-Cbl-DEX-embedded Erythrocytes. Samples of 75 µL were injected onto a 1200 series 
Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 quadrupole 
mass spectrometer from a 384 well plate. The mobile phase consisted of H2O:CH3CN (0.1% 
FA) (gradient provided in Table 2.8). The column used was a Viva C4 analytical column 5 µm, 
50 x 21.2 mm. Concentrations were determined by taking the area under UV absorbance trace 
at 365 nm from 4.3 - 4.8 min where the C18-Cbl-COL cleavage products were shown to elute 
and this integration was compared to known standards (Figure 2.10). LC gradient is given in the 






DEX LC-MS Assay. The following experiments were analyzed using the DEX LC-MS Assay: 
RBC Drug Loading Capacity Samples and Photo-release of COL and DEX from C18-Cbl-COL- 
and C18-Cbl-DEX-embedded Erythrocytes. Samples of no less than 120 µL were boiled for 10 
min to denature and precipitate any protein and lipids present in the erythrocyte samples. 
Protein was then pelleted by centrifugation at 21,000 g. Samples of 75 µL were injected onto a 
1200 series Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 
quadrupole mass spectrometer from a 384 well plate. The mobile phase consisted of 
H2O:CH3CN (0.1% FA) (gradient provided in Table 2.8). The column used was a Viva C4 
analytical column 5 µm, 50 x 21.2 mm. Concentrations were determined by taking the area 
under UV absorbance trace at 239 nm from 4.5 - 4.9 min (if erythrocytes were present in the 
experiment) where DEX was shown to elute. If no RBCs were present, integration occurred from 
















Table 2.8. The solvent gradient used for analytical MTX, COL, and DEX LC-MS assays. All 

































0 1 97 3 
1 1 97 3 
8 1 20 80 
10 1 20 80 
11 1 97 3 
15 1 97 3 
145 
  
Octanol/Water Partition MTX. Octanol (100 µL) containing C18-Cbl-MTX (5 µM) was thoroughly 
mixed with PBS (500 µL) in a 1.5 mL clear centrifuge tube and allowed to equilibrate for 30 min 
in the dark before undergoing centrifugation for 10 min at 21,000 g. Samples were photolyzed 
with a 525 nm LED for 0 min, 1 min, 2 min, 5 min, 10 min, and 20 min before being mixed by 
shaking and allowed to equilibrate for 15 min. This was followed by a 10 min centrifugation at 
21,000 g. The octanol layer was removed and 100 µL aliquots were taken from the remaining 
aqueous layer and loaded onto a 384 well plate. The concentration of MTX was determined by 
the MTX LC-MS assay. 
Octanol/Water Partition TAM. Octanol (100 µL) containing the C18-Cbl-TAM (10 µM) was 
thoroughly mixed with PBS (300 µL) in a 1.5 mL clear centrifuge tube and allowed to equilibrate 
for 30 min in the dark before undergoing centrifugation for 10 min at 21,000 g in a quartz 
fluorescence cuvette with a 200 µL viewing window. The fluorescence of the aqueous layer was 
measured using a PTI Model 710 LPS-220 (ʎex: 555 nm ʎem: 570 - 600 nm). The solution was 
transferred to a clear 1.5 mL centrifuge tube and photolyzed using a 525 nm centered LED 
array for 0 min, 1 min, 2 min, 3 min, and 10 min. The solutions were transferred back to the 
cuvette for 10 min centrifugation at 21,000 g and the fluorescence was measured again. All 
samples were measured in triplicate. 
Erythrocyte Storage. Erythrocytes were washed 3x with RBC buffer (PBS, 1 mM MgCl2) and 
diluted to 10% hematocrit. Erythrocytes were stored for no more than one month at 4 °C. 
Erythrocyte Loading Procedure. Lipidated compounds were added at various loading 
concentrations to erythrocytes (10% hematocrit). The erythrocytes were then incubated at RT 
for 20 min and subsequently washed 3x and stored at 10% hematocrit in RBC buffer. RBCs 





Widefield Microscopy with Cbl-TAM Loaded Erythrocytes. 10% hematocrit erythrocytes 
were loaded with 10 µM C18-Cbl-TAM using the Erythrocyte Loading Procedure. 2 µL of loaded 
erythrocytes were then added to 200 µL RBC buffer and imaged using widefield microscopy. 
Images were taken using 20 µs exposure times and a Cy3 filter cube 333 ms apart. 
Hemolysis Assay. To a 1.5 mL Eppendorf tube containing 100 µL of a Cbl drug conjugate (C18-
Cbl-MTX, C18-Cbl-COL, or C18-Cbl-DEX) in PBS at various concentrations (5 µM, 10 µM, 20 µM, 
and 40 µM) was added 100 µL RBCs in RBC buffer (10% hematocrit). Two controls were 
performed: 100 µL of RBCs treated with PBS buffer and RBCs treated with SDS (100% 
hemolysis). Final concentrations were 0.05% SDS; 0 µM, 2.5 µM, 5 µM, 10 µM, and 20 µM 
lipidated complex. Cells were mixed by flicking before centrifugation at 300 g for 30 min. 
Samples were rehomogenized and allowed to incubate at 4 °C overnight. Samples were 
pelleted at 1000 g for 5 min. 150 µL of the supernatant was plated in a 96 well plate and 
analyzed at 550 nm by UV Vis. SDS samples were diluted 10-fold in order to accurately 
measure heme concentration. SDS absorbance multiplied by 10 was considered to be complete 
hemolysis and PBS treated blood was considered to be completely intact and the absorbance 
from those samples was subtracted from the background of the rest. 
% Hemolysis =  
sample absorbance
100% Abs of Lysate*10
*100% 
RBC Drug Loading Capacity. 10% hematocrit RBCs were loaded with varying concentrations 
of C18-Cbl-MTX, C18-Cbl-COL, and C18-Cbl-DEX using the Erythrocyte Loading Procedure. C18-
Cbl-MTX was loaded at 6 µM, 4 µM, 2 µM, and 1 µM. C18- Cbl-COL was loaded at 10 µM, 8 µM, 
6 µM, 4 µM, and 2 µM. The cells were diluted to 5% hematocrit and photolyzed for 2 h using a 
board containing 525 nm centered LEDs. The cells were then spun down at 1000 g. 




Dihydrofolate Reductase (DHFR) Inhibition Assay. DHFR activity was monitored using the 
Sigma Dihydrofolate Reductase Assay Kit. This kit was used to monitor conversion of NADPH 
to nicotinamide adenine dinucleotide phosphate (NADP+). Briefly, assay buffer was prepared 
containing 1.5 mU DHFR, 100 µM NADPH, and 1x assay buffer (provided with kit). Inhibition of 
DHFR activity at various MTX concentrations or various photolyzed C18-Cbl-MTX concentrations 
(100 nM - 5 µM) was monitored using a fluorescent plate reader (λex: 340 nm λem: 450 nm). 
Treatment of HeLa Cells with COL. HeLa cells were plated in a 6-well glass bottom plate 
(Mattek) at a density of 1.5 x 105 cells per well and maintained at 37 ºC in a humidity-controlled 
incubator with a 5% CO2 atmosphere in Dulbecco's Modified Eagle's medium (DMEM) (10% 
FBS, 1% PenStrep). The following day, cells were treated with COL (Sigma C9754; 1 mM stock 
in DMSO) or DMSO for either 30 min or 1 h at 37 ºC in a humidity-controlled incubator. At the 
conclusion of the incubation period, cells were fixed with 1 mL of methanol at room temperature 
for 10 min. Cells were washed 2 x 1 mL with PBS and blocked for 1 h in 5% donkey serum. 
Blocking was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell 
Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Cells were then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 
secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and a 








Treatment of HeLa Cells with C18-Cbl-COL-Loaded RBCs. HeLa cells were plated in 24-well 
glass bottom plates (Mattek) at a density of 3.3 x 104 cells per well and maintained at 37 ºC in a 
humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). 
The following day, cells were washed 2x with PBS, followed by the addition of 100 µL of L-15 
media. Cells were then treated with 250 µL of a suspension of C18-Cbl-COL loaded erythrocytes 
in PBS (6 µM loading concentration at 5% hematocrit) or 250 µL PBS (control cells). Cells were 
then either kept in the dark at 37 ºC in a humidity-controlled incubator or exposed to 530 nm 
LED flood light (PAR38; 500 - 570 nm emission; 5 mW power) for 5, 10, or 20 min at room 
temperature. All cells incubated for 1 h in a 37 ºC in a humidity-controlled incubator post-
photolysis. At the conclusion of the incubation period, cells were washed 3 x 1 mL with PBS and 
then fixed with 1 mL of methanol at room temperature for 10 min. Cells were washed 2 x 1 mL 
with PBS and blocked for 1 h in 5% Donkey Serum. Blocking was followed by overnight 
incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in 
antibody dilution buffer (1% bovine serum albumin (BSA); 0.3% Triton-X-100; PBS). Cells were 
then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 secondary 
antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. After washing 
cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and a FITC filter 









Treatment of HeLa Cells with DEX. HeLa cells were plated in a 6-well glass bottom plate 
(Mattek) at a density of 7.5 x 104 cells per well and maintained at 37 ºC in a humidity-controlled 
incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% PenStrep). The following day, 
cells were treated with varying concentrations of DEX (1 mM stock in DMSO) or DMSO for 1 h 
at 37 ºC in a humidity-controlled incubator. At the conclusion of the incubation period, cells were 
fixed with 4% PFA in PBS for 10 min at room temperature, then washed 1x with PBS, and then 
treated with 1 mL of methanol at room temperature for 5 min. Cells were washed 2 x 1 mL with 
PBS and subsequently incubated overnight at 4 ºC with rabbit anti-GRα antibody (abcam 3580) 
at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then 
washed with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary 
antibody (Life Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room 
temperature. Cells were washed with PBS (3 x 5 min) and Hoescht 33342 (100 µg/mL in PBS) 
applied for 30 min before an additional wash with PBS. Images were subsequently acquired 
with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 40X 
phase contrast objective and a FITC filter cube (Semrock). Metamorph software was employed 












Treatment of HeLa Cells with C18-Cbl-DEX Loaded RBCs. HeLa cells were plated in 12-well 
glass bottom plates (Mattek) at a density of 2.5 x 104 cells per well and maintained at 37 ºC in a 
humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). 
The following day, cells were washed 2x with PBS, then treated with 500 µL of a suspension of 
C18-Cbl-DEX loaded red blood cells in L-15 media (1 µM loading concentration at 5% 
hematocrit) or 500 µL L-15 (control cells). Cells were then either kept in the dark at 37 ºC in a 
humidity-controlled incubator or exposed to 530 nm LED flood light (PAR38; 500 – 570 nm 
emission; 5 mW power) for 10, 20, or 30 min at room temperature. All cells incubated for 1 h in 
a 37 ºC in a humidity-controlled incubator post-photolysis. At the conclusion of the incubation 
period, cells were washed 3 x 1 mL with PBS and then fixed with 4% paraformaldehyde (PFA) 
in PBS for 10 min at room temperature, then washed 1x with PBS and treated with 1 mL of 
methanol at room temperature for 5 min. Cells were subsequently washed 2 x 1 mL with PBS 
and then incubated overnight at 4 ºC with rabbit anti-GRα antibody (abcam 3580) at 1:100 S-11 
dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Next, cells were washed 
with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary antibody (Life 
Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. 
Cells were finally washed with PBS (3 x 5 min). Images were subsequently acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 40X phase 









Photolytic Release of TAM and FAM from C18-Cbl-TAM and C18-Cbl-FAM Embedded 
Erythrocytes. Erythrocytes were taken from 10% hematocrit stock solutions. RBCs were 
loaded with 1 µM C18-Cbl-TAM or C18-Cbl-FAM as described in the Erythrocyte Loading 
Procedure. For those experiments requiring lipidated fluorophores, 5 µM were also loaded from 
stock solutions in DMSO. Erythrocytes were resuspended to 10% hematocrit and exposed to 
LEDs centered at varying wavelengths for set time points. After photolysis, the erythrocyte 
solution was centrifuged at 1,000 g and the supernatant was analyzed for TAM (λex: 550 nm λem: 




















Cbl-DEX Light Independent Translocation Test. HeLa cells were plated in 6 well glass 
bottom plates (Mattek) at a density of 8.8 x 104 cells per well and maintained at 37 ºC in a 
humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). 
The following day, cells were washed 2x with PBS, then treated with 250 µL of a suspension of 
C18-Cbl-DEX loaded erythrocytes in L-15 media (1 µM loading concentration at 5% hematocrit) 
or 250 µL L-15 (control cells). HeLa cells were then incubated in the dark for 1 h at 37 ºC in a 
humidity-controlled incubator. After the 1 h pre-incubation, HeLa cells were washed 3 x 1 mL 
with PBS (dark room; red safe light) to remove the erythrocytes and 2 mL of L-15 added to each 
well. The washed HeLa cells were then exposed to a green LED light source (PAR38; 500 – 
570 nm emission; 5 mW power) or kept in the dark for 15 min at room temperature. All cells 
were incubated for 1 h in a 37 ºC in a humidity-controlled incubator post-photolysis. At the 
conclusion of the second incubation period, cells were washed 3 x 1 mL with PBS and then 
fixed with 4% PFA in PBS for 10 min at room temperature, then washed 1x with PBS and 
treated with 1 mL of methanol at room temperature for 5 min. Cells were subsequently washed 
2 x 1 mL with PBS and then incubated overnight at 4 ºC with rabbit anti-GRα antibody (abcam 
3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Next, cells 
were washed with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary 
antibody (Life Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room 
temperature. Cells were finally washed with PBS (3 x 5 min). Images were subsequently 
acquired with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 
camera, 40X phase contrast objective and a FITC filter cube (Semrock). Metamorph software 






Assessment of the C18-Cbl-TAM:C18-Cy5 Ratio for Optimal TAM Release. To 10% 
hematocrit erythrocytes, various concentrations of C18-Cbl-TAM (0 to 10 µM) and various 
concentrations of C18-Cy5 were added (0 to 20 µM). Erythrocytes were photolyzed using the 
660 nm LED board for 30 min. After photolysis, erythrocytes were spun down at 1,000 g for 3 
min and the supernatant was analyzed for TAM (λex: 550 nm λem: 580 nm) release using a 










Light Power Measurements. All light measurements were recorded with a Coherent Field Max 
II detector. Each measurement is reported as the average of 13 readings and the error is 
reported as the standard deviation. The light was measured in a fashion consistent with 
photolytic release of drugs erythrocytes. 
Confocal Images of Erythrocytes Loaded with C18-Cy5. C18-Cy5 was loaded onto 
erythrocytes (10% hematocrit) at a concentration of 5 µM using the Erythrocyte Loading 
Procedure. 2 µL of loaded erythrocytes were then added to 200 µL RBC buffer and imaged 
using confocal microscopy. Images were taken using 4% laser power, and 10 µs/pixel in line 
scan mode with a 635 nm laser. 
MTX Photolysis from Erythrocyte Membranes. C18-Cbl-MTX and either C18-Cy5, C18-AF700, 
C18-Cy7, C18-DY800 were loaded onto erythrocytes according to the Erythrocyte Loading 
Procedure using a concentration of 1 µM (C18-Cbl-MTX) and 5 µM (C18-fluorophore), 
respectively. After loading, erythrocytes were resuspended to 5% hematocrit and exposed to 
660 nm, 725 nm, or 780 nm centered LEDs for 30 min. Other loaded erythrocytes were 
photolyzed for 2 h using 525 nm LEDs to free all bound MTX to assess the total amount of drug 
loaded. After photolysis, the erythrocyte solution was centrifuged at 1,000 g and the supernatant 
analyzed for MTX using the MTX LC-MS assay. 
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Photo-release of COL and DEX from C18-Cbl-COL- and C18-Cbl-DEX-loaded Erythrocytes. 
C18-Cbl-COL (5 µM) or C18-Cbl-DEX (0.5 µM) were loaded with either C18-DY800 or C18-Cy5 
fluorophore according to the Erythrocyte Loading Procedure. C18-DY800 was added to a final 
concentration of 5 and 2.5 µM for C18-Cbl-COL and C18-Cbl-DEX erythrocytes, respectively. C18-
Cy5 was added to a final concentration of 25 and 2.5 µM for C18-Cbl-COL and C18-Cbl-DEX 
erythrocytes, respectively. Erythrocytes were resuspended to 5% hematocrit. The C18-DY800 
samples were exposed to 525 nm for 2 h or 780 nm for 0 and 30 min and the C18-Cy5-
containing samples were exposed to 525 nm and 660 nm in similar fashion. After photolysis, the 
erythrocyte solution was centrifuged at 1,000 g and the supernatant analyzed for COL or DEX 


















Treatment of HeLa Cells with C18-Cbl-DEX/C18-Cy5-loaded Erythrocytes. HeLa cells were 
plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, the HeLa cells were washed 3x with PBS, then 
treated with 200 µL of a suspension of C18-Cbl-DEX/C18-Cy5 (0.5 µM/2.5 µM) loaded 
erythrocytes in L-15 media (5% hematocrit) or 200 µL L-15 (control cells). Samples were either 
kept in the dark or exposed to a 660 nm LED array for 10, 20, or 30 min using the appropriate 
filter sets. All samples were placed in a 37 ºC in a humidity-controlled incubator post-photolysis 
until harvest 1 h after the end of the last photolysis interval. HeLa cells were washed 3 x 1 mL 
with PBS and then fixed with 4% PFA in PBS for 10 min at room temperature, then washed 1x 
with PBS and treated with 1 mL of methanol at room temperature for 5 min. Cells were 
subsequently washed 2 x 1 mL with PBS and then incubated overnight at 4 ºC with rabbit anti-
GRα antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-
X-100; PBS). Next, cells were washed with PBS (3 x 5 min) before incubation with anti-rabbit 
AlexaFluor 488 secondary antibody (Life Technologies A21206) at 1:500 dilution in antibody 
dilution buffer for 1 h at room temperature. Cells were finally washed with PBS (3 x 5 min). 
Images were subsequently acquired with an inverted Olympus IX81 microscope equipped with a 
Hamamatsu C8484 camera, 60X oil objective and a FITC filter cube (Semrock). Metamorph 









Treatment of HeLa Cells with Cbl-COL/C18-Cy5-loaded Erythrocytes. HeLa cells were 
plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, HeLa cells were washed 3x with PBS, then 
treated with 200 µL of a suspension of C18-Cbl-COL/C18-Cy5 (5 µM/25 µM) loaded erythrocytes 
in L-15 (5% hematocrit) or 200 µL L-15 (control cells). Samples were then either kept in the dark 
at 37 ºC in a humidity-controlled incubator or exposed to a 660 nm LED array for 10, 20, or 30 
min using the appropriate filter sets. All samples were incubated for 1 h in a 37 ºC in a humidity-
controlled incubator post-photolysis. At the conclusion of the incubation period, HeLa cells were 
washed 3 x 1 mL with PBS and then fixed with 1 mL of methanol at room temperature for 10 
min. Cells were washed 2 x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking 
was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 
3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells 
were then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 
secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a FITC filter 










Treatment of HeLa Cells with C18-Cbl-COL/C18-DY800-loaded Erythrocytes. HeLa cells were 
plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, cells were washed 3x with PBS, then treated with 
200 µL of a suspension of C18-Cbl-COL/C18-DY800 (5 µM/5 µM) loaded erythrocytes in L-15 
(5% hematocrit) or 200 µL L-15 (control cells). Samples were then either kept in the dark at 37 
ºC in a humidity-controlled incubator or exposed to a 780 nm LED array for 10, 20, or 30 min 
using the appropriate filter sets. All samples were incubated for 1 h in a 37 ºC in a humidity-
controlled incubator post-photolysis. At the conclusion of the incubation period, HeLa cells were 
washed 3 x 1 mL with PBS and then fixed with 1 mL of methanol at room temperature for 10 
min. Cells were washed 2 x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking 
was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 
3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells 
were then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 
secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a FITC filter 










CETSA Assay of HeLa Cells Treated with C18-Cbl-MTX-loaded RBCs. HeLa cells were 
plated in 12-well tissue culture plates at a density of 9.4 x 104 cells per well and maintained at 
37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% 
Pen-Strep). The following day, cells were washed 3x with PBS, then treated with 300 µL of a 
suspension of C18-Cbl-MTX-loaded erythrocytes in L-15 (5 µM MTX loading concentration at 5% 
hematocrit), 300 µL L-15 (control cells), or 300 µL L-15 with 10 µM MTX (positive control). 
Samples were then either kept in the dark at 37 ºC in a humidity-controlled incubator, or 
exposed to a green LED light source (PAR38; 500 – 570 nm emission; 5 mW power) for 10, 20, 
or 30 min. At the end of the photolysis interval, all samples were incubated for 1 h in a 37 ºC in 
a humidity-controlled incubator. The cells were then washed with 3 x 1 mL with PBS and 
trypsinized with 300 µL 0.05% Trypsin (Gibco) for 5 min at 37 ºC. Trypsinized cells were then 
pelleted (5 min, 2000 rpm, 4 ºC), washed 1 x 300 µL PBS, and then pelleted again. After 
removal of the supernatant, cell pellets were heated at 52 ºC in a temperature-controlled heat 
block for 3 min, and then cooled for 3 min at room temperature. 30 µL of lysis buffer (25 mM Tris 
HCl/2 mM DTT/1X Pierce HALT protease and phosphatase inhibitor) was added to each pellet, 
which were then subjected to 2 freeze-thaw cycles in liquid N2. The resulting solutions were then 
spun at 17000 g for 20 min at 4 ºC. The resulting supernatants were removed and combined 
with 6X LSB-BME and boiled for 4 min at 95 ºC, then analyzed by western blot (overnight 
incubation at 4 ºC with Santa Cruz anti-DHFR E18 primary antibody (1:1000 in TBST/5%BSA) 
and Cell Signaling anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody 
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CHAPTER 3: LOADING ERYTHROCYTE CARRIERS WITH COBALAMIN 
PHOTOTHERAPEUTICS. GENERATION 2 - INTERNAL ENCAPSULATION 
 
Reproduced with permission from Hughes, R.M.; Rodgers Z.; Marvin, C.M.; Oien, N.P.; Smith, 
W.J.; Lawrence, D.S. Phototriggered Secretion of Membrane Compartamentalized Bioactive 
Agents. Angew Chem Int Ed Engl. 2016, 128, 16080-16083. © 2014 WILEY-VCH Verlag GmbH 
& Co. KGaA, Weinheim.  
 
The work in this chapter was a collaboration between the authors Robert M. Hughes, Christina 
M. Marvin, Zachary L. Rodgers, Song Ding, Nathan P. Oien, Weston J. Smith, and David S. 
Lawrence. The first author of the published work, Robert M. Hughes, wrote the publication and 
contributed the most experimental effort and scientific ideas. Christina M. Marvin, the author of 
this dissertation, performed the RBC loading and quantification of Cbl-BODIPY in Section 3.2, 
specifically producing Figures 3.2 and 3.4 - 3.10. Christina also performed the RBC loading for 
Sections 3.3 - 3.5. 
 
3.1. Background 
Light serves as a stimulus for nearly all forms of life, as exemplified by phototropism,1 
displayed by plants and insects, and the circadian clock,2 which is found in organisms that range 
from cyanobacteria to humans. Light, which can be applied with exquisite spatial and temporal 
precision, possesses photophysical properties (intensity, wavelength) that are readily 
modulated. These attributes, when applied in conjunction with chemically and biologically 
engineered photoresponsive molecules, have been used to probe and perturb biological 
phenomena in cells, tissues, and organisms. A wide variety of bioactive compounds have been 
converted into light-responsive derivatives by either 1) modifying essential functional groups 
with photocleavable moieties or 2) introducing light-triggered configurational switches that 
reversibly convert the inactive and active forms of the bioagent.3–6 By contrast, genetically 
encoded “optogenetic” proteins are typically constrained or transferred to specific intracellular 
sites required for their mechanism of action.7–9 Is the opposite possible? Can bioagents be 
restricted to specific inert compartments and subsequently photoreleased on command?
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 The advantage of this approach is that it is not necessary to impair, alter, or modify the 
innate biochemical activity of the agent under study. 
It was recently reported that vitamin B12 (cobalamin; “Cbl”) serves as a molecular 
platform for the photorelease of drugs due to the presence of an extraordinary photo-cleavable 
Co-C bond.10–13 B12 is not membrane permeable, but rather is transported into cells by a 
receptor-mediated, endosome-dependent mechanism.14 We wondered whether Cbl-bioagent 
conjugates might retain the membrane impermeability properties of the parent B12 and thus 
could be ensconced within lipid-enclosed compartments until needed. Previously, it was shown 
that light responsiveness of Cbl conjugates can be tuned to specific wavelengths deep into the 
red, far-red, and near-IR regions.11 These wavelengths penetrate tissue more effectively than 
UV and short visible wavelengths; a decided advantage in vivo.15 With these features in mind, 
the interior of erythrocytes was chosen as a membrane-enclosed environment to explore the 
conjecture that illumination can be used to control the secretion of biologically active 
compounds (Figure 3.1). It was anticipated that loading Cbl-bioagent conjugates into the interior 
of erythrocytes would be straightforward since red blood cells swell upon exposure to a 
hypotonic buffer, creating pores in the plasma membrane.16–18 After passive diffusion of the Cbl-
bioagent into the erythrocyte, subsequent resealing with an isotonic buffer should entomb the 



















Figure 3.1. Light-mediated release of compartmentalized light-responsive compounds. 
Membrane-impermeable Cbl-bioagents are retained inside erythrocytes. Photolysis produces 


















3.2. Encapsulation of a Cbl-reporter and Demonstration of Light-Controlled Release 
BODIPY®650 (BODIPY) is an extensively employed membrane-permeable fluorescent 
dye.19 The Cbl-BODIPY conjugate was prepared (Scheme 3.1, Figure 3.2) from Cbl-
propylamine (where R = NH2) and the corresponding BODIPY succinimidyl ester derivative. 
Photolysis of Cbl-BODIPY furnished the anticipated product (scission at the Co-C bond) as 
confirmed by LC–MS (Figure 3.3). Erythrocytes were loaded with Cbl-BODIPY using a modified 
































Scheme 3.1. Cbl-Drug conjugates. Conjugates were prepared from 3 (where R = NH2 or CO2H): 








Figure 3.2. Excitation and emission spectra of Cbl-BODIPY. Left: The excitation and emission 
spectra of Cbl-BODIPY (1.5 µM) acquired in L-15 with 10% FBS using a PTI PicoMaster 
TCSOC Fluorescence Lifetime Spectrofluorometer. Right: Excitation and emission spectra with 
Cbl-BODIPY (1.5 µM) that had been photolyzed under a 660 nm LED array (LED power = 3.30 


















Figure 3.3. Photolysis of conjugate Cbl-BODIPY (3c). (a) Reverse-phase HPLC trace of 
conjugate 3c incubated in PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was 
recorded at 254 nm. (b) Reverse-phase HPLC trace of conjugate 3c in PBS (25 µM, pH = 7.4) 
irradiated with light with a wavelength of 645 nm for 15 min. The chromatogram was recorded at 
254 nm. (c) Reverse-phase HPLC trace of conjugate 3c irradiated with light with a wavelength 
of 645 nm for 15 min. The chromatogram was recorded at 600 nm. (d) Electrospray mass 
spectrometry (ESMS) spectrum of 3c recorded in positive-ion mode (peak a). Characteristic 
molecular and fragment ions: [M+2H]2+ (m/z 958.7). (e) ESMS spectrum of photolyzed product 
B12a recorded in positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-
H2O]+ (m/z 1329.6), [M-H2O+H]2+ (m/z 664.9). (f) ESMS spectrum of photolyzed product 3c′ 










Integrity of the resealed cells will be an important parameter for future clinical 
applications. Analysis of the wash steps for hemoglobin release indicated that structural 
damage from loading was low to modest (< 30% hemolysis, Figure 3.4) and did not increase 
significantly when Cbl-BODIPY was loaded. Subsequent washing of the erythrocytes with 
serum-containing cell culture medium removed free Cbl-BODIPY that had not been installed 






































Figure 3.4. Effects of hypotonic loading procedure on RBC integrity. Lysis (%) is determined by 
the absorbance (550 nm) of 10% hematocrit sampled compared to a completely lysed control 
(0.05% w/v SDS). a) Hypotonic swelling in the presence or lack of Cbl-BODIPY induces 
comparable lysis (~ 30%). However, lack of swelling and storage in isotonic PBS maintains the 
membranes integrity. b) The percent lysis arising during each washing step after hypotonic 





















Figure 3.5. Cbl-BODIPY recovered in wash steps after loading into human erythrocytes. 
Fluorescence of the supernatant of pelleted Cbl-BODIPY-loaded erythrocytes and the 
supernatants of successive erythrocyte washes. By the third wash, the majority of non-
internalized Cbl-BODIPY has been removed from the solution containing Cbl-BODIPY-loaded 
erythrocytes. Black bars: erythrocytes loaded with Cbl-BODIPY; grey bars: erythrocytes 












Light-triggered (660 nm; LED power = 3.30 ± 0.02 mW cm-2; 0 - 5 min) BODIPY release 
was monitored from loaded erythrocytes in 10% hematocrit solutions. The time-dependent 
release of BODIPY from Cbl-BODIPY-loaded erythrocytes was quantified by spinning down the 
blood cells after illumination and measuring the fluorescence in the supernatant (released 
BODIPY) and the pellet (retained BODIPY; Figures 3.6 - 3.8). Control experiments were 
performed under identical conditions in the dark. As anticipated, Cbl-BODIPY is retained by 
erythrocytes in the dark, with only a negligible amount of BODIPY present in the supernatant (< 
1%) as a percentage of total Cbl-BODIPY loaded (Figure 3.6). By contrast, 660 nm illuminated 
(3 min) samples display robust BODIPY release (80.7 ± 6.4%). Various illumination times were 
explored and we found that maximal Cbl-BODIPY photolysis occurs at 3 min of illumination 
(Figure 3.7). Additional controls included non-swollen or already sealed RBCs treated with Cbl-
BODIPY. These experiments demonstrated no BODIPY release upon light exposure, indicating 























Figure 3.6. BODIPY release from Cbl-BODIPY-loaded erythrocytes. The percentage of 
BODIPY retained by (pellet; white bars) and released from (supernatant; black bars) 
erythrocytes as a function of total loaded Cbl-BODIPY under dark and 660 nm conditions. 
BODIPY is retained by erythrocytes maintained in the dark. By contrast, 80.7 ± 6.4% of BODIPY 







Figure 3.7. Time-dependent release of BODIPY from Cbl-BODIPY-loaded erythrocytes. Cbl-
BODIPY-loaded erythrocytes were illuminated under a 660 nm LED array for various times at 
room temperature. Immediately after illumination, the erythrocytes were pelleted by 
centrifugation (1000 x g, 3 min) and the supernatants collected. Fluorescence in the 
supernatants was measured on a SpectraMax® Gemini EM dual-scanning microplate 
spectrofluorometer with Softmax Pro v. 5 software (λex = 645 nm, λem = 675 nm) and converted 










Figure 3.8. Cbl-BODIPY standard curves. BODIPY standard curves used with the BODIPY 
fluorescent assay were generated by titration of known amounts of Cbl-BODIPY and 
subsequent analysis of fluorescence on a SpectraMax® Gemini EM dual scanning microplate 
spectrofluorometer (λex = 645 nm, λem = 675 nm). The standard curve used for calculating 
release into erythrocyte supernatants was prepared in L-15 + 10% fetal bovine serum (FBS) (Δ). 
The standard curve used for calculating amount recovered in cell lysate was prepared using a 
resealed erythrocyte lysate (□). The latter was generated by swelling and resealing erythrocytes 
as described in the Erythrocyte Loading Procedure and then completely lysing the erythrocytes 
through suspension of the resulting pellet in 10X volume of 0.05% Triton X-100. To obtain an 
accurate fluorescent measurement of BODIPY, all Cbl-BODIPY was converted into BODIPY by 
illumination of the samples under a 660 nm LED array for 15 min at room temperature. 
Concentrations used: 2.5 µM, 1.25 µM, 0.625 µM, 0.313 µM, 0.156 µM, 0.078 µM, 0.039 µM, 






















Figure 3.9. Cbl-BODIPY release after incubation. Incubation with a) swollen then sealed RBCs 
or b) unopened RBCs. The fluorescence in RBC supernatant and washes were monitored for 
free BODIPY. Photolysis (660 nm) of RBCs yielded little BODIPY release to the supernatant. 












Cbl-BODIPY-loaded erythrocytes were stored for several days to test their long-term 
retention and stability (Figure 3.10). While the majority of fluorescent material remains 
encapsulated, fluorescence observed in the supernatant does increase slightly over several 
days of storage. It should be noted that the in vitro storage was not performed in blood banking 
conditions and that the serum containing media used as a storage buffer, while healthy for most 





























Figure 3.10. RBC internalization of Cbl-BODIPY over several days. RBCs were loaded with 
Cbl-BODIPY (5 μM) and monitored for BODIPY leached into the supernatant (white bars) or 
retained in the RBCs (black bars) overall several days. Photolysis (660 nm) of RBCs and 
supernatant yielded free BODIPY for monitoring using a fluorescent standard curve. Over 
several days, some BODIPY leaks out of the RBC but the vast majority remains retained within 
















Finally, it was demonstrated that Cbl-BODIPY photolysis could be performed inside 
erythrocytes and that the released BODIPY could migrate to its intracellular site of action. 
BODIPY migrates to membrane potentials within organelles like the mitochondria and 
endoplasmic reticulum (ER).20,21 Therefore, HeLa cells were plated and incubated with Cbl-
BODIPY (5 μM) loaded erythrocytes (10% hematocrit). Plates were either kept in the dark or 
illuminated with red light (660 nm, 10 min) (Figure 3.11). HeLa cells were also stained with 
MitotrackerGreen® (mitochondria) and ER Blue/White to identify localization. After incubation, 
three wash steps were performed to remove erythrocytes. In the dark, almost no BODIPY 
staining of the HeLa cells’ organelles was observed. In contrast, red light exposure produced 
obvious BODIPY staining of the mitochondria and ER as indicated by colocalization with both 
the MitotrackerGreen® and ER Blue/White markers. The Cbl-BODIPY studies show the 































Figure 3.11. Cbl-BODIPY localization in HeLa cells after release from RBCs. Cbl-BODIPY (5 
μM) was loaded into RBCs (5% hematocrit) and incubated with HeLa cells. Cells were either 
Top: left in the dark or Bottom: photolyzed (660 nm, 10 min). HeLa cells were fixed and 
visualized for BODIPY fluorescence and localization using a confocal microscope. BODIPY 
localizes to the internal membranes of cells with potential gradients so MitoTracker Green and 
ER Blue/White markers were used to stain the mitochondria and ER, respectively. BODIPY co-








3.3. Therapeutic Release from Cbl Constructs inside of Erythrocytes 
Several Cbl conjugates containing MTX, COL and PTX were subsequently prepared. 
These green light-sensitive Cbl-bioactives were prepared by coupling Cbl-propylamine to MTX 
and succinyl-PTX (Schemes 3.2 and 3.4, Figures 3.27 and 3.29). By contrast, Cbl-butyrate was 
appended to the free amine of the deacetylated form of colchicine (Scheme 3.3, Figure 3.28). 
We confirmed by LC-MS that these species suffer photolysis via scission of the Co-C bond 
(Figures 3.30 - 3.32).  
These species were introduced into erythrocytes using the hypotonic-loading protocol 
described previously. The bioactive agents were subsequently released from erythrocytes by 
illumination at 525 nm, and their biological impact on co-plated HeLa cells monitored. The effect 
of photoreleased MTX on HeLa cells was assessed by the “CETSA assay” (Figures 3.12 and 
3.13).22,23 Following exposure to MTX-containing erythrocytes, HeLa cells were exposed to 
elevated temperatures, lysed, and the lysate centrifuged to separate soluble proteins from their 
insoluble counterparts. In the absence of MTX, elevated temperatures denature dihydrofolate 
reductase (DHFR) rendering it insoluble and poorly observable by western blot. By contrast, 
MTX-bound DHFR is more resistant to heat-induced denaturation. Only a small amount of 
DHFR is detected when HeLa cells are incubated in the dark with Cbl-MTX embedded within 
erythrocytes. On the other hand, illumination results in MTX release as evidenced by the 
















Figure 3.12. Cell-based assays for internalized MTX release at 525 nm. a) DHFR western blot 
(CETSA assay) of HeLa cells incubated with Cbl-MTX-loaded erythrocytes in the dark or b) 
following exposure to 525 nm light. c) Quantification of western blot optical density is consistent 































Figure 3.13. CETSA assay of 525 nm-induced release of MTX from Cbl-MTX loaded 
erythrocytes. Top: Western blot of DHFR in supernatant post-treatment. Bottom: Quantitation of 





Likewise, 525 nm-illuminated erythrocytes containing Cbl-COL-induced COL take-up by 
HeLa cells. In the absence of COL, microtubules extend from the nucleus to the cell surface 
(Figure 3.14). By contrast, upon COL photorelease, micro-tubule polymerization is blocked, 
leading to shortened and disrupted microtubule morphology (Figures 3.14 and 3.15). Finally, 
erythrocytes conveying Cbl-PTX released an active paclitaxel derivative upon 525 nm exposure, 
which stabilizes micro-tubules against depolymerization as revealed by coalescence (Figures 




























Figure 3.14. Cell-based assays for internalized COL release at 525 nm. Left: Immunostained 
HeLa cell microtubules incubated with Cbl-COL-loaded erythrocytes in the dark. Right: Cells 
exposed to 525 nm light. Structurally compromised microtubules are consistent with COL 

































Figure 3.15. Immunostained HeLa cell microtubules after exposure to Cbl-COL-loaded 







Figure 3.16. Cell-based assays for internalized PTX release at 525 nm. Left: Immunostained 
HeLa cell microtubules incubated with Cbl-PTX-loaded erythrocytes in the dark. Right: Cells 
exposed to 525 nm light. Condensed microtubules are consistent with PTX photorelease. Scale 
bars = 10 mm. 





















Figure 3.17. 525 nm release of PTX from Cbl-PTX-loaded erythrocytes. (a) HeLa cells after 24 
h exposed to a solution of loaded erythrocytes. Left: Cells in the dark. Right: Cells illuminated at 
525 nm. (b) HeLa cells in the presence of media only. Left: Cells in the dark. Right: Cells in the 














3.4. Extending Therapeutic Release into the Optical Window of Tissue Penetration 
Having established the methodology for the encapsulation and on-command light-
triggered release of bioactive compounds from erythrocytes, the wavelength window of release 
was extended into the 650 - 800 nm realm. It has previously been shown that Co-C photolysis 
can be induced by red, far red, or NIR light using Cbl derivatives possessing appended long 
wavelength, light-harvesting fluorophores.11 Given the unique excitation wavelengths of 
individual fluorophores, it was investigated whether specific agents could be released from 
erythrocytes in a wavelength-designated fashion.  
Red light-sensitive analogs of Cbl-MTX and Cbl-PTX were prepared using Cy5 as an 
appended long wavelength antenna (λex = 660 nm, Scheme 3.5). We also synthesized a 
corresponding near IR responsive analog of Cbl-COL by affixing “FL800” to the ribose ring (λex = 
780 nm; (Schemes 3.5-3.6, Figure 3.33). The synthetic routes to Cy5-Cbl-MTX, Cy5-Cbl-PTX, 
and FL800-Cbl-COL employ fluorophore-labeled derivatives of compounds Cbl-propylamine and 
Cbl-butyrate as the starting materials. In addition, the ribose 5’-OH was activated (1,1’-carbonyl-
di-triazole) and subsequently reacted with ethylenediamine, to provide a handle upon which the 
long wavelength fluorophores are secured (Schemes 3.7-3.13, Figures 3.34-3.36). All three 
fluorophore-Cbl-bioactive conjugates furnish the photolyzed Co-C cleaved products at their 











The phototherapeutic agents were encapsulated in erythrocytes by exposure to a 
hypotonic solution. In contrast to the Cbl derivatives Cbl-MTX, Cbl-COL, and Cbl-PTX, analogs 
Cy5-Cbl-MTX, FL800-Cbl-COL, and Cy5-Cbl-PTX respond to wavelengths beyond which the 
native Cbl complex absorbs light. Both erythrocyte-embedded Cy5-Cbl-MTX and Cy5-Cbl-PTX 
release their bioactive cargo at 660 nm. When co-cultured with HeLa cells, light-triggered MTX 
secretion from erythrocytes was again confirmed by the CETSA assay and PTX release was 
demonstrated by microtubule immunostaining (Figures 3.18 and 3.19). In addition, FL800-Cbl-
COL is designed to respond to near-IR wavelengths. 780 nm exposure of erythrocytes 
containing FL800-Cbl-COL triggered COL secretion and depolymerization of HeLa cell 































Figure 3.18. CETSA assay of 660 nm release of MTX from Cy5-Cbl-MTX loaded erythrocytes. 
Top: Western blot of DHFR in supernatant after various treatment conditions. Bottom: 














Figure 3.19. 660 nm-induced release of PTX from Cy5-Cbl-PTX loaded erythrocytes. (a) HeLa 
cells after 16 h in the presence of supernatant from a solution of loaded erythrocytes left in the 
dark (left) or light (right). (b) HeLa cells in the presence of media only in the dark (left) or light 










Figure 3.20. 780 nm-induced release of COL from FL800-Cbl-COL loaded erythrocytes. (a) 
HeLa cells in the presence of loaded erythrocytes. Left: in the dark or Right: in the light. (b) 









An additional phototherapeutic based on the cytotoxic agent doxorubicin (DOX) was 
synthesized with the intention to expand the long wavelength toolbox to another 
chemotherapeutic. Delivery of DOX directly to a tumor site would be especially ideal. Normally, 
the anthracycline DOX easily penetrates cell membranes and intercalates DNA, inhibiting 
topoisomerase II and resulting in cell death.25,26 Due to its effectiveness, DOX has become a 
frontline chemotherapy for several cancers. However, it results in several side effects, including 
severe cardiotoxicity, from non-specific interactions with healthy tissue. The risk of permanent 
cardiac damage is so severe, that patients are restricted to a cumulative lifetime dose of 550 
mg/m2 DOX. Once this limit is reached, an alternative treatment must be prescribed because 
the risk of permanent heart damage is greater than the chemotherapeutic benefits. Light 
directed DOX therapy directly at the tumor site could greatly reduce this risk and possibly 
extend the lifetime dose.  
Cy5SO3- -Cbl-DOX (λmax = 646 nm) was synthesized in the same manner as FL800-Cbl-
COL (Schemes 3.14 - 3.16). Cy5SO3- -Cbl-DOX (10 μM) was loaded into erythrocytes and 
incubated with HeLa cells in the dark or illuminated with 660 nm light (Figure 3.21). Dox 
contains an anthraquinone fluorophore (λex = 480 nm, λem = 580 nm) linked to a daunosamine 
sugar, allowing for visualization of DOX location using fluorescence microscopy.27 In the dark, 
no nuclear staining is observed and overall DOX fluorescence remains low, likely due to 
quenching interactions with the Cbl.11,28,29 After exposure to 660 nm light, DOX fluorescence 
intensity greatly increased and characteristic nuclear staining was observed, indicating DOX 
localization in the nucleus. These results demonstrate the feasibility of chemotherapeutic 
release from erythrocytes, Efficacy of released agents in a tumor environment will be further 





















Figure 3.21. Dox localization studies when released from CySO3--Cbl-Dox loaded RBCs. HeLa 
cells were plated with the loaded RBCs (10% hematocrit, CySO3--Cbl-Dox, 10 μM). Top: cells 
left in the dark. Bottom: Cells photolyzed with 660 nm. Images of the Dox, HOESCHT, and Cy5 
fluorescence were taken every 60 s on a widefield microscope. In the dark, Dox fluorescence 
remains low presumably through Cbl based quenching of the anthraquinone. Upon photolysis, 
Dox fluorescence increases substantially and migrates to the nucleus where it co-localizes with 
















3.5. Potential for Orthogonal Drug Delivery 
Given the fact that the long wavelength excitation spectra of the BODIPY and FL800 
fluorophores in this study are non-overlapping (Figure 3.22), we investigated the orthogonal 
light-triggered secretion of bioactive compounds by simply modulating the wavelength of 
illumination. We considered two possible loading strategies: 1) Cbl derivatives co-loaded into 
the same erythrocytes and 2) Cbl derivatives loaded indifferent erythrocytes and subsequently 
mixed to create a single pool of blood cells. Both possibilities were explored using the 650 nm 
sensitive Cbl-BODIPY and the 780 nm responsive FL800-Cbl-COL. Both approaches furnished 
erythrocyte-encapsulated Cbl-bioagent conjugates that differentially release their cargo in 
response to orthogonal wavelength embedded commands (Figures 3.23 - 3.26). For example, 
erythrocytes loaded with both Cbl-BODIPY and FL800-Cbl-COL, when exposed to 660 nm, 
selectively release BODIPY, which is taken up by HeLa cells (Figure 3.23a). By contrast, 780 
nm exposure triggers COL discharge and subsequent structural disruption of HeLa microtubules 
(Figure 3.23b). Both compounds resist release from erythrocytes when illuminated at non-
absorbing wavelengths (Figures 3.24 and 3.26). Analogous studies were performed with 
erythrocytes that were separately loaded with Cbl-BODIPY or FL800-Cbl-COL and 
subsequently mixed into a single pool (Figures 3.25 and 3.26). These results confirm 

















Figure 3.22. Absorbance spectra of Cbl-BODIPY and FL800-Cbl-COL. Comparison of the 
absorbance spectra of Cbl-BODIPY (blue) and FL800-Cbl-COL (red). The absorbance spectra 








Figure 3.23. Orthogonal release of BODIPY and COL from erythrocytes separately loaded with 
Cbl-BODIPY and FL800-Cbl-COL. Conjugates are encapsulated in erythrocytes and uptake by 
HeLa cells. Left: Fluorescence of BODIPY650 in HeLa cells. Right: HeLa cell microtubules. (a) 
Erythrocytes exposed to 660 nm light release BODIPY, which is taken up by HeLa cells as 
demonstrated by red fluorescence. By contrast, (b) no COL is released under these conditions 
as demonstrated by intact microtubules. Erythrocytes exposed to 780 nm light. Under these 
circumstances, (c) no BODIPY is released. (d) COL is delivered to HeLa cells as evidenced by 
the presence of compromised microtubules. Results from experiments conducted in the dark or 























Figure 3.24. Orthogonal release of BODIPY and COL from erythrocytes co-loaded with Cbl-
BODIPY and FL800-Cbl-COL. The impact of COL on microtubules was assessed via 
immunostaining with an anti-tubulin antibody and observed with the FITC filter cube centered at 
488 nm. By contrast, the uptake of BODIPY by HeLa cells was directly observed with the Cy5 
filter cube centered at 625 nm. Treatments shown are (a) both 780 nm and 660 nm light, (b) 660 
























Figure 3.25. Orthogonal release of COL and BODIPY from erythrocytes separately loaded 
FL800-Cbl-COL and Cbl-BODIPY and then pooled. Treatments shown are (a) both 780 nm and 









Figure 3.26. Assessment of light-independent BODIPY release in the experiments described in 
Figures 3.24 - 3.25. Corrected Total Cell Fluorescence was calculated using ImageJ for n = 10 








In conclusion, it was shown that long wavelength responsive bioactive species can be 
constructed by appending membrane-impermeable Cbl by a photocleavable Co-C bond. It is 
anticipated that this strategy could prove applicable to other membrane enclosed 
compartments, such as endosomes, the cytoplasm, or various organelles in conjunction with 
robust delivery moieties. These studies are in progress. In addition, we have shown that photo-
secretion can be triggered by pre-assigned wavelengths, an easily modulated photo-physical 
property of light. Finally, it has not escaped our attention that on-command selective release of 
therapeutic agents from biocompatible delivery vehicles30 offers a strategy that addresses many 



















3.7. Materials and Methods 
CyanoCbl was purchased from Lalilab, Inc. BODIPY®650-NHS ester was purchased 
from Lumiprobe Co. All other reagents were purchased from Sigma-Aldrich and used without 
prior purification.  
ChloroFL800,24 Cy5,31 N-deacetyl-COL,32 2'-succinyl-PTX,33 ethylenediamine-Cbl-
cyano,34 Cbl-BODIPY®650,11 Cbl-butyrate (R = CO2H),11 and Cbl-propylamine (R = NH2),11 
were synthesized as previously described.  
Final Cbl-drug conjugates’ purity was assessed using an Agilent 1200 series LC-MS 
scanning in positive ion mode. Samples were loaded onto a reverse phase C18 column and 
eluted using a gradient binary solvent system (A: H2O with 0.1% formic acid, B: CH3CN w/ 0.1% 
formic acid). The initial A:B ratio was held at 97:3 for equilibration (0 - 5 min) and then changed 
to 5:95 (5 - 18 min). Compound elution was monitored at 280 nm and relative purity was 
assessed by integrating the area under the chromatogram’s curve. Only samples with > 95% 
purity were used for RBC loading. Cbl conjugates were characterized using a high resolution 






















Scheme 3.2. Synthesis of Cbl-MTX. Cbl-MTX is synthesized from Cbl-propylamine (R = NH2) 
and MTX. MTX (30 mg, 66 µmol), HBTU (25 mg, 66 µmol), and DIPEA (58 µL, 332 µmol) were 
dissolved in DMF (5 mL) and stirred for 5 min. Cbl-propylamine (3a) (98 mg, 71 µmol) was 
added and the solution stirred overnight. The reaction was purified via reverse phase 
chromatography (120g, RP-C18, Biotage) using a binary solvent system (A: H2O w/ 0.1% v/v 
TFA, B: CH3OH w/ 0.1% v/v TFA) with a gradient change from 0% B to 100% B over eight 
column volumes. The solvent was removed via lyophilization to yield the product as an orange 












HR ESI MS C85H116CoN22O18P calculated for [M+2H+]+2: m/z = 912.4027, found 
912.4038.  
1 H NMR (DMSO-d6, 400 MHz) δ = 9.28 (s, 1 H), 9.07 (d, J = 4.7 Hz, 1 H), 8.79 (s, 1 H), 
8.73 - 8.77 (m, 1 H), 8.67 - 8.72 (m, 1 H), 8.61 (br. s., 1 H), 7.77 - 7.88 (m, 2 H), 7.63 - 7.76 (m, 
3 H), 7.48 - 7.62 (m, 3 H), 7.32 - 7.47 (m, 2 H), 7.06 - 7.22 (m, 2 H), 6.90 - 7.02 (m, 1 H), 6.74 - 
6.88 (m, 5 H), 6.63 (br. s., 1 H), 6.20 - 6.35 (m, 1 H), 4.85 - 4.93 (m, 3 H), 4.71 - 4.80 (m, 1 H), 
4.64 (dd, J = 8.6, 4.7 Hz, 1 H), 4.12 - 4.34 (m, 3 H), 4.06 (br. s, 1 H), 3.69 (d, J = 12.5 Hz, 2 H), 
3.51 (d, J = 9.8 Hz, 1 H), 3.27 - 3.30 (m, 2 H), 3.22 - 3.26 (m, 2 H), 2.88 - 2.99 (m, 1 H), 2.72 - 
2.82 (m, 1 H), 2.69 (s, 1 H), 2.52 - 2.58 (m, 2 H), 2.31 - 2.48 (m, 10 H), 2.12 - 2.30 (m, 10 H), 
2.08 (br. s, 1 H), 1.72 - 2.01 (m, 9 H), 1.68 (br. s, 3 H), 1.39 (br. s, 3 H), 1.18 - 1.31 (m, 6 H), 


























Scheme 3.3. Synthesis of Cbl-COL. Cbl-COL is synthesized from Cbl-butyrate (R = CO2H) and 
deacetylated-COL, which contains a free amine. Cbl-butyrate 3b (58 mg, 41 µmol), HBTU (10 
mg, 26 µmol), and DIPEA (15 µL, 86 µmol) were dissolved in DMF (2 mL) and stirred for 5 min. 
Amino-COL (10 mg, 28 µmol) was added and the solution was stirred overnight. The product 
was purified via reverse phase chromatography (120g, RP-C18, Biotage) using a binary solvent 
system (A: H2O w/ 0.1% v/v TFA, B: CH3OH w/ 0.1% v/v TFA) with a gradient change from 0% 
B to 100% B over eight column volumes. The solvent was removed via lyophilization to yield the 












HR ESI MS C86H116CoN14O20P calculated for [M+2H+]+2: m/z = 878.3853, found 
878.3939.  
1 H NMR (D2O, 400 MHz) δ = 9.04 (s, 1 H), 7.34 (s, 1 H), 7.26 (s, 1 H), 7.14 (d, J = 11 
Hz, 1 H), 6.97 (s, 1 H), 6.64 (br. s, 2 H), 6.32 (d, J = 4.7 Hz, 1 H), 4.75 (t, J = 4.7 Hz, 1 H), 4.55 
(d, J = 3.1 Hz, 1 H), 4.23 (d, J = 9.8 Hz, 1 H), 4.17 - 4.10 (m, 1 H), 3.94 (d, J = 8.6 Hz, 1 H), 3.85 
(t, J = 8.6 Hz, 2 H), 3.78 - 3.71 (m, 6 H), 3.69 - 3.63 (m, 2 H), 3.61 (d, J = 3.5 Hz, 1 H), 3.58 (d, J 
= 3.9 Hz, 1 H), 3.35 (s, 3 H), 3.18 - 3.10 (m, 2 H), 3.06 - 2.98 (m, 1 H), 2.68 - 2.47 (m, 4 H), 2.36 
- 2.20 (m, 7 H), 2.15 (m, 7 H), 2.00 (d, J = 8.2 Hz, 6 H), 1.63 (m, 7 H), 1.36 (br. s., 3 H), 1.24 (s, 
3 H), 0.98 (d, J = 6.3 Hz, 3 H), 0.91 (s, 2 H), 0.64 - 0.55 (m, 3 H), 0.51 (br. s., 2 H), 0.23 - 0.12 




























Scheme 3.4. Synthesis of Cbl-PTX. Cbl-PTX is synthesized from Cbl-propylamine (R = NH2) 
and 2’- succinyl-PTX. 2'-succinyl-PTX (20 mg, 21 µmol), HCTU (8.7 mg, 21 µmol) and DIPEA 
(8.1 mg, 11 µL, 63 µmol) were dissolved in anhydrous DMF (2 mL) and incubated at room 
temperature for 10 min. To this reaction mixture was added Cbl-propylamine (3a) (30.8 mg, 21 
µmol) and the reaction was incubated at room temperature for 16 h. The product was purified 
via reverse phase chromatography (60 g, RP-C18, Biotage) using a binary solvent system (A: 
H2O w/ 0.1% v/v TFA, B: CH3CN w/ 0.1% v/v TFA) with a gradient change from 0% B - 60% B 











HR ESI MS C116H149CoN15O30P calculated for [M+2H+]+2 : m/z = 1161.9905, found 
1161.9921.  
1 H NMR (DMSO-d6, 400 MHz) δ = 9.20 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 7.6 Hz, 2H), 
7.84 (d, J = 7.7 Hz, 2H), 7.78 - 7.34 (m, 15H), 7.16 (dd, J = 15.2, 8.0 Hz, 3H), 7.03 - 6.60 (m, 
5H), 6.34 - 6.27 (m, 2H), 5.80 (t, J = 9.2 Hz, 1H), 5.50 (t, J = 8.6 Hz, 1H), 5.41 (d, J = 7.1 Hz, 
1H), 5.29 (d, J = 8.8 Hz, 1H), 4.90 (d, J = 9.7 Hz, 2H), 4.76 (q, J = 6.4 Hz, 2H), 4.68 - 3.93 (m, 
25H), 3.82 - 3.49 (m, 5H), 3.40 - 2.71 (m, 5H), 2.47 - 2.01 (m, 33H), 1.94 - 1.19 (m, 37H), 0.58 - 



























































































Figure 3.30. Photolysis of Cbl-MTX (3d). (a) Reverse-phase HPLC trace of Cbl-MTX incubated 
in PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was recorded at 254 nm. 
(b) Reverse-phase HPLC trace of Cbl-MTX in PBS (25 µM, pH = 7.4) irradiated with light with a 
wavelength of 525 nm for 15 min. The chromatogram was recorded at 254 nm. (c) ESMS 
spectrum of 3d recorded in positive-ion mode (peak a). Characteristic molecular and fragment 
ions: [M+2H]2+ (m/z 912.6). (d) ESMS spectrum of photolyzed product B12a recorded in 
positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-H2O]+ (m/z 1329.6), 
[M-H2O+H]2+ (m/z 664.9). (e) ESMS spectrum of photolyzed product 3d'' recorded in positive-
ion mode (peak c). Characteristic molecular and fragment ions: [M+H]+ (m/z 512.2). (f) ESMS 
spectrum of photolyzed product 3d' recorded in positive-ion mode (peak d). Characteristic 


















































Figure 3.31. Photolysis of Cbl-COL (3e). (a) Reverse-phase HPLC trace of Cbl-COL incubated 
in PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was recorded at 254 nm. 
(b) Reverse-phase HPLC trace of Cbl-COL in PBS (25 µM, pH = 7.4) irradiated with light with a 
wavelength of 525 nm for 15 min. The chromatogram was recorded at 254 nm. (c) ESMS 
spectrum of Cbl-COL recorded in positive-ion mode (peak a). Characteristic molecular and 
fragment ions: [M+2H]2+ (m/z 878.6). (d) ESMS spectrum of photolyzed product B12a recorded 
in positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-H2O]+ (m/z 
1329.6), [M-H2O+H]2+ (m/z 664.9). (e) ESMS spectrum of photolyzed product 3e' recorded in 
positive-ion mode (peak c). Characteristic molecular and fragment ions: [M+H]+ (m/z 442.2). (f) 
ESMS spectrum of photolyzed product 3e" recorded in positive-ion mode (peak d). 
Characteristic molecular and fragment ions: [M+H]+ (m/z 443.1). (g) ESMS spectrum of 
photolyzed product 3e"" recorded in positive-ion mode (peak e). Characteristic molecular and 



















































Figure 3.32. Photolysis of Cbl-PTX (3f). (a) Reverse-phase HPLC trace of Cbl-PTX incubated in 
PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was recorded at 254 nm. (b) 
Reverse-phase HPLC trace of Cbl-PTX in PBS (25 µM, pH = 7.4) irradiated with light with a 
wavelength of 525 nm for 15 min. The chromatogram was recorded at 254 nm. (c) Reverse-
phase HPLC trace of isolated 3f". The chromatogram was recorded at 254 nm. (d) ESMS 
spectrum of Cbl-PTX recorded in positive ion mode (peak a). Characteristic molecular and 
fragment ions: [M+2H]2+ (m/z 1162.6). (e) ESMS spectrum of photolyzed product B12a recorded 
in positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-H2O]+ (m/z 
1329.6), [M-H2O+H]2+ (m/z 664.9). (f) ESMS spectrum of photolyzed 3f′ recorded in positive-ion 
mode (peak c). Characteristic molecular and fragment ions: [M+H]+ (m/z 1012.6). (g) ESMS 
spectrum of photolyzed product 3f" recorded in positive-ion mode (peak d). Characteristic 




























Scheme 3.5. Long wavelength phototherapeutics. Cy5 derivatives of Cbl-MTX (where R = MTX) 























Scheme 3.6. Synthesis of FL800. Synthesis of FL800 from previously reported chloro-FL800.24 
 
Chloro-FL800 (150 mg, 215 µmol) was dissolved in DMF (10 mL) and purged with Ar for 
10 min. 4-mercaptophenylacetic acid (216 mg, 1.29 mmol) was added and the solution stirred 
for 2 h. The solution was treated with chloroform (10 mL) and purified via flash chromatography 
(Biotage 60 g silica column, monitored at 773 nm) with a binary gradient (A: CHCl3, B: MeOH). 
The ratio (A:B) was held at initially 9:1 for 3 column volumes, steadily changed to 1:1 over 12 
column volumes, and then maintained at 1:1 for an additional 2 volumes. The solvent was 
removed under reduced pressure to produce a dark green powder in near quantitative yield 
(169 mg, 95%, λmax = 786 nm).  
HR ESI MS C44H49N2O8S3 calculated for [M-1]-1 : m/z = 829.2657, found 829.2631. 
1 H NMR (DMSO-d6, 400 MHz) δ = 8.63 (d, J = 14.1 Hz, 2 H), 7.53 - 7.47 (m, 4 H), 7.38 
(t, J = 7.8 Hz, 2 H), 7.25 - 7.15 (m, 6 H), 6.50 (d, J = 14.1 Hz, 2 H), 4.33 (t, J = 7.4 Hz, 4 H), 2.77 
















































Scheme 3.8. Synthesis of Cy5-Cbl-MTX. Synthesis of Cy5-Cbl-MTX from ethylenediamine-Cbl-
MTX and Cy5. Cbl-MTX (35 mg, 19 µmol) and CDT (16 mg, 96 µmol) were dissolved in DMF 
(500 µL) under Ar and reacted for 2 h. Ethylenediamine (14.4 µL, 192 µmol) was added to the 
solution and allowed to react overnight. The product was precipitated and purified via reverse 
phase chromatography (120g, RP-C18, Biotage) using a binary solvent system (A: H2O with 
0.1% v/v TFA, B: CH3OH with 0.1% v/v TFA) with a gradient change from 0% B to 100% B over 









Cy5 (7.7 mg, 15.9 µmol), HBTU (5.7 mg, 15.1 µmol), and DIPEA (12.2 µL, 79.5 µmol) 
were mixed in DMF (600 µL). After 5 min, ethylenediamine-Cbl-MTX (20 mg, 10.5 µmol) was 
added and reacted overnight. The reaction was diluted with deionized water (2.4 mL) and 
purified via HPLC (semi-preparative C18 column) using a binary gradient solvent system (A: H2O 
with 0.1% TFA, B: CH3CN with 0.1% TFA). Equilibration (10 min) was followed by a steadily 
changing gradient 97:3 A:B to 5:95 A:B over 50 min. Eluents were monitored at 646 nm and 
lyophilized to give a blue solid (15.9 mg, 68%, λmax = 646 nm).  
HR ESI MS C120H159CoN26O20P calculated for [M++H+]+2: m/z = 1188.0724, found 
1188.0661; [M++2H+]+3: m/z = 792.3840, found 792.3809.  
1 H NMR (DMSO-d6, 400 MHz) δ = 8.70 (d, J = 3.1 Hz, 1 H), 8.32 (t, J = 12.7 Hz, 2 H), 
7.64 - 7.77 (m, 4 H), 7.61 (d, J = 7.0 Hz, 2 H), 7.47 (s, 1 H), 7.33 - 7.42 (m, 4 H), 7.17 - 7.32 (m, 
4 H), 6.81 (br. s, 3 H), 6.72 (br. s, 2 H), 6.49 - 6.62 (m, 3 H), 6.21 - 6.33 (m, 3 H), 4.87 (br. s, 1 
H), 3.59 (d, J = 2.7 Hz, 3 H), 3.38 (q, J = 7.0 Hz, 2 H), 3.24 (br. s, 2 H), 2.67 (br. s, 1 H), 2.32 (d, 
J = 4.7 Hz, 6 H), 2.23 (br. s, 3 H), 1.67 (s, 12 H), 1.51 (br. s, 4 H), 1.34 (br. s, 4 H), 1.19 - 1.29 
(m, 5 H), 1.14 (d, J = 5.9 Hz, 2 H), 1.09 (t, J = 7.0 Hz, 2 H), 0.94 (d, J = 7.4 Hz, 3 H), 0.87 (br. s, 




















Scheme 3.9. Synthesis of (Fmoc)ethylenediamine-Cbl-propylamine. Synthesis of 
































Scheme 3.10. Synthesis of Cy5-Cbl-PTX. Synthesis of Cy5-Cbl-PTX from 
(Fmoc)ethylenediamine-Cbl-propylamine. 
 
Ethylenediamine-Cbl-cyano (50 mg, 34.7 µmol) and N-(9-
fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu, 117 mg, 347 µmol) were dissolved in 
DMF (10 mL) and stirred at room temperature. After 12 h, the product was precipitated into cold 
acetone (3 x 40 mL) to remove unreacted Fmoc-OSu. The resulting red solid was collected by 
centrifugation, re-dissolved in MeOH (5% w/v NH4Br, 5 mL), and purged with Ar for 30 min. Zn 
dust (451 mg, 6.94 mmol) was added and the solution was shaken for 1 h. 3-bromopropylamine 
hydrobromide (46 mg, 208 µmol) was quickly added and the reaction mixture was shaken for 





The Zn dust was removed by filtration and the solution precipitated with anhydrous ether 
(150 mL) yielding (Fmoc)ethylenediamine-Cbl-propylamine as an orange solid (>90% purity 
determined by HPLC). The crude sample was re-dissolved in anhydrous DMF (2 mL) and added 
into a DMF solution (2 mL) containing 2'-succinyl-PTX (33 mg, 34.7 µmol), HCTU (14.4 mg, 
34.7 µmol) and DIPEA (13.5 mg, 18 µL, 104 µmol). The reaction was incubated at room 
temperature for 16 h. To remove the Fmoc protecting group, piperidine (200 µL) was added into 
the reaction mixture and mixed at room temperature for additional 30 min. The reaction mixture 
was precipitated with anhydrous ethyl ether (3 x 40 mL) to remove piperidine. The crude sample 
was collected via centrifugation, mixed with Cy5-NHS ester (27 mg, 52 µmol) and DIPEA (10 
mg, 13 µL, 78 µmol) in DMF (2 mL) and allowed to react overnight. The product was purified via 
reverse phase chromatography (60 g, RP-C18, Biotage) using a binary solvent system (A: H2O 
with 0.1% v/v TFA, B: CH3CN with 0.1% v/v TFA) with a gradient change from 0% B to 60% B 
over 18 column volumes. Lyophilization yielded the product as a blue solid (31 mg, 32%).  
HR ESI MS C151H192CoN19O32P calculated for [M++H+]+2: m/z = 1437.1559, found 
1437.1793; [M++2H+]+3: m/z = 958.4397, found = 958.4426.  
1 H NMR (DMSO-d6, 400 MHz) δ = 9.21 (d, J = 8.5 Hz, 1 H), 8.32 (t, J = 13.1 Hz, 2 H), 
8.01 - 7.95 (m, 2 H), 7.94 - 7.79 (m, 4 H), 7.79 - 7.32 (m, 20 H), 7.30 - 7.10 (m, 5 H), 6.98 - 6.83 
(m, 4 H), 6.65 (s, 1 H), 6.56 (t, J = 12.2 Hz, 1 H), 6.43 - 6.17 (m, 4 H), 5.81 - 5.76 (m, 2 H), 5.49 
(t, J = 8.6 Hz, 2 H), 5.41 (d, J = 7.1 Hz, 2 H), 5.29 (d, J = 8.9 Hz, 2 H), 5.19 - 4.16 (m, 30 H), 
4.13 - 3.98 (m, 7 H), 3.79 (s, 1 H), 3.65 - 3.50 (m, 4H), 3.38 - 2.91 (m, 7 H), 2.43 - 2.05 (m, 30 
H), 1.78 - 1.63 (m, 24 H), 1.59 - 0.88 (m, 29 H), 0.60 (br. s, 2 H), 0.19 (br. s, 2 H), -0.07 (br. s, 2 
















Scheme 3.11. Synthesis of ethylenediamine-Cbl-butyrate. Synthesis of ethylenediamine-Cbl-
butyrate from ethylenediamine-Cbl-cyano. 
 
Ethylenediamine-cyanoCbl (0.5 g, 359 µmol) was dissolved in MeOH (5% w/v NH4Br, 15 
mL) and the solution purged with Ar for 20 min. Activated Zn dust (23.9 g, 369 mmol) was 
added and the solution shaken for 20 min causing a solution color change from red to dark blue. 
4-bromobutyric acid (174 mg, 1.1 mmol) was quickly added causing a solution color change to 
orange. After 30 min of additional shaking, the Zn dust was allowed to settle and the MeOH 
supernatant added to chilled ether (2 x 30 mL) inducing the precipitation of an orange solid. The 
resulting orange solid was re-dissolved in deionized water (15 mL) and purified via reverse 
phase chromatography (120g, RP-C18, Biotage) using a binary solvent system (A: H2O with 
0.1% v/v TFA, B: CH3CN with 0.1% v/v TFA). A:B was held constant at 9:1 for 3 column 
volumes, steadily changed over the next 10 volumes to 3:2 and then held constant for an 
additional 2 volumes. The eluted product was dried via lyophilization to produce an orange 




HR ESI MS C69H101N15O17PCo calculated for [M+H+]+ : m/z = 1502.6642, found 
1502.6648; [M+2H+]+2: m/z = 751.8356, found 751.8363.  
1 H NMR (DMSO-d6, 400 MHz) δ = 7.99 - 7.82 (m, 4 H), 7.65 (br. s, 2 H), 7.56 - 7.41 (m, 
3 H), 7.38 (br. s, 1 H), 7.18 (br. s, 1 H), 7.13 (br. s, 1 H), 7.06 - 6.92 (m, 3 H), 6.86 (br. s, 1 H), 
6.79 (br. s, 1 H), 6.65 (br. s, 1 H), 6.39 (br. s, 2 H), 4.79 - 4.69 (m, 1 H), 4.44 (br. s, 1 H), 4.41 - 
4.26 (m, 4 H), 4.19 (d, J = 9.8 Hz, 1 H), 4.09 (dd, J = 4.3, 11.7 Hz, 1 H), 3.86 (br. s, 1 H), 3.32 - 
3.19 (m, 4 H), 3.11 (d, J = 6.3 Hz, 1 H), 2.93 - 2.79 (m, 3 H), 7 2.62 - 2.52 (m, 2 H), 2.43 - 2.36 
(m, 8 H), 2.36 - 2.17 (m, 12 H), 2.15 - 1.99 (m, 2 H), 1.93 (br. s, 3 H), 1.84 (d, J = 13.3 Hz, 4 H), 
1.79 - 1.59 (m, 8 H), 1.52 (br. s, 1 H), 1.49 - 1.40 (m, 3 H), 1.38 - 1.22 (m, 8 H), 1.20 - 0.98 (m, 7 


























Scheme 3.12. Synthesis of FL800-Cbl-butyrate. Synthesis of FL800-Cbl-butyrate from 
ethylenediamine-Cbl-butyrate and FL800. FL800 (15.0 mg, 18.1 µmol), DIC (6.8 mg, 53.9 
µmol), and N-hydroxysuccinimide (6.2 mg, 53.9 µmol) were mixed in anhydrous DMF (350 µL) 
and allowed to react for 12 h. H2O (30 µL) was then added to quench excess DIC and generate 
an FL800-NHS ester stock solution. Ethylenediamine-Cbl-butyrate (12.6 mg, 8.42 µmol) was 
mixed with FL800-NHS ester solution (200 uL, 46.3 mM, 9.26 µmol FL800-NHS) and DIPEA 
(29.3 µL, 168 µmol) and allowed to react for 12 h. The solution was diluted with deionized water 
(2.8 mL) and purified via HPLC (semipreparative C18 column) using a binary gradient solvent 
system (A: H2O w/ 0.1% v/v TFA, B: CH3CN w/ 0.1% v/v TFA). Equilibration (10 min) was 
followed by steadily changing the gradient from 97:3 A:B to 5:95 A:B over 50 min. Eluents were 










HR ESI MS C113H148N17O24PS3Co calculated. For [M-+3H+]+2: m/z = 1158.4690, found 
1158.4701; [M+4H+]+3 : m/z = 772.6487, found 772.6763.  
1 H NMR (DMSO-d6, 400 MHz) δ = 8.59 (d, J = 13.3 Hz, 2 H), 8.11 - 8.01 (m, 2 H), 7.86 
- 7.77 (m, 1 H), 7.66 - 7.58 (m, 1 H), 7.47 (m, 3 H), 7.36 (t, J = 7.8 Hz, 2 H), 7.24 - 7.16 (m, 4 H), 
6.98 (s, 1 H), 6.80 (s, 1 H), 6.49 (d, J = 13.3 Hz, 2 H), 6.40 - 6.30 (m, 2 H), 4.32 (d, J = 7.0 Hz, 4 
H), 3.52 - 3.50 (m, 1 H), 3.14 - 3.10 (m, 1 H), 3.04 - 2.92 (m, 4 H), 2.77 (br. s, 3 H), 2.70 - 2.65 
(m, 1 H), 2.61 - 2.53 (m, 3 H), 2.38 (d, J = 5.1 Hz, 4 H), 2.26 (br. s., 7 H), 2.00 (br. s, 4 H), 1.95 - 
1.75 (m, 7 H), 1.67 (br. s., 4 H), 1.60 - 1.55 (m, 1 H), 1.41 (s., 9 H), 1.33 - 1.19 (m, 6 H), 1.12 (d, 




























Scheme 3.13. Synthesis of FL800-Cbl-COL. Synthesis of FL800-Cbl-COL from FL800-Cbl-
butyrate and amino-COL. 
FL800-Cbl-butyrate (2.1 mg, 900 nmol), HCTU (486 µg, 1.2 µmol), and DIPEA (3.1 uL, 
18 µmol) were mixed in DMF (100 µL) for 10 min. Aminocolchicine (640 µg, 1.8 µmol) was 
added, and the solution was reacted for an additional 2 h. The solution was diluted with 
deionized water (2.9 mL) and purified via HPLC (semi-preparative C18 column) using a binary 
gradient solvent system (A: H2O with 0.1% v/v TFA, B: CH3CN with 0.1% v/v TFA). Equilibration 
(10 min) was followed by a steadily changing gradient 97:3 A:B to 5:95 A:B over 50 min. Eluents 
were monitored at 700 nm, collected, and lyophilized to give a green solid (654 µg, 31% [from 










HR ESI MS C133H169N18O28PS3Co calculated for [M-+3H+]+2: m/z = 1328.0425, found 
1328.0464; [M-+4H+]+3: m/z = 885.6972, found 885.6997.  
1 H NMR (DMSO-d6, 400 MHz) δ = 8.59 (d, J = 13.7 Hz, 2 H), 8.30 - 8.12 (m, 2 H), 7.64 
(s, 1 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.37 (t, 7.8 Hz, 2 H), 7.28 - 7.13 (m, 3 H), 7.11 - 6.96 (m, 2 H), 
6.96 - 6.85 (m, 1 H), 6.85 - 6.71 (m, 2 H), 6.54 - 6.42 (m, 2 H), 4.41 - 4.27 (m, 2 H), 4.26 - 4.12 
(m, 2 H), 3.91 - 3.83 (m, 2 H), 3.82 - 3.75 (m, 1 H), 3.67 - 3.56 (m, 2 8 H), 3.54 - 3.46 (m, 2 H), 
3.19 - 3.10 (m, 2 H), 3.04 - 2.87 (m, 3 H), 2.82 - 2.74 (m, 1 H), 2.70 - 2.64 (m, 1 H), 2.60 - 2.53 
(m, 2 H), 2.40 - 2.34 (m, 2 H), 2.34 - 2.30 (m, 1 H), 2.29 - 2.26 (m, 3 H), 2.25 - 2.12 (m, 2 H), 
2.05 - 1.95 (m, 1 H), 1.92 - 1.87 (m, 1 H), 1.71 - 1.63 (m, 2 H), 1.61 - 1.53 (m, 1 H), 1.51 - 1.48 
(m, 1 H), 1.44 - 1.35 (m, 3 H), 1.29 - 1.19 (m, 4 H), 1.12 - 1.05 (m, 2 H), 0.91 - 0.76 (m, 2 H), 











































































































Figure 3.37. Photolysis of Cy5-Cbl-MTX (3g). (a) Reverse-phase HPLC trace of Cy5-Cbl-MTX 
incubated in PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was recorded at 
254 nm. (b) Reverse-phase HPLC trace of Cy5-Cbl-MTX in PBS (25 µM, pH = 7.4) irradiated 
with light with a wavelength of 645 nm for 15 min. The chromatogram was recorded at 254 nm. 
(c) ESMS spectrum of Cy5-Cbl-MTX recorded in positive-ion mode (peak a). Characteristic 
molecular and fragment ions: [M+3H]3+ (m/z 792.4), [M+4H]4+ (m/z 594.6). (d) ESMS spectrum 
of photolyzed product 3g′ recorded in positive-ion mode (peak b). Characteristic molecular and 
fragment ions: [M+H]+ (m/z 512.2). (E) ESMS spectrum of photolyzed product 3g" recorded in 
positive-ion mode (peak c). Characteristic molecular and fragment ions: [M+H]+ (m/z 496.2). (f) 
ESMS spectrum of photolyzed product B12a recorded in positive-ion mode (peak d). 
Characteristic molecular and fragment ions: [M-H2O+H]2+ (m/z 940.2), [M-H2O+2H]3+ (m/z 




















































Figure 3.38. Photolysis of Cy5-Cbl-PTX (3h). (a) Reverse-phase HPLC trace of Cy5-Cbl-PTX 
incubated in PBS (25 µM, pH = 7.4) in the dark for 15 min. The chromatogram was recorded at 
254 nm. (b) Reverse-phase HPLC trace of Cy5-Cbl-PTX in PBS (25 µM, pH = 7.4) irradiated 
with light with a wavelength of 645 nm for 15 min. The chromatogram was recorded at 254 nm. 
(c) Reverse-phase HPLC trace of isolated 3h". The chromatogram was recorded at 254 nm. (d) 
ESMS spectrum of Cy5-Cbl-PTX recorded in positive ion mode (peak a). Characteristic 
molecular and fragment ions: [M+2H]2+ (m/z 1437.8), [M+3H]3+ (m/z 958.9). (e) ESMS spectrum 
of photolyzed product Cy5-B12a recorded in positive-ion mode (peak b). Characteristic 
molecular and fragment ions: [M-H2O+H]2+ (m/z 940.2), [M-H2O+2H]3+ (m/z 627.2). (f) ESMS 
spectrum of photolyzed product 3h' recorded in positive-ion mode (peak c). Characteristic 
molecular and fragment ions: [M+H]+ (m/z 1012.6). (g) ESMS spectrum of photolyzed product 
3h" recorded in positive ion mode (peak d). Characteristic molecular and fragment ions: [M+H]+ 



















































Figure 3.39. Photolysis of FL800-Cbl-COL (3i). (a) Reverse-phase HPLC trace of conjugate 3i 
incubated in PBS in the dark for 60 min. The chromatogram was recorded at 254 nm. (b) 
Reverse-phase HPLC trace of FL800-Cbl-COL in PBS (pH = 7.4) irradiated with light with a 
wavelength of 730 nm for 60 min. The chromatogram was recorded at 254 nm. (c) ESMS 
spectrum of FL800-Cbl-COL recorded in positive-ion mode (peak a). Characteristic molecular 
and fragment ions: [M+2H]3+ (m/z 885.2). (d) ESMS spectrum of photolyzed product DY-B12a 
recorded in positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-H2O]2+ 
(m/z 1130.5), [M-H2O+H]3+ (m/z 754.1). (e) ESMS spectrum of photolyzed 3i' recorded in 
positive-ion mode (peak c). Characteristic molecular and fragment ions: [M+H]+ (m/z 442.2). (f) 
ESMS spectrum of photolyzed product 3i'' recorded in positive-ion mode (peak d). 
Characteristic molecular and fragment ions: [M+H]+ (m/z 444.1). (g) ESMS spectrum of 
photolyzed product 3i''' recorded in positive-ion mode (peak e). Characteristic molecular and 


























































Scheme 3.16. Synthesis of Cy5SO3--Cbl-Dox. 
Characterization of Photolysis Products of Cbl-BODIPY, Cbl-MTX, Cbl-COL, Cbl-PTX, 
Cy5-Cbl-MTX, FL800-Cbl-COL, and Cy5-Cbl-PTX. Cbl-BODIPY, Cbl-MTX, Cbl-COL, Cbl-PTX, 
Cy5-Cbl-MTX, FL800-Cbl-COL, and Cy5-Cbl-PTX (25 µM) in PBS were illuminated for 15 min 
using an Oriel Xe flash lamp (800 mJ, 62 Hz) as the light source with selective bandpass filters 
for 546 ± 10, 646 ± 10, and 780 ± 10 nm. Photolyzed samples of Cbl-BODIPY, Cbl-MTX, Cbl-
COL, Cbl-PTX, Cy5-Cbl-MTX, and FL800-Cbl-COL were analyzed by LC/MS using a linear 
gradient binary solvent system (solvent A: 0.1% formic acid/H2O; solvent B: 0.1% formic 
acid/methanol) with a ratio of A:B that varied from 95:5 to 5:95 (0 - 25 min). Photolyzed samples 
of Cy5-Cbl-PTX were analyzed by LC/MS using a linear gradient binary solvent system (solvent 
A: 0.1% formic acid/H2O; solvent B: 0.1% formic acid/methanol) with a ratio of A:B that varied 
from 50:50 to 5:95 (0 - 25 min). 
Loading of Phototherapeutics into Human Erythrocytes. Packed human erythrocytes (100 
µL) were washed 3X with erythrocyte buffer (L-15 media supplemented with 10% FBS) by 
suspension to 10% hematocrit and centrifugation (1000g, 3 min). Then, the 100 µL pellet was 
swollen in 10X the volume of water containing the appropriate concentration of the compound to 
be loaded and incubated on ice for 5 min. The erythrocytes were resealed by addition of 0.1 
volume of 10X PBS in order to render the solution isotonic. To ensure proper resealing, the 
erythrocytes were incubated at room temperature for 30 min before 3 wash steps in erythrocyte 
buffer.16  
Cbl-BODIPY Loading into Erythrocytes. Packed human erythrocytes (100 µL) washed 3X 
with erythrocyte buffer (L-15 media supplemented with 10% FBS) were exposed to Cbl-BODIPY 
as described in General Procedure for Loading of Phototherapeutics into Human Erythrocytes. 
Briefly, 100 µL of packed human erythrocytes were swollen in 10X the volume of water 
containing 5 µM Cbl-BODIPY and incubated on ice for 5 min. The erythrocytes were resealed by 
addition of 0.1 volume of 10X PBS and incubated at room temperature for 30 min. The 
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erythrocyte pellet was washed 3X in L-15 + 10% FBS by centrifugation (1000g, 3 min) and each 
supernatant was collected. The supernatants were collected and analyzed in order to assess 
whether any un-internalized Cbl-BODIPY remained in solution. Fluorescence in the 
supernatants was measured on a SpectraMax® Gemini EM dual-scanning microplate 
spectrofluorometer with Softmax Pro v. 5 software (λex = 645 nm, λem = 675 nm). To obtain 
accurate fluorescent measurements of BODIPY, all Cbl-BODIPY was cleaved by illumination of 
the supernatants under a 660 nm LED array for 15 min at room temperature. Fluorescence 
remaining after the third wash was calculated with an equation obtained by plotting fluorescence 
against wash number. This value was subtracted from all fluorescent measurements obtained 
during the light/dark experiments.  
BODIPY Release from Cbl-BODIPY-loaded Erythrocytes in Light and Dark. Erythrocytes 
were loaded with Cbl-BODIPY as described in Cbl-BODIPY loading into erythrocytes. 100 µL of 
a pellet of Cbl-BODIPY-loaded erythrocytes was suspended to 10% hematocrit in erythrocyte 
buffer. The erythrocytes were divided into two equal volume aliquots of 500 µL each. One 
aliquot was exposed to a 660 nm LED array (8x10’’ MacNan red and magenta colored film gels) 
for 3 min at room temperature while the other aliquot was kept in the dark. All erythrocytes were 
pelleted by centrifugation (1000g, 3 min) and the supernatants collected. The pellet (100 µL) 
was washed 5X in erythrocyte buffer in order to remove any residual compound. The pellet was 
then lysed completely by addition of 10X the volume of 0.05% Triton X-100. Fluorescence in the 
supernatants and the lysed cells was measured on a SpectraMax® Gemini EM dual-scanning 
microplate spectrofluorometer with Softmax Pro v. 5 software (λex = 645 nm, λem = 675 nm) and 
converted to released BODIPY concentration using a standard curve. To obtain accurate 
fluorescent measurements of BODIPY, all Cbl-BODIPY was cleaved by illumination of all 
samples under a 660 nm LED array for 15 min at room temperature. Final concentrations were 
calculated by subtracting concentration values obtained from mock loaded erythrocytes (treated 
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as described in the Loading of Phototherapeutic into Human Erythrocytes but in the absence of 
fluorescent compound) from the values obtained from the loaded erythrocytes.  
Analysis of HeLa cells Exposed to Erythrocytes Loaded with Phototherapeutics. 
Treatment and analysis of HeLa cells exposed to Cbl-MTX loaded erythrocytes. HeLa cells were 
plated in 12-well tissue culture plates at a density of 1.0 x 105 cells per well and maintained at 
37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% 
Pen-Strep). The following day, cells were washed 3X with PBS, then treated with 200 µL of a 
suspension of Cy5-Cbl-MTX loaded erythrocytes in L-15 (10 µM Cy5-Cbl-MTX; 10% hematocrit) 
with 10% FBS or 200 µL L-15 with 10% FBS (control cells). Cells were then either kept in the 
dark at room temperature, or exposed to a 525 nm LED array for 45 min at room temperature. 
At the end of the photolysis interval, all cells were incubated for 45 min in a 37 ºC in a humidity-
controlled incubator. Next, cells were washed 3 x 1 mL with PBS and trypsinized with 300 µL 
0.05% Trypsin (Gibco) for 5 min at 37 ºC. Trypsinized cells were then pelleted (5 min, 2000 rpm, 
4 ºC), washed 1 x 300 µL PBS, and then pelleted again. After removal of the supernatant, cell 
pellets were heated at 52 ºC in a temperature controlled heat block for 3 min, and then cooled 
for 3 min at room temperature. 30 µL of lysis buffer (25 mM Tris HCl/2 mM DTT/1X Pierce HALT 
protease and phosphatase inhibitor) was added to each pellet, which were then subjected to 2 
freeze-thaw cycles in liquid N2. The resulting solutions were then spun at 17000 x g from 20 min 
at 4 ºC. The resulting supernatants were removed and combined with 6X LSB-BME and boiled 
for 4 min at 95 ºC, then analyzed by western blot (Overnight incubation at 4 ºC with Santa Cruz 
anti-DHFR E18 primary antibody (1:1000 in TBST/5%BSA) and Cell Signaling anti-GAPDH 








Treatment and Analysis of HeLa cells Exposed to Cbl-COL-loaded Erythrocytes. HeLa 
cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well 
and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, cells were washed 3x with PBS, then treated with 
200 µL of a suspension of Cbl-COL loaded erythrocytes in L-15 with 10% FBS (10 µM Cbl-COL; 
10% hematocrit) or 200 µL L-15 with 10% FBS (control cells). Cells were then either kept in the 
dark or exposed to a 525 nm LED array (8x10’’ MacNan green colored film gels) for 45 min at 
room temperature. All cells were incubated for 45 min in a 37 ºC humidity-controlled incubator 
post-photolysis. At the conclusion of the incubation period, cells were washed 3 x 1 mL with 
PBS and then fixed with 4% paraformaldehyde in PBS at room temperature for 10 min. Cells 
were washed 2 x 1 mL with PBS, blocked and permeabilized for 20 min in antibody dilution 
buffer (1% BSA; 0.3% Triton-X-100; PBS) at 4 ºC. Blocking was followed by overnight 
incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:10 11 incubation 
with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 
dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were 
acquired with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 
camera, 60X oil objective and a FITC filter cube (Semrock). Metamorph software was employed 










Treatment and Analysis of HeLa cells Exposed to Cbl-PTX-loaded Erythrocytes. HeLa 
cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well 
and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, a 1 mL aliquot of loaded erythrocytes (2 µM Cbl-
PTX; 10% hematocrit) was divided in two 500 µL portions. One portion was exposed to 525 nm 
light for 30 min at room temperature, and the other kept in the dark for 30 min at room 
temperature. Both aliquots were then spun down to pellet the erythrocytes (3 min at 1000g), and 
the resulting supernatants harvested and applied directly to a PBS-washed layer of adherent 
HeLa cells in a Mattek dish. The cells were wrapped in foil to protect them from light exposure, 
and returned to a tissue culture incubator for overnight incubation. 24 h post-treatment, cells 
were gently washed with PBS, and fixed with 4% paraformaldehyde in PBS for 10 minutes at 
room temperature. Cells were then washed 2 x 1 mL with PBS, blocked and permeabilized for 
20 min in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS) at 4 ºC. Blocking was 
followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) 
at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then 
washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 secondary 
antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. After washing 
cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, 60X oil objective and a FITC filter cube (Semrock). 








Treatment and Analysis of HeLa cells Exposed to Cy5-Cbl-MTX-loaded Erythrocytes. 
HeLa cells were plated in 12-well tissue culture plates at a density of 1.0 x 105 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM 
(10% FBS, 1% Pen-Strep). The following day, cells were washed 3x with PBS, then treated with 
200 µL of a suspension of Cy5-Cbl-MTX loaded erythrocytes in L-15 (10 µM Cy5-Cbl-MTX; 10% 
hematocrit) with 10% FBS or 200 µL L15 with 10% FBS (control cells). Cells were then either 
kept in the dark at room temperature, or exposed to a 660 nm LED array for 45 min at room 
temperature using red and fuchsia color film gels (MacNan). At the end of the photolysis 
interval, all cells were incubated for 45 min in a 37 ºC in a humidity-controlled incubator. Next, 
cells were washed 3 x 1 mL with PBS and trypsinized with 300 µL 0.05% Trypsin (Gibco) for 5 
min at 37 ºC. Trypsinized cells were then pelleted (5 min, 2000 rpm, 4 ºC), washed 1 x 300 µL 
PBS, and then pelleted again. After removal of the supernatant, cell pellets were heated at 52 
ºC in a temperature controlled heat block for 3 min, and then cooled for 3 min at room 
temperature. 30 µL of lysis buffer (25 mM Tris HCl/2 mM DTT/1X Pierce 12 HALT protease and 
phosphatase inhibitor) was added to each pellet, which were then subjected to 2 freeze-thaw 
cycles in liquid N2. The resulting solutions were then spun at 17000 x g from 20 min at 4 ºC. The 
resulting supernatants were removed and combined with 6X LSB-BME and boiled for 4 min at 
95 ºC, then analyzed by western blot (Overnight incubation at 4 ºC with Santa Cruz anti-DHFR 
E18 primary antibody (1:1000 in TBST/5%BSA) and Cell Signaling anti-GAPDH antibody 








Treatment and Analysis of HeLa cells Exposed to Cy5-Cbl-PTX-loaded Erythrocytes. 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per 
well and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in 
DMEM (10% FBS, 1% Pen-Strep). The following day, a 1 mL aliquot of loaded erythrocytes (5 
µM Cy5-Cbl-PTX; 10% hematocrit) was divided in two 500 µL portions. One portion was 
exposed to 660 nm light for 40 min at room temperature, and the other kept in the dark for 40 
min at room temperature. Both aliquots were then spun down to pellet the erythrocytes (3 min at 
1000g), and the resulting supernatants harvested and applied directly to a PBS washed layer of 
adherent HeLa cells in a Mattek dish. The cells were wrapped in foil to protect them from light 
exposure, and returned to a tissue culture incubator for overnight incubation. 16 h post-
treatment, cells were gently washed with PBS, and fixed with 4% paraformaldehyde in PBS for 
10 min at room temperature. Cells were then washed 2 x 1 mL with PBS, blocked and 
permeabilized for 20 min in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS) at 4 ºC. 
Blocking was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell 
Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Cells were then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 
secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a FITC filter 








Treatment and Analysis of HeLa cells Exposed to FL800-Cbl-COL-loaded Erythrocytes. 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per 
well and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in 
DMEM (10% FBS, 1% Pen-Strep). The following day, cells were washed 3x with PBS, then 
treated with 200 µL of a suspension of FL800-Cbl-COL loaded erythrocytes in L-15 with 10% 
FBS (10 µM FL800-Cbl-COL; 10% hematocrit) or 200 µL L-15 with 10% FBS (control cells). 
Cells were then either kept in the dark or exposed to a 780 nm LED array for 45 min at room 
temperature using the appropriate filter sets. All cells were incubated in the dark for an 
additional 45 min in a 37 ºC in a humidity-controlled incubator post-photolysis. At the conclusion 
of the incubation period, cells were washed 3 x 1 mL with PBS and then fixed with 1 mL of 4% 
paraformaldehyde in PBS at room temperature for 10 min. Cells were washed 2 x 1 mL with 
PBS and blocked and permeabilized for 20 min in antibody dilution buffer (1% BSA; 0.3% 
Triton-X-100; PBS) at 4 ºC. Blocking was followed by overnight incubation at 4 ºC with mouse 
anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before incubation with 
anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution in 
antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil 
objective and FITC and Cy5 filter cubes (Semrock). Metamorph software was employed for 








Treatment and Analysis of HeLa cells Exposed to Erythrocytes Loaded with both FL800-
Cbl-COL and Cbl-BODIPY. HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a 
density of 1.0 x 105 cells per well and maintained at 37 ºC in a humidity-controlled incubator with 
a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were 
washed 3x with PBS, then treated with 200 µL of a suspension of FL800-Cbl-COL and Cbl-
BODIPY loaded erythrocytes in L-15 with 10% FBS (erythrocytes were co-loaded with 10 µM 
FL800-Cbl-COL and 2 µM Cbl-BODIPY at 10% hematocrit) or 200 µL L-15 with 10% FBS 
(control cells). Cells were then either kept in the dark or exposed to a 660 nm LED array or 780 
nm LED array for 40 min at room temperature using the appropriate filter sets (red and 
magenta, respectively), followed by a 40 min incubation period in the dark at room temperature. 
Cells treated with both light conditions were treated with 780 nm light for 40 min followed by 660 
nm light for 40 min. At the conclusion of the incubation period, cells were washed 3 x 1 mL with 
PBS and then fixed with 1 mL of 4% paraformaldehyde in PBS for 10 min. Cells were washed 2 
x 1 mL with PBS and blocked and permeabilized for 20 min in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS) at 4 ºC. Blocking was followed by overnight incubation at 4 ºC with 
mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer 
(1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before 
incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 
1:500 dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were 
acquired with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 
camera, 60X oil objective and FITC and Cy5 filter cubes (Semrock). Metamorph software was 






Treatment and Analysis of HeLa cells Exposed to Pooled Erythrocytes Separately 
Loaded with FL800-Cbl-COL and Cbl-BODIPY. HeLa cells were plated in 35 mm glass bottom 
dishes (Mattek) at a density of 1.0 x 105 cells per well and maintained at 37 ºC in a humidity-
controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The 
following day, cells were washed 3X with PBS, then treated with 200 µL of a suspension of 
FL800-Cbl-COL and Cbl-BODIPY loaded erythrocytes in L-15 with 10% FBS (separate aliquots 
of erythrocytes were loaded with 10 µM FL800- Cbl-COL and 10 µM Cbl-BODIPY, respectively, 
at 10% hematocrit and then pooled in a 2:1 ratio immediately prior to the cell treatment). Cells 
were then either kept in the dark 14 or exposed to a 660 nm LED array or 780 nm LED array for 
40 min at room temperature and red and fuchsia color film gels (MacNan), followed by a 40 min 
incubation period in the dark at room temperature. Cells treated with both light conditions were 
treated with 780 nm light for 40 min followed by 660 nm light for 40 min. At the conclusion of the 
incubation period, cells were washed 3 x 1 mL with PBS and then fixed with 1 mL of 4% 
paraformaldehyde in PBS for 10 min. Cells were washed 2 x 1 mL with PBS and blocked and 
permeabilized for 20 min in antibody dilution buffer (1% BSA; 0.3% TritonX-100; PBS) at 4 ºC. 
Blocking was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell 
Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Cells were then washed with PBS (3 x 5 min) before incubation with anti-mouse AlexaFluor 488 
secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and FITC and Cy5 
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CHAPTER 4: LIGHT ACTIVATED DRUG DELIVERY: GENERATION 3, PRE-CLINICAL 
MODELS 
 
The work in this chapter was a collaboration between Christina M. Marvin, Song Ding, Rachel E. 
White, Natalia Orlova, Qunzhao Wang, and Emilia M. Zywot, Paul A. Dayton, and David S. 
Lawrence. Christina M. Marvin, the author of this dissertation, authored the chapter and 
contributed the most experimental effort and scientific ideas.  
 
4.1. Background  
The American Cancer Society has predicted that more than 1.5 million new cases of 
cancer will be diagnosed in 2018, resulting in approximately 600,000 deaths.1 
Chemotherapeutics remain the most widely administered therapy to treat solid tumors. 
However, therapeutic potential is most often limited by systemic toxicity caused by off target 
side effects.2,3 Given this challenge, drug platforms that locally deliver efficacious therapeutic 
agents at a tumor site, while sparing healthy tissue, are highly sought after.4–6 For example, 
antibody-drug conjugates (ADC) bind to cancer-specific antigens on tumor cells and the 
subsequent release of the covalently bound drug induces cell death. However, uneven 
distribution at the tumor site impedes therapeutic efficacy.7 In addition, the low drug payload of 
ADCs, combined with relatively few copies of the cancer antigen on the cell surface, limits the 
number of drug molecules that can be delivered to the diseased site.8–10 Nanoparticles offer 
attractive properties as alternative drug delivery vehicles. However, their short circulation time 
(often on the order of minutes) and effective drug release at the diseased site remain active 
areas of research. In the latter instance, external triggers, including light, have been used to 
elicit drug discharge in a spatially-selective fashion.11 Indeed, given the ability to modulate light 
spatially, temporally, by intensity, and by wavelength, it is not surprising that a wide variety of 
light responsive agents, from proteins to drugs, have been reported.12–14 
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Nonetheless, the development of long-lived, widely distributed phototherapeutic agents 
that respond to tissue-penetrating wavelengths remains a sought-after goal. 
The challenges associated with targeted delivery have been tackled in the Lawrence lab 
using a finely tuned photo-activatable drug delivery system in which vitamin B12 (B12) acts as a 
scaffold for the light-sensitive release of appended therapeutic agents. This system has the 
potential to release a wide array of small molecule drugs with unprecedented spatial and 
temporal control at wavelengths absorbed by the corrin ring of B12 (<560 nm). Modifications 
with red and far-red fluorophores permit use in biological systems by extending the platform’s 
ability to collect light into the optical window of tissue (600 - 1000 nm).15 The bioavailability and 
circulation of the B12-drug conjugates have been enhanced by sequestering these agents into 
red blood cell (RBC) carriers. RBCs are biocompatible, circulate for up to 3 months, and have a 
large payload capacity, thus making them attractive drug carriers.16,17 
4.2. Design on the B12-based Phototherapeutic, Cy5-B12-TAX 
 
The encapsulation of B12-based phototherapeutics into murine RBCs (mRBCs) was 
accomplished using a newly modified dialysis loading procedure17–19 and demonstrate spatially-
focused photo-triggered release of a cytotoxic agent into healthy and disease animal models 
(Figure 4.1). This report presents the first biological application of this system in vivo. A B12-
taxane conjugate (B12-TAX) was chosen as a model chemotherapeutic. Taxanes are 
medicinally useful anti-mitotic chemotherapeutics used to treat various solid tumors including 
breast, gastric, prostate, and non-small cell lung cancers, but are known to elicit undesired off 























Figure 4.1. RBC loading and photo-induced TAX release. (a) Native mRBCs are swollen in 
hypotonic PBS (80 mOsm/L) with glucose, creating pores in the cell membrane that allow Cy5-
B12-TAX to enter the cell interior. The cells are subsequently resealed by restoring the solution 
to isotonic conditions (300 mOsm/L). (b) Photo-triggered release of TAX from carrier mRBCs. 
Loaded mRBCs are injected into circulation. Illumination of the tumor region with appropriate 
long wavelength light results in photolytic cleavage of Co-C bond, freeing the membrane 
permeable TAX from the membrane impermeable B12 anchor, thereby enabling TAX delivery to 






The photoresponsive TAX species was synthesized by attaching a Cy5 fluorophore to 
the ribose 5’-OH and a TAX ligand onto the Co of B12 (Scheme 4.1).22 Appendage of the red 
fluorophore Cy5 to B12 results in long wavelength controlled photolysis and drug release. Since 
both the drug and the light absorbing fluorophore can be finely tuned, B12-based 
phototherapeutics have the potential to treat a wide range of diseases within the optical window 
of tissue, from arthritis to solid tumors.  
4.3. Adaption of an Osmotic Loading Procedure to Mouse RBCs 
The lifetime of chemotherapeutics is typically on the scale of hours to days. RBC carriers 
have the potential to extend circulation to weeks or months. A modified RBC loading procedure 
based on creating an osmotic gradient between the inside and the outside of the RBC 
membrane was developed to take advantage of these natural vesicles. Briefly, washed mRBCs 
were incubated with Cy5-B12-TAX or the control conjugate Cy5-B12-OH2 (Scheme 4.2). The 
mixtures were dialyzed against hypotonic PBS containing 6 mM glucose. Low salt conditions 
promote entry of water into the RBCs, inducing the cells to swell and generating pores in the 
membrane through which B12 conjugates can enter. Following dialysis, the pores were resealed 
in isotonic PBS, trapping membrane impermeable B12-drug conjugates within the RBC interior. 
Widefield microscopy images indicate successful loading and normal morphology of loaded 
mRBCs (Figure 4.2). This procedure produces a final loading concentration of 39 ± 4 μM Cy5-
B12-TAX/RBC with a cell recovery of 53 ± 6%. The control B12 derivative, Cy5-B12-OH2 is 
loaded at a concentration of 32 ± 2 μM Cy5-B12-OH2/RBC, with a cell recovery of 63 ± 4% 

















Figure 4.2. mRBCs internally and externally loaded with fluorescent material. Top: Transmitted 
images of internally loaded (Cy5-B12-TAX and Cy5-B12-OH2), externally loaded (DiD), and native 









Figure 4.3. Loading efficiency of Cy5-B12-R conjugates. Concentrations of Cy5-B12-TAX (39 ± 





















Figure 4.4. Quantification of [Cy5-B12-R]/RBC. Standard curves at 645 nm for (a) Cy5-B12-









Figure 4.5. UV-Vis absorbance spectra of Cy5-B12-TAX (solid black line) and Cy5-B12-OH2 
(solid grey line). Conjugates were extracted from mRBCs with ethanol. The Cy5 peak at 649 nm 



















































































































mRBCs loaded with Cy5-B12-TAX, Cy5-B12-OH2, or the membrane labeling dye, 1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine (DiD) were characterized using imaging flow 
cytometry. Figure 4.6 shows the results of histograms of in-focus singlets. Cells that display a 
fluorescent intensity value over 1 x 104 (linear region of interest) are considered to be loaded.  
Using this threshold, 99.4% and 99.7% of the Cy5-B12-TAX and Cy5-B12-OH2 exposed cells 
contain the B12-conjugate, respectively. Narrow distributions indicate that internally loaded 
mRBCs are uniformly loaded. In contrast, the widened histogram of cells externally decorated 
with DiD indicates a heterogeneous dispersal of the fluorophore amongst the RBC population, 
yielding a loading efficiency of only 49.2%.  
Flow cytometry side scattering (SSC) is related to the complexity of structures in the cell 
interior and surface shape.23 Figure 4.7 demonstrates that side scattering variability is more 
significant in cells subjected to the internal loading procedure, suggesting a less consistent 
internal composition. Since at least 90% of RBC internal composition is hemoglobin24,25 and this 
component is visibly exchanged with the environment during internal loading, it is suspected 
that heterogeneous loss of this protein may relate to the observed side scattering effect. Slight 
alterations in surface shape due to membrane disruption in some cells after the loading 
procedure may also play a role.26 Alternatively, mRBCs decorated with DiD exhibit a narrow 
side scattering pattern that more closely resembles native mRBCs. These experiments indicate 
that while external loading may preserve the internal characteristics of mRBCs to a greater 
degree, internal loading has the potential to load more material with a more uniform composition 
per RBC.  
Images from the flow cytometry study in Figure 4.8 reveal that DiD is retained on the 
membrane, whereas the B12 conjugates are loaded in the cell interior. Due to the imaging 
modality associated with widefield microscopy and flow cytometry imaging, internally loaded 
cells occasionally appear to be only membrane loaded due to apparent fluorescent differences 
between the edge and the center created by the RBC’s biconcave shape.  
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Validation that mRBCs entrap Cy5-B12-TAX in the cell interior is demonstrated by 
confocal microscopy images of Cy5-B12-TAX in Figure 4.9, in which both the center and edge 












































Figure 4.6. Flow cytometry histograms of internally and surface loaded mRBCs. Measurements 
of native mRBCs (magenta), DiD mRBCs (green), Cy5-B12-OH2 mRBCs (blue), and Cy5-B12-
TAX mRBCs (black) reveal that internally loaded Cy5-B12-OH2 and Cy5-B12-TAX load 
homogenously with a loading efficiency of 94.8% and 99.4%, respectively. DiD loading is 
heterogeneous with a loading efficiency of 49.3%. Cells with a fluorescent intensity of at least 
1x104 (defined by the straight line region of interest) are considered loaded. Normalized cell count 






















Figure 4.7. Plots of Cy5 intensity vs SSC. These plots demonstrate variability of internal 
complexity, as visualized by increased variability in side scatter, undergone by mRBCs when 









Figure 4.8. Internal vs external loading visualized with on an imaging flow cytometer. Top: 
Fluorescenc and Bottom: bright-field images of mRBCs. DiD labels the exterior, while the Cy5-























Figure 4.9. Loaded mRBCs viewed with confocal microscopy confirm loading in the internal 
cavity. (a) Fluorescent confocal microscopy taken as a Z stack through mRBCs loaded with 
Cy5-B12-TAX. The left and right images were taken on different planes of the same cells. The 
biconcave shape of the cell creates different fluorescent patterns on different planes. Yellow 
dashed lines are representative straight line region of interest. Scale bar = 6 µm. (b) 
Quantification across straight-line regions of interest in 15 representative cells confirm loading in 
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4.4. Considerations when Adapting RBC Loading to Mouse Species 
Loaded mRBCs retain fluorescent conjugates for at least 5 h in vitro, the length of time 
for the reported in vivo experiments. It is noted that loaded mRBCs display lower stability and 
membrane integrity than native mRBCs when stored in vitro for 24 h (Figure 2.10). However, 
this behavior in mouse cells is likely irrelevant to their human counterparts. As reported 
previously and demonstrated in Figure 4.11. mRBCs are significantly more fragile and 
susceptible to lysis than their human counterparts27 during ex vivo processing and under 
environments that mimic in vivo conditions.28 This fragility suggests that preclinical work with 
resealed mRBCs should be conducted within hours of loading in order to obtain the most 
relevant physiological results. By contrast, internally loaded human RBCs exhibit a lifetime and 
























Figure 4.10. Loaded and native mRBCs stored in PBS for 24 h. Top: Transmitted and Bottom: 
fluorescent images. Internally loaded (left) and native (right) mRBCs immediately after loading 








Figure 4.11. Comparison of RBC viability during in vitro storage between human and mouse 
species. Human and mouse RBCs were either loaded with Cy5-B12-TAX or left untreated and 
stored in DMEM + 1% FBS for 5 days. The RBC volume (% pellet) and percent hemolysis were 
measured. (a) By day 5, both the loaded and untreated mouse RBCs had almost completely 
lysed as measured by the remaining pellet. Loaded human RBCs maintained 70 ± 7% of their 
starting volume and untreated human RBCs maintained 89 ± 3% of their volume. (b) 
Spectrometric measurement of hemoglobin in the supernatant confirmed cell lysis in mouse 




4.5. B12-loaded mRBCs Circulation Studies Demonstrate RBC Viability in vivo 
The circulation and cytotoxicity of TAX released at a localized area in the vasculature 
were first evaluated in healthy FVB mice. Intravital imaging (Figure 4.12) was used to assess 
whether loaded mRBCs maintain their cargo during circulation, through monitoring cells 
internally loaded with non-photocleavable B12≡Cy529,30 (Scheme 4.3) or externally loaded with 
DiD. Non-photocleavable models were necessary since the laser wavelength (633 nm) cleaves 
the otherwise photo-sensitive Co-C bond in Cy5-B12 derivatives. For each experiment, one ear 
was secured under the onboard microscope laser while the second ear was kept in the dark. A 
633 nm laser at 30% laser power illuminated a roughly 0.5 mm diameter region every 5 s for a 
total of 90 min. Loaded DiD fluorescence is fairly consistent, retaining 69 ± 2% of its 
fluorescence over 90 min. Loaded B12≡Cy5 clearance is initially more rapid, but still maintains 
53 ± 5% of its fluorescence after 90 min (Figures 4.13 - 4.14). The initial clearance of a 
subpopulation of loaded mRBCs is most likely due to damage during the loading procedure, 
which may structurally weaken the relatively fragile mRBCs. As noted above, mice may be ideal 
candidates for preclinical investigation, but mRBCs are less than ideal models for circulation 
studies given their frailty relative to the more robust human cells. To validate that mRBC carriers 
extend B12 circulation, B12≡Cy5 was directly injected into the bloodstream in the absence of 
mRBC carriers. Within 1 min, the fluorescent conjugate was observed to leak out of blood 


















Figure 4.12. Intravital imaging setup. Imaging of the vasculature of the ear of an FVB mouse. 
Fluorescently labeled mRBCs were tail vein injected at 75 - 90% hematocrit and the blood 
vessels were observed under a 10X objective using a 633 nm laser. 
 
Figure 4.13. Circulation assessed via intravital imaging of mouse ear vasculature. mRBCs and 
free drug were injected via tail vein injection. Top: DiD loaded mRBCs. Middle: B12≡Cy5-loaded 











Figure 4.14. Quantification of circulating labelled RBCs. mRBCs loaded with DiD remain in 
circulation with a slope of -6 after the first 20 min and 76% of the initial fluorescence remaining 
after 90 min. Intensity of B12≡Cy5 loaded mRBCs likewise initially drops during the first 20 min, 
with a slope of -21. The fluorescence intensity remains stable (47% of the initial fluorescence) 
from 20 min to 90 min post-injection. By contrast, the free B12≡Cy5 conjugate is quickly and 
continuously cleared from vasculature, disseminating into the tissue. Plots are an average of 6 










































4.6. Site-specific TAX Release and Visualization of Endothelial Damage  
TAX (as well as other taxane derivatives) is a cytotoxic agent31–33 and it has been shown 
that endothelial cells, which line blood vessels, are particularly susceptible to taxane cytotoxicity 
at sub-clinical concentrations.34 Cy5-B12-TAX loaded mRBCs were administered to FVB mice 
and a small region of one ear illuminated as described above. The excitation laser (633 nm) on 
the intravital imaging microscope both activates and visualizes photosensitive therapeutics. A 
large extravasation of Cy5 fluorescence overtakes the imaging frame within 90 min, signifying 
release of loaded fluorescent material (Figure 4.15). Fluorescent extravasation is not observed 
with either DiD or B12≡Cy5 loaded mRBCs (Figure 4.13). There are several possible 
explanations for the extravasation of fluorescence. First, blood vessel integrity is known to be 
compromised by taxanes and therefore it is possible that microhemorragic events have 
occurred as a consequence of TAX photo-release. However, significant tissue infiltration by 
RBCs via histopathology (vide infra) was not observed. Second, the observed spread of 
fluorescence into the surrounding tissue may be a consequence of light-triggered mRBC rupture 
induced by taxane release, resulting in the discharge of the Cy5-B12-OH2 photo-byproduct. 
However, illumination of Cy5-B12-TAX loaded mRBCs in vitro does not lead to the release of 
fluorescent material, consistent with the notion that the mRBCs are intact following drug release 
(Figure 4.16). Third, TAX-induced endothelial layer damage could lead to hemolysis of 
circulating RBCs and the release of the Cy5-B12 conjugate, which would extravasate into the 
surrounding tissue (vide supra). Damage to the endothelium is known to activate the 
coagulation cascade35, resulting in vessel congestion (packed RBCs), the deposition of fibrin 
particles and subsequent rupture of RBCs as they circumnavigate the impaired vessel.36 
Indeed, these events are observed in a variety of conditions (microangiopathic hemolytic 
anemias37,38 and with various agents (venoms and drugs).33,36 
The fluorescent extravasation observed via intravital imaging implies spatially localized 
vascular damage at the site of illumination. Following intravital imaging, mice were euthanized 
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and the ears harvested, which were immediately fixed, subsequently embedded in paraffin, and 
sectioned. Hematoxylin and eosin (H&E)-stained images reveal that the blood vessels in the 
light-treated ear (Figure 4.17) are filled with abundant, packed red blood cells (congestion), 
which is consistent with damage to the endothelium.39 The vasculature of the treated area is 
extremely distended, with the lumina surrounded by an out-stretched layer of endothelial cells. 
In contrast, the non-illuminated ear (Figure 4.17) displays no venous congestion, and the lumen 
contains a moderate number of RBCs with free space between cells. The same histological 
indications of vascular damage are observed when a high concentration of free docetaxel is 
topically administered to the ear vasculature. Damage is absent in healthy mouse ears (Figures 
4.18 - 4.19). Finally, little to no histological damage is observed when Cy5-B12-OH2 loaded 
mRBCs were injected into mice and photo-illuminated during intravital imaging. It should be 
noted that with Cy5-B12-OH2-loaded mRBCs, no significant extravasation is observed under 
microscopy as was seen with Cy5-B12-TAX. A minimal disturbance in microvasculature (Figure 
4.20) was observed, which may be due to the photosensitizing effects of Cy5, resulting in the 
production of reactive oxygen species.40 Photodynamic therapy studies have demonstrated that 
smaller microvasculature structures are more sensitive to photosensitizer-induced vessel 
damage than larger vessels.41,42 Endothelial damaged observed in histological slicing is also 
minimal in mice injected with Cy5-B12-OH2 under the intravital imaging conditions (Figure 4.19). 
In short, illumination of mRBCs conveying Cy5-B12-OH2 has little or no effect on the integrity of 
the vasculature relative to that of mRBCs transporting Cy5-B12-TAX. Finally, it was noted that 
the maximum tolerated dose of docetaxel injected intravenously to mice is 10 mg kg-1 (300 
μg/mouse). In contrast, the sum total TAX content in the transfused mRBCs is only 1 μg/mouse. 
RBC-mediated circulation of Cy5-B12-TAX ensures the widespread dispersal of sequestered, 
and therefore inactive, TAX. The release of a high payload at the target site appears to account 

















Figure 4.15. mRBC stability under 660 nm light. mRBCs were internally loaded, one sample 
with Cy5-B12-TAX and the other with Cy5-B12-OH2. Both samples were incubated for 10 min 
either under 660 nm LED light or in the dark. Little to no increase of Cy5 fluorescence in the 
supernatant of pelleted cells was observed with either a) Cy5-B12-TAX loaded mRBCs or b) 
Cy5-B12-OH2 loaded mRBCs after incubation. A slight decrease in fluorescence in the Cy5-
B12-TAX loaded sample under 660 nm was observed, most likely a result of photobleaching 
Cy5 material not completely removed after washes. c) Lack of substantial hemolysis increase in 
light conditions compared to dark conditions was confirmed by measuring the absorbance of 













































































Figure 4.16. Light-directed physiological effect of photo-released taxane derivative from Cbl 
scaffold. Representative time lapse of the extraversion of Cy5-B12-TAX when circulating mRBC 
carriers are illuminated with a 633 nm laser. Over time, fluorescence originally encapsulated in 
the RBCs is seen to escape from the vasculature and spread into the surrounding tissue.  0 min, 
immediately after injection. 15 min, fluorescence extraversion is seen in the upper right corner. 
58 min, more fluorescence in the upper right corner is observed. 1 h and 25 min, large 





















Figure 4.17. Histological differences between treated and untreated mouse ears. Left: 
Illuminated ear treated with a 633 nm laser in 5 s pulses for 1.5 h. Right: Non-illuminated ear 
kept in the dark. Endothelial agitation is only be observed in the illuminated ear. Black arrows 





Figure 4.18. Histology controls for TAX release from Cy5-B12-TAX loaded mRBCs. Left: A drop 
of highly concentrated free docetaxel (0.4 mM) in DMSO was placed on a mouse ear. Vessel 
morphology is observed that is analogous to that in the illuminated ear in Figure 4.16. Middle: 
Blood vessels in untreated mouse ear. Right: Blood vessels in mouse injected with Cy5-Cbl 






Figure 4.19. Untreated FVB wild type ears. H&E staining shows normal ears, with no venous 
congestion and a healthy (moderate) amount of RBCs contained in the lumina. The left and right 














Figure 4.20. mRBCs loaded with Cy5-B12-OH2 do not elicit a major disruptive response in the 
main vasculature endothelium. (a) mRBCs loaded with Cy5-B12-OH2 were injected via tail vein 
and visualized with intravital imaging. Unlike the Cy5-B12-TAX injection, there is no large 
observable release of fluorescence into the tissue. There is some increased fluorescence in the 
less robust microvasculature, possibly due to Cy5-induced radicals. (white arrows) (b) H&E 
staining of both illuminated and dark ears of mice injected with Cy5-B12-OH2. Minimal 
congestion and inflammation is evidenced by neuropil presence and a moderate amount of red 
blood cells is contained in the lumina. The left and right panels represent the left and right ears, 












4.7. Endothelial Damage in a Tumor Model Visualized via Ultrasound 
To further validate the local effect of released TAX on blood vessel integrity and confirm 
spatially-delimited impact in a disease model, Cy5-B12-TAX loaded mRBCs were intravenously 
injected into Nu/Nu-tumor-bearing mice. The tumor microenvironment and surrounding 
vasculature were visualized with acoustic angiography, using microbubbles as contrast agents 
(Figure 4.21).43,44 After injection of the Cy5-B12-TAX-containing mRBCs, TAX was released at 
the tumor site by spatial illumination of the tumor with a 100 mW, 655 nm laser for 5 min. 3D 
images of the tumor and surrounding tissue were acquired every 10 min for a total of 40 min 
(Figure 4.22).  
Microbubble retention was quantified in Figure 4.23 by taking the ratio of the sum of 
microbubble coverage within the tumor volume over the sum of the total tumor area for the 
entire 3D volume. Results obtained with Cy5-B12-TAX loaded mRBCs and light treatment 
showed microbubble tumor-retention values (calculated as the amount of contrast agent in a 
region) more than double the initial baseline 40 min after light treatment. This increase in 
contrast intensity suggests that surrounding blood vessel disruption occurs with enough potency 
to promote contrast agent pooling in the tumor. These results correlate well with the intravital 
imaging studies, in which extravasation begins to be observed within 15 min and intensifies by 
60 min (Figure 4.15). Contrast agent accumulation at the tumor site was not observed with 
mock loaded mRBCs, Cy5-B12-OH2 loaded mRBCs with light treatment, or Cy5-B12-TAX in the 
dark. These controls further validate that the vessel-damaging action of the photo-released 

















Figure 4.21. Ultrasound imaging setup. A mouse is placed under a water bath, with ultrasound 
gel applied to the tumor site to help connect the tissue and the transducer used for imaging. 
Illumination was performed using a 100 mW, 660 nm laser positioned at an angle of 90° in 






























Figure 4.22. Vascular effects in a tumor model. Maximum intensity projection acoustic 
angiography images acquired of the flank of SVR-tumor-bearing, female Nu/Nu mice. Images 
were acquired before injection (baseline) and 5, 15, 25, 35, and 45 min after beginning of light 
treatment (or dark incubation in the case of the control). Mice were either (a) injected with Cy5-
B12-TAX and treated with a 655 nm laser (100 mW) at the tumor site (b) injected with Cy5-B12-
TAX and kept in the dark (c) injected with Cy5-B12-OH2 and treated with a 655 nm laser or (d) 
injected with mock loaded mRBCs and treated with a 655 nm laser. Tumors are indicated by 
dotted regions. (e) An expanded image of (a) where the mouse was injected with Cy5-B12-TAX 













Figure 4.23. Quantitative analysis of microbubble retention at the tumor, normalized to the 
baseline. Microbubble retention in the tumor, signifying endothelial damage, is significantly 




















The spatially-focused release of a biologically active agent from B12-based 
phototherapeutics conveyed by erythrocytes was explored, demonstrating on-command 
localized drug delivery in an in vivo model. RBC-based phototherapeutics offer a biocompatible, 
localized delivery alternative for a wide range of potent therapeutics, with light providing both 
spatial and temporal control over where and when a drug is released. These properties have the 
potential to reduce side effects and decrease the administered dose. Our system extends 
phototherapeutics into the optical window of tissue, where light enjoys the greatest depth of 
penetration. In addition, phototherapeutics in combination with RBCs offer a number of potential 
advantages relative to synthetic drug carriers, including enhanced circulatory lifetime, 
biocompatibility, and a large drug payload per carrier. As natural carriers, RBCs serve as a 
barrier, protecting the phototherapeutic from clearance mechanisms while protecting healthy 
tissue from the undesired assault of the cytotoxic agent. These advantages suggest that B12-
based phototherapeutics, in combination with RBCs carriers, have the potential to serve as a 















4.9. Materials and Methods 
All chemical reagents were purchased from Sigma or Thermo Fisher Scientific. Human 



























Scheme 4.1. Synthesis of Cy5-B12-TAX  
Precursors N-Deboc docetaxel and FmocAM2-B12-AC4 were synthesized according to 
the previously procedures reported.45 To prepare conjugate Cy5-B12-TAX, FmocAM2-B12-AC4 
(100 mg, 58 µmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) (22 mg, 55 µmol) and N,N-diisopropylethylamine (DIPEA) (40 µL, 
232 µmol) were reacted in 4 mL anhydrous DMF for 2 h at room temperature in the dark. DMF 
(2 mL) containing N-Deboc docetaxel (41 mg, 58 µmol) was added and the reaction was 
incubated at room temperature for another 5 h. To remove the Fmoc protecting group, 
piperidine (286 µL, 290 µmol) was added into the reaction mixture and mixed at room 
temperature for additional 30 min. The reaction mixture was precipitated with anhydrous ethyl 
ether (6 x 40 mL) to remove piperidine. The crude sample was collected via centrifugation, 
mixed with Cy5-NHS ester (30 mg, 52 µmol) and DIPEA (40 µL, 232 µmol) in DMF (2 mL) and 




The reaction mixture was precipitated by diethyl ether (3 x 40 mL), filtered and dried 
under vacuum for 2 h. The product was purified via reverse phase chromatography (30 g, RP-
C18, Biotage) using a binary solvent system (A: H2O with 0.1% v/v TFA, B: MeOH with 0.1% v/v 
TFA) with a gradient change from 50% B to 70% B over 12 column volumes. Lyophilization 
yielded the product as a blue solid (60 mg, 41%).  
1H NMR (DMSO-d6, 400 MHz) δ 8.33 (t, J = 13.1 Hz, 2H), 8.17 (d, J = 8.7 Hz, 1H), 8.00 - 
7.80 (m, 3H), 7.77 - 7.58 (m, 7H), 7.57 - 7.06 (m, 17H), 7.05 - 6.76 (m, 5H), 6.71 - 6.45 (m, 3H), 
6.32 - 6.23 (m, 4H), 5.80 (t, J = 8.9 Hz, 1H), 5.72 – 3.81 (m, 34H), 3.74 - 3.46 (m, 6H), 3.45 - 
2.57 (m, 9 H), 2.40 -1.96 (m, 28H), 1.96 - 1.44 (m, 24H), 1.44 – 0.75 (m, 29H), 0.55 (br.s, 2H), 
0.32 (br.s, 2H), 0.04 (br.s, 2H), -0.27 (br.s, 2H). HR ESI MS C139H181N18O29PCo calculated for 




























Figure 4.24. LC-MS chromatogram of purified Cy5-B12-TAX. Top: Purified product detected by 
the fluorescent detector (λex: 640 nm; λem: 670 nm). Bottom: Purified product detected by the UV 









































Figure 4.25. Photolysis of Cy5-B12-TAX. (a) Reverse-phase HPLC trace of Cy5-B12-TAX in 
PBS (25 μM, pH = 7.4) irradiated at 646 nm for 30 min. The chromatogram was recorded at 254 
nm. (b) ESMS spectrum of the photolyzed Cy5-B12-TAX derivative was recorded in positive ion 
mode (peak a). Characteristic molecular and fragment ions: [M+Na]+ (m/z 816.6), [M+K]+ (m/z 
832.4). c) ESMS spectrum of photolyzed Cy5-B12-TAX recorded in positive-ion mode (peak b). 
Characteristic molecular and fragment ions: [M-H2O]2+ (m/z 940.1), [M-H2O+H]3+ (m/z 627.2).  
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To characterization of the photolysis product of Cy5-B12-TAX, Cy5-B12-TAX (25 μM) in 
PBS was illuminated for 30 min using an Oriel Xe flash lamp (800 mJ, 62 Hz) as the light source 
with selective bandpass filters for 646 ± 10 nm. Photolyzed samples were analyzed by LC/MS 
using a linear gradient binary solvent system (solvent A: 0.1% formic acid/H2O; solvent B: 0.1% 

























Scheme 4.3. Synthesis of B12≡Cy5. To synthesis of non-photocleavable conjugate B12≡-NH2, 
precursor of B12≡Cy5, compound B12≡-NH2 was synthesized following modified procedure 
from literature.2 The reaction was carried by stirring using 1 equivalent of cyanocobalamin, 1 
equivalent of copper (I) acetate (CuOAc), 2 equivalents of 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) and 10 equivalents of 1,1-dimethylpropargylamine in dimethylacetamide (DMA) overnight 
under N2. The product was purified via reverse phase chromatography with water-methanol 
(containing 0.1% TFA) solvent system (Yield 71%).  
1H NMR (DMSO-d6, 400 MHz) δ 7.86 (s, 1H), 7.63 (s, 2H), 7.51 (s, 2H), 7.34 (s, 1H), 
7.27 (s, 1H), 7.17 (s, 1H), 7.06 (d, J = 7.6 Hz, 2H), 6.98 (s, 1H), 6.92 (s, 1H), 6.79 (s, 1H), 6.66 
(s, 1H), 6.54 (s, 1H), 6.47 (s, 1H), 6.36 (s, 1H), 6.24 (d, J = 2.9 Hz, 1H), 6.02 (d, J = 4.3 Hz, 1H), 
5.79 (s, 1H), 4.47 (s, 1H), 4.24 (d, J = 7.4 Hz, 1H), 4.20 (d, J = 11.3 Hz, 1H), 4.11 (d, J = 8.3 Hz, 
1H), 3.89 (s, 2H), 3.70 (dd, J = 10.1, 5.4 Hz, 2H), 3.55 (dd, J = 18.4, 11.5 Hz, 3H), 3.03 (d, J = 
10.7 Hz, 1H), 2.69 (m, 3H), 2.50-2.30 (m, 11H), 2.30 - 2.22 (m, 2H), 2.16 (d, J = 11.5 Hz, 
6H),2.10-2.14 (broad s, 1H), 2.04 (d, J = 14.3 Hz, 1H), 1.88 (s, 4H), 1.80 (t, J = 14.3 Hz, 3H), 
1.72 (s, 2H), 1.67 (s, 3H), 1.56 (dt, J = 15.3, 7.7 Hz, 3H), 1.34 (s, 3H), 1.21-1.19 (s, 1H), 1.20 (d, 
J = 6.2 Hz, 6H), 1.07 (d, J=6.11 Hz, 3 H), 0.98 (s, 5H), 0.97(s, 3H), 0.27 (s, 3H). 






B12≡Cy5 was synthesized using B12≡-NH2 (1 equivalent), Cy5-COOH (1 equivalent), 
HATU (1 equivalent) and DIPEA (4 equivalents) in DMF and mixing for 0.5 h. The product was 
purified via reverse phase chromatography with water-methanol (containing 0.1% TFA) solvent 
system (Yield 90%).  
1H NMR (DMSO-d6, 400 MHz) δ 8.33 (t, J = 13.2 Hz, 2H), 7.85 (s, 1H), 7.66 - 7.56 (m, 
5H), 7.52 (s, 1H), 7.41 (s, 3H),7.38-7.32 (m, 1H), 7.34 (s, 3H), 7.32 - 7.20 (m, 3H), 7.14 (s, 1H), 
7.04 (s, 1H), 6.94 (s, 1H), 6.88 (s, 1H), 6.80 (s, 1H), 6.65 (s, 1H), 6.60 – 6.50 (m, 2H), 6.44 (s, 
1H), 6.30 - 6.21 (m, 3H), 6.00 (s, 1H), 5.74 (s, 1H), 4.46 (s, 1H), 4.22 (s, 1H), 4.07 (s, 5H), 3.88 
(s, 2H), 3.61 (s, 3H), 3.55 (s, 5H), 2.55 (s, 92H), 2.38 (d, J = 16.0 Hz, 9H), 2.27 (s, 1H), 2.15 (d, 
J = 14.2 Hz, 6H), 2.05 (s, 1H), 1.88 (s, 4H), 1.78 (s, 1H), 1.70 - 1.65 (m, 25H), 1.56 (s, 2H), 1.42 
(s, 2H), 1.31 (s, 2H), 1.23 (s, 8H), 1.15 (s, 4H), 1.10 - 1.02 (m, 10H), 1.01 - 0.91 (m, 5H), 0.24 
(s, 3H). (C99H133CoN16O15P)+: Exact Mass calculated 1875.9, found (ESI+, m/z) 626.2 

























Figure 4.26. LC-MS chromatogram of purified non-photocleavable conjugate B12≡-NH2 












Figure 4.27. LC-MS chromatogram of purified non-photocleavable conjugate B12≡Cy5. Top: 
Product detected by the fluorescent detector (λex: 645 nm; λem: 675 nm). Bottom: Product detected 








RBC Internal Loading Procedure: Whole blood was collected from FVB or Nu/Nu mice via 
cardiac puncture. RBCs were isolated from whole blood using Ficoll and washed 3x in isotonic 
PBS (300 mOsm). RBCs were loaded with either Cy5-B12-OH2, B12≡Cy5, or Cy5-B12-TAX 
using a modified dialysis procedure.1b The conjugates were suspended in an 8:1 solution of 
Diluent C:DMSO and mixed with washed RBC pellets so that the final hematocrit was 70% and 
the B12 conjugate concentration was 200 μM. The mixture was placed in a 1 kDa dialysis bag 
with 1 kDa MWCO (Spectra/Por 6, Spectrum)  and dialyzed against hypotonic buffer (80 
mOsm/L PBS containing 6 mM glucose) for 20 min to open pores and allow influx of the B12 
conjugates. The dialysis film was then transferred to isotonic PBS and incubated for 10 min at 
37 °C to reseal the cells. The RBCs were washed 3x in isotonic PBS to remove unloaded 
material and released hemoglobin. Quantitative loading efficiencies were obtained by extracting 
the conjugate into ethanol and measuring Cy5 absorbance at 645 nm.  
RBC Surface Loading Procedure: RBCs were prepared from whole blood the same way as in 
the RBC Internal Loading Procedure. To load material, RBCs were suspended to 10% 
hematocrit in PBS containing 0.02% FBS and mixed with the membrane staining dye DiD 
(Thermo Fisher Scientific) at a concentration of 10 µM. The mRBCs and dye were incubated at 
37 °C with mild vertical rotation for 30 min and then washed 3x in isotonic PBS to remove 
unloaded material.  
Widefield Microscopy: RBCs were diluted to 0.05% hematocrit in PBS, plated on 35 mm 
MatTek glass bottom dishes, and incubated at room temperature for 15 min to allow the 
suspended cells to fall to the bottom of the plate. Widefield images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu FLASH 4V3, 60X oil objective 





Confocal Microscopy: Confocal microscopy images were taken with an Olympus FV1000 
scanning confocal microscope with an IV81 base. Images were acquired using a 60X oil 
objective. A 635 nm laser was used for excitation of Cy5. All images were acquired at a 
resolution of 512 x 512 and a pixel dwell time of 10 μs/pixel. All processing was performed using 
ImageJ software.  
Imaging Flow Cytometry: B12 conjugate loading was evaluated by an imaging flow cytometer 
(Image Stream, Amnis, Seattle, USA) acquiring 2000 - 10000 images of in focus singlets in the 
bright field channel and the fluorescence emission channel at 660 - 740 nm (Cy5) for each 
sample. First, a gradient root mean square histogram was used to gate for cells in focus. Then, 
a scatter plot of aspect ratio/area was used to gate for single cells. The acquired images were 
analyzed with IDEAS software (Amnis). Scatter plots of Cy5 intensity/side scattering were used 
to compare and contrast the internal complexity of the cells. For loading quantification, cells with 
a fluorescent intensity of at least 1x104 were defined as loaded. 
Mouse and Human in vitro Fragility Tests: Whole blood was collected from Jb1 mice by 
cardiac puncture and mRBCs were isolated via a standard Ficoll procedure. Human RBCs were 
purchased from Zen-Bio. RBCs were internally loaded with Cy5-B12-TAX using the RBC 
Internal Loading Procedure. All the procedures involving light-sensitive drug were conducted 
with a minimal light exposure. After the loading procedure, the cells were washed 3X in 1X PBS, 
the pellet volume was measured, and the cells were diluted to 10% hematocrit in clear DMEM 
media (gibco) with 1X glutaMAX (gibco) and 1% FBS. The cells were suspended and divided 
into four equal aliquots and stored at 4 0C in dark. After 1, 2, 3 and 5 days, the cells were 
centrifuged and the supernatant absorbance was measured at 420 nm to determine hemoglobin 
leakage. A completely lysed pellet was measured at 420 nm to determine the absorbance at 
100% lysis. The pellet size was estimated in order to determine the rate of cell lysis. Human 
RBCs were treated the same except that washes were conducted with L-15 media. Storage 
conditions and analysis were identical for the untreated samples.   
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Sensitivity of mRBCs to hemolysis under light conditions: Whole blood was collected from 
DBAIJ mice by cardiac puncture and isolated via a standard Ficoll procedure. RBCs were 
internally loaded with Cy5-Cbl-docetaxel or Cy5-Cbl-OH2 using the RBC Internal Loading 
Procedure. All the procedures involving light-sensitive drug were conducted with a minimal light 
exposure. The loading procedure was performed three times for each sample to ensure 
sufficient volume and each sample was pooled and diluted to 5% hematocrit. The cells loaded 
with each compound were then separated into nine 300 uL aliquots. Three aliquots were 
completely lysed by adding Triton X-100 to final concentration of 0.05%. Three other aliquots 
were incubated for 10 mins in the dark and the last three aliquots were illuminated for 10 
minutes under 660 nm LED light. The cells from the dark and light experiments were spun down 
and the supernatant was collected. Triton X-100 was added to the recovered supernatants so 
that the final Triton concentration was 0.05%. The supernatants were analyzed for both Cy5 
fluorescence (λex = 645 nm, λem = 675 nm) and hemoglobin absorbance (λmax = 420 nm). 
Fluorescence was measured using SpecraMax GeminiEM (Molecular Devices) while 
absorbance was measured with a DeNovix DS-11 FX + spectrophotometer/fluoromenter, using 
the microvolume setting.  
Intravital Imaging: Intravital imaging microscopy experiments were performed using an 
Olympus IV-100 laser scanning confocal microscope. Images were acquired using a 10x air, 0.4 
NA, WD 3.1 thirteen mm objective and 1.5 zoom value. Images were acquired every 5 s for 90 
min at a resolution of 512 x 512 and a pixel dwell time of 10 μs/pixel. All images were acquired 
using healthy female FVB mice between the ages of 15-20 weeks. Hair was removed from both 
ears using hair removal cream and the left ear was immobilized by two-sided tape on an 
aluminum block. The mice were anesthetized with 2% isoflurane and placed onto a heated 
stage (37 °C) to maintain their core body temperature throughout the 90 min imaging procedure. 
Blood vessels were located in the left ear by illuminating it with a bright white light while imaging 
in the green fluorescence channel.  
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Tissue autofluorescence appears green, while the vessels appear as dark voids. Suspensions 
of 100 μL containing RBC pellets at 75 - 90% hematocrit in PBS were injected via tail vein 
injection. Prior to injection, RBCs were internally loaded with either Cy5-B12-OH2 or Cy5-B12-
TAX (n = 3 animals). As controls, groups of mice were also injected with 100 μL RBCs at 75 - 
90% hematocrit internally loaded with B12≡Cy5, mixed with free B12≡Cy5, or externally loaded 
with DiD (n = 6 vessels). Both Cy5 and DiD fluorophores were excited using a 633 nm laser and 
detected in the 647 nm channel. The image files from each scan were exported to ImageJ 
software for analysis. All procedures were performed under the institution’s IACUC (Institutional 
Animal Care and Use Committee) guidelines.  
Measurement of Circulation Time: The quantitative fluorescent intensity of a straight-line 
region of interest containing vasculature was measured and background fluorescence of an 
empty vessel was subtracted from each measurement. Selected regions of interest (n = 3) for 
mice in each category were used to calculate the average fluorescence intensity at each time 
point. Each point in each time series was normalized to the highest fluorescent value to account 
for random variation between animals on various days. The percent retention data are 
presented as mean ± standard deviation. 
Histology: For histological analysis, ears were harvested less than 5 min after euthanasia at 
room temperature and the illuminated blood vessels (as well as the corresponding vessel in the 
non-illuminated ear) were marked with tissue staining dye. Ears were immediately immersion-
fixed in 10% neutral buffered formalin in a 1:15 tissue:fixative volume ratio for 48 h at room 
temperature. The tissue was post-fixed in 70% ethanol at a 1:15 tissue:ethanol volume ratio and 
embedded in paraffin. Then, 4 μm cross-sections were stained with H&E and microscopically 






Ultrasound Animal Care and Imaging: Homozygous Nu/Nu mice were housed in an approved 
Division of Comparative Medicine facility until time of imaging. At five weeks old, mice were 
given a 100 µL subcutaneous injection of 7 x 106 SVR angiosarcoma cells/mL. Tumor 
measurements were recorded three times a week and mice were imaged when tumor size was 
between 5 - 10 mm in the largest dimension. Mice were placed on a heating pad warmed to 37 
˚C and kept under 1.5% isoflurane anesthesia for the duration of the imaging experiment. 
Ultrasound gel applied to the tumor site helped couple tissue with the transducer used for 
imaging. Once imaging was completed, mice were euthanized with an overdose of isoflurane 
followed by a secondary physical method. All animal imaging performed was approved by the 
UNC IACUC.  
Ultrasound Contrast Agent and RBC Administration: Perfluorocarbon microbubbles made 
in-house were injected in each animal via a 27G tail-vein catheter. Microbubbles were sized 
using an AccuSizer 780A (Particle Sizing Systems, Santa Barbara, CA, USA) before 
administration in order to ensure that an accurate dosing scheme was maintained throughout 
the course of the study. Microbubbles were diluted to 5 x 109 MB/mL and were delivered via a 
50 µL volume followed by a 50 µL saline flush. Microbubble doses were administered before 
each imaging time point. Before the start of treatment, 100 µL of prepared mRBCs were injected 









Ultrasound Imaging Protocol: Mice were imaged with a Vevo 770 imaging system using a 
custom-built dual frequency transducer (VisualSonics, Toronto, ON, Canada). The ultrasound 
probe, which is mounted on a motion stage to allow for 3D data collection, transmits at 4 MHz 
and receives at 28 MHz. 16 mice were divided into the following four experimental groups: Cy5-
B12-TAX loaded mRBCs with light treatment, Cy5-B12-TAX loaded mRBCs without light 
treatment (dark), Cy5-B12-OH2 loaded mRBCs with light treatment, and mock loaded mRBCs 
with light treatment. First, a 3D B-mode scan was collected using a 3 Hz frame rate and a 100 
µm step size. Scan length varied based on tumor size. Additional 3D acoustic angiography 
scans were collected before treatment (baseline) and at 0, 10, 20, 30, and 40 min following the 
end of treatment. Light-treated animals were exposed to a 655 nm 100 mW laser that was 
aligned at the tumor site. The tumor was illuminated for a total of 5 min.   
Ultrasound Data Analysis: Data was analyzed using a custom-built MATLAB program 
(MathWorks, Natick, MA, USA). Individual regions of interest (ROIs) were drawn slice by slice 
on the B-mode set for each animal. These ROIs were applied to the contrast images and 
adjusted as necessary to account for animal motion and breathing. Images were binarized using 
Otsu’s method and the area of thresholded signal within the 3D ROI set was calculated. This 
value was divided by the area of the entire 3D ROI set. Finally, this metric for microbubble 
retention was normalized to the baseline value for each animal. A two-factor analysis of 
variance (ANOVA) evaluating imaging time points and experimental group was performed to 
test for statistical significance. This was followed by Dunnett’s multiple comparison for imaging 
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CHAPTER 5: LIGHT-MEDIATED DRUG THERAPY AND CELL CARRIERS: A CHAPTER FOR 
NON-SCIENTISTS 
 
5.1. What’s in your Medicine Cabinet?  
Have you ever grabbed a cold remedy or prescription drug from the pharmacy knowing 
full well that this treatment may result in unintended side effects? Side effects result from 
medicine attacking healthy parts of the body instead of just the problem areas. The more 
powerful the medicine, the more intense and life-threatening those effects tend to be. For 
instance, while seasonal allergy sufferers often experience medicine-induced drowsiness, 
doctors are actually forced to restrict life-saving chemotherapeutics from cancer patients 
because the side effects become life-threatening. Researchers in the drug discovery and 
delivery fields are developing systems that target drugs directly to disease sites so that 
treatment spares healthy parts of the body and patients experience fewer unintended 
symptoms. 
Researchers are exploring more effective ways to deliver drugs to disease sites. Many 
approaches involve attaching drugs to synthetic drug carriers that better accumulate at disease 
sites. Unfortunately, medical providers often have concerns over introducing foreign material 
into the body. For almost a decade, our lab has instead focused on using vitamins, in 
combination with carriers derived from human cells, as a means to deliver drugs in a targeted 
fashion. I will first describe the two main parts of our unique drug delivery system: 1. vitamin 
B12 (B12) as a light-controlled launching pad to regulate the time and space of drug delivery 




5.2. The Light-Induced Chemical Launching Pad 
 Before application to drug delivery was even a thought, our lab developed a unique light 
system to study biological processes in human cells, taking advantage of B12 photochemistry 
(light chemistry). While many people are familiar with B12 as a diet supplement, a lesser known 
property of B12 is its interaction with and subsequent response to light. My lab realized they 
could take advantage of this sensitivity to create a light-induced drug release system. Let’s look 
at the molecule more closely (Figure 5.1) while we discuss its important functionalities for drug 
delivery.  
The three parts of B12 we will look at more closely are the Co-C bond (a cobalt metal 
bound to a carbon atom, Figure 5.1, blue arrow), the corrin ring (a large carbon-based ring that 
is the “core” of vitamin B12, Figure 5.1, green arrow), and a 5΄-OH (a highly reactive chemical 



























Figure 5.1. Vitamin B12. Highlighted groups are important for light-induced drug release. We 
substitute the C in the Co-C bond (blue) with drugs and other small molecules, which can be 
released on command by illuminating the molecule with low energy light. The corrin ring (green) 
absorbs light, which breaks the Co-C bond. The 5΄-OH (red) is not affected by light and can be 













The Co-C bond holds drugs to vitamin B12 like a grappling hook that we can release on 
command. Normally, the Co holds a molecule that the body naturally breaks off and uses. 
However, we can easily substitute that C with a drug or other chemical of interest. Out of all the 
bonds on vitamin B12, why this one? Chemical bonds are usually very strong, but the Co-C link 
is weak enough to break with a low energy source, such as colored light.  
The corrin ring naturally captures green light (550 nm) of medium energy. We believe 
the green energy results in excited electrons that destabilize the Co-C bond, causing it to fall 
apart. This photochemistry has been understood since the 1970s. However, useful applications 
of this property have been limited…until now. 
We discovered that when the C is replaced with a light-absorbing molecule called a 
fluorophore, we can speed up the bond breakage. Essentially, the fluorophore acts like a TV or 
radio antenna to amplify the light capturing effect. While this novel discovery was very exciting, 
we knew that it would have limited usefulness in the human body in its current state. You can 
see why if you’ve ever placed laser pointers of different colors under your fingertip. Green laser 
pointers do not penetrate human tissue very well because green light is absorbed and scattered 
as it travels through the body. By contrast, red lasers do penetrate the skin. When you place a 
green and then a red light against your finger, you can see the difference (Figure 5.2). The 
wavelength range (600 - 1000 nm) that best penetrates skin is collectively called the “optimal 
window of tissue penetration”. In order to create a biologically useful system, we realized we 
could attach fluorophore antennas to B12, which would force it to respond to red light instead of 






















Figure 5.2. Visible light penetration. a) The visible light spectrum. Short wavelengths near the 
blue end have high energy while long wavelengths near the red end have low energy. b) Blood, 
skin, and fat strongly absorb light. This absorption is minimalized between 600 - 1000 nm. c) 
Light penetration of household LEDs through a human finger. Left: Biological species in the 
body easily prevent green light from penetrating human tissue, such as a fingertip or small 
finger. Right: Alternatively, red light in the “optimal window of tissue penetration” transverses 





We can fasten red light absorbing antennas to the 5΄-OH group on the bottom of the 
corrin ring. With antennas, B12 strongly absorbs red light and releases drugs attached to the 
Co-C bond. Until our work began, light-activated drug release systems only responded to blue 
or green light or else required incredibly high-intensity light sources. Our antenna technique 
represents the first of its kind to use simple light sources, such as laser pointers, to release 
cargo with biologically useful red light. 
In summary, we used chemical modification techniques to design a launching pad for the 
light-controlled release of various drugs within the optical window of tissue penetration. Figure 
5.3 illustrates a fully constructed B12 phototherapeutic, Cy5-B12-Paclitaxel. Paclitaxel is a 
common chemotherapeutic. Imagine administering Cy5-B12-Paclitaxel and illuminating only the 
tumor site so that drug is only delivered to that area. Light could be as simple as LEDs or as 
complicated as fiber optic cables, depending on the need. While initial clinical studies would be 
done in a hospital, we eventually imagine a system where after injection, a patient could self-
dose at home with a specially designed laser (Figure 5.4). 
Such a direct, non-invasive delivery method has the potential to reduce common side 
effects associated with chemotherapy such as allergic reactions, muscle pains, and heart 























   
   
 
 
Figure 5.3. Cy5-B12-Paclitaxel. An example of an antenna-B12-Drug conjugate. Cy5 serves as 
a long wavelength antenna with the ability to capture red light and use that light energy to 





















Figure 5.4. Site-directed drug delivery. Top: Often, we take medication to treat a very specific 
symptom, such as shoulder pain. We usually take medicine either orally (shown) or though 
injection. Our circulation system carries active ingredients all over our body. Medication is now 
damaging not only the site of the symptom, but also healthy areas, such as our stomach. 
Bottom: Site-directed delivery has the potential to alleviate side effects caused by off-target 
action. The ingredient that is spread all over our body is now inactive, not damaging healthy 
tissue it comes in contact with. External activation, such as with a light source, would treat only 











5.3. Repurposing RBCs as Drug Carriers 
 As mentioned before, synthetic drug carriers are non-ideal for clinical use due to 
concerns with administering unnatural materials into the body. Some popular nanomaterials 
have been clinically approved, but scientists still struggle to create more targeted drugs that are 
safe, effective, and long-lasting. With this challenge in mind, we investigated carriers derived 
from patient’s own cells to carry our phototherapeutics. We determined that RBCs possess the 
flexibility, storage capacity, safety, and circulation time that we desired in a drug carrier. In the 
1970s, much research was conducted to load and use RBCs as drug carriers. However, as 
HIV/AIDS became more widespread in the 1980s, many researchers turned away from using 
blood products in favor of “safer” synthetic materials. Since the 1990s, a resurgence of interest 
in RBC carriers has led to the formation of two companies and the investment in automated 
equipment that loads various therapeutics into RBCs.  
With our light-activated launching pad and cell carrier in hand, we set out to combine 
these two strategies and create a fully functional drug delivery system. My graduate research 
touched on three generations of RBC-B12 drug delivery: membrane decoration, internal 













5.4. Generation 1: Membrane Decoration and Anti-inflammatories 
 Most synthetic drug carriers act like balls covered with Velcro, to which drugs can be 
attached on the outside. We used this idea to design the first generation of B12-loaded RBC 
carriers in which lipid anchors (fats composed of long chains of carbon) hold B12-drugs and 
antennas on the outside membrane. This strategy is technologically the easiest of all the loading 
strategies since lipids naturally stick to membranes when the two are mixed together. Thus, it 
was an ideal system to test light-mediated drug release from cells for the first time.  
Human blood is surprisingly easy to purchase in a lab from companies who contract out 
to blood banks. By spinning blood (FedEx overnight!) in a centrifuge for 10 minutes, we 
separate RBCs from other blood components (plasma, white blood cells, and water). Then, we 
attach lipid anchors to B12-drugs and to antennas and create the final system by simply mixing 

























Figure 5.5. Attaching drugs to membranes. We attach lipidated antennas and lipidated B12-
drugs to RBC membranes through simple mixing and incubation. The antennas absorb red light 


















Which drugs did we test with our system? For the first generation, we chose an array of 
anti-inflammatories with potential value in arthritis treatment (methotrexate, dexamethasone, 
and colchicine). Our light system would be an advantageous alternative to frequent injections of 
arthritis drugs, many of which also cause side effects. How would an arthritis phototherapeutic 
work? Since the drug is encapsulated into RBCs, we imagine using standard blood transfusion 
techniques already approved. Then, light treatment could be administered directly to the joint, 
moderating side effects. Natural RBCs circulate for up to 120 days, and our hope is to achieve a 




5.5. Generation 2: Internal Encapsulation and Extension to Chemotherapeutics 
 With our first generation drug delivery system in hand, we recognized that membrane 
loading comes with some challenges. The most notable that, unlike a lab dish, proteins and 
other cell membranes also circulate in the human body and can pull off anchored material from 
the RBC membrane. While creating a stronger anchor is one approach, we also recognized that 
we could tap a different part of the RBC: the cell interior.  
The RBC interior is unique in ways that make it especially advantageous as a drug 
carrier over other mammalian cells (Figure 5.6). Most human cells are loaded wall-to-wall with 
the components you may recognize from a high school biology text: organelles, mitochondria, a 
nucleus, etc. Removing any of those components will result in cell death. On the other hand, an 
RBC is filled with the oxygen-carrying protein, hemoglobin. While removing hemoglobin would 
prevent normal RBC function, it would not immediately kill the cell. Your body would continue to 























Figure 5.6. Advantages of RBCs over other cell types for drug loading. Typical human cells 
contain many critical components. Removing these components or altering the inside of a cell 
often results in cell death. On the other hand, RBCs are mainly empty inside except for the 
oxygen-carrying protein hemoglobin. Hemoglobin can be removed and other components added 
















To entrap the antenna-B12-drug design (Figure 5.1), we used osmotic gradients to open 
and reseal temporarily pores in the RBC membrane. Osmotic gradients are the difference in 
particle concentration between two sides of a semipermeable membrane, such as the inside 
and outside of an RBC.  
As shown in the center panel of Figure 5.7, RBCs like to be in osmotic equilibrium, 
where the salt concentration is the same on both sides of the membrane (isotonic). If the 
concentration gradient is higher or lower on one side, the membrane will exchange water with 
its environment to offset that difference. For example, if the salt concentration is lower on the 
outside, water rushes in through the membrane to try and lower the salt concentration on the 
inside (hypotonic conditions). Because RBC membranes are flexible, water influx causes them 
to swell. If the salt concentration is higher on the outside of the membrane, water rushes out 
and the RBCs shrink (hypertonic conditions). But why do pores form? RBCs are often described 
as fluid-filled sacks held together with an elastic band. Pores form when the cell swells and 
reaches a maximum volume. If the cell swells too much, the membrane (aka the elastic band) 





















Figure 5.7. Osmotic gradients alter cell shapes. RBCs morph their shape when exposed to 
different salt environments. Hypertonic conditions (high salt levels) cause cells to shrink, while 
hypotonic conditions (low salt levels) cause cells to swell. Water either enters or leaves in an 

















Our approach to loading cells is to lower the outside salt environment so that the RBCs 
swell like a balloon. Instead of breaking, the ballooned cell forms pores through which our 
material rushes in while hemoglobin rushes out. We then increase the salt concentration again 
so the cells shrink back to their normal shape. Shrinking the cells effectively reseals the pores 
































Figure 5.8. Encapsulating drugs into RBC interiors. To load RBCs, we place the cells in low salt 
conditions so that they swell and form pores through which antenna-B12-drugs enter. We then 
reseal the cells by increasing the environmental salt concentration, trapping the molecules. 

















The cell interior provides exquisite two-way protection unavailable with membrane 
loading. It prevents other biological surfaces from pulling off the B12-drug while also protecting 
the body from any harmful effects of exposed therapeutics. While we continued our investigation 
of the anti-inflammatories methotrexate and dexamethasone, the RBC protective shield gave us 
the confidence to also explore cell-damaging chemotherapeutics, such as doxorubicin and 
paclitaxel. The debilitating side effects caused by chemotherapeutics are widely known. Using 
non-invasive light treatment to target cancer drugs directly to tumor sites has the potential to 
increase the effectiveness of an administered dose and greatly improve the quality of life for 
patients. 
5.6. Generation 3: Re-design with Rodent RBCs and Pre-Clinical Studies 
 We were very excited to demonstrate that light-controlled release was possible from 
both the outside and inside of human RBCs. However, we quickly realized the limitations we 
would face when taking our technology to the next level. Human RBCs are the most relevant to 
human patients, but rigorous pre-clinical animal studies would be necessary before clinical trials 
could be considered. The next few months would exemplify the struggles faced while translating 
science from bench to clinic, the reality of unfruitful leads, and how challenges lead to more 
complete understanding and ultimate success. 
 As a chemistry lab, we lacked experience with the details of animal work. Our 
collaborators played key roles in the success of my project and it could not have been 
completed without them. We worked closely with the UNC Institutional Animal Care and Use 
Committee (IACUC) to design and receive approval for an animal protocol. Every experiment 
conducted with an animal must be approved by this committee, made up of at least one 
executive officer, a scientist, a non-scientist, a veterinarian, and a community member not 
affiliated with the institution. They rigorously review your proposed experiments to ensure the 
humane treatment of every animal in the institution. As we found out, this process often takes 1-
2 months to complete.  
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Once the protocol was approved, we worked closely with both an arthritis clinician and a 
bioengineer who studies cancer. One of these collaborators recommended that we adapt our 
human RBC loading procedure to rat cells. Rats are larger and easier to work with than mice 
and our collaborator used them more often in his lab. No problem, I had spent the past year 
perfecting my RBC loading technique and certainly rat RBCs can’t be that different from human 
RBCs, right? Wrong! For 6 months I struggled through countless trials and errors in my effort to 
load rat RBCs, only to watch them fall apart into a rubble pile of broken cells at the bottom of a 
tube every time. Finally, out of frustration, I decided to look at the rubble on a microscope to see 
what a pile of broken cells looks like up close. I was shocked! Huge crystals littered the slide, 
intermixed with seemingly untouched RBCs (Figure 5.9). I was expecting cell debris – not 



























Figure 5.9. Unidentified rat RBC crystals. After months of failed loading attempts, I discovered 




I eventually found a study from the 1980s in which a lab observed that rat hemoglobin, 
unlike any other hemoglobin in the animal kingdom, crystalizes when there is too much in 
solution. This limit was reached when we released hemoglobin through the membrane pores 
during loading. Through this process, we learned a vital lesson when working with RBCs from 
different species: Even though a human system and non-human system may look and behave 
very similarly, seemingly unimportant or unknown molecular differences may play the most 
important role in the success of biological inquiry. 
After ensuring that mouse hemoglobin does not crystalize, we focused our attention on 
this alternative model. Once again, we immediately noticed differences between human and 
mouse RBC loading. Mouse RBCs are more fragile than human RBCs so we altered the loading 
procedure to ensure that the swelling and resealing were less harsh on the cells. At least this 
problem was workable! Even with a milder procedure, we do not expect mouse RBCs to last as 
long as their human counterparts in circulation. Like many pre-clinical evaluations, mouse 
experiments are the most relevant but are still not perfectly translatable to humans.  
After the experiments were completed, we worked closely with the core facilities to 
process and help interpret our results. Core facilities are departments run by the institution that 
provide services and expertise in certain procedures. For instance, we wanted to ask the 
question: if we use light to deliver a drug to a certain spot on a mouse ear, can the architecture 
of the blood vessel tell us if the released drug is effective? To answer this question, we needed 
to prepare tissue slides, a procedure for which we did not have the equipment nor the expertise. 
We delivered the samples to the histology core, where their experts processed the sample, 
provided slides, and helped interpret the results. A majority of the figures in my final graduate 
school paper are a result of the teamwork between myself, my lab, and the multiple core 




5.7. My Results 
 All three generations of drug loaded RBCs provided us with a greater understanding of 
our system and prompted new ideas for improvement. The first generation, membrane 
decoration, demonstrated that we could attach our system to an RBC carrier and release drugs 
with long wavelength light antennas. As shown in Figure 5.10, we monitored drug release from 
B12-drugs modified with various fluorophore antennas Cy5 (646 nm), AlexaFluor700 (700 nm), 
Cy7 (747 nm), and DyLight800 (784 nm). We demonstrated that brightly colored LED lights only 
release the drug when the system is illuminated with the color that most closely corresponds to 
































Figure 5.10. Release of a chemical group with long wavelength antennas. We attached a 
fluorescent molecule (representing a drug) to the Co-C position with various light antennas on 
5΄-OH and monitored molecule release from Co-C. Top: LED lights used to illuminate the loaded 
RBCs. Cy5, AF700, Cy7, and DY800 are 4 different antennas. Arrows represent which LEDs 
activate each antenna. Bottom: About 0.3 or 30% of the molecules loaded were released from 











Internally loaded RBCs provide more space and protection from the environment 
compared with membrane loaded RBCs, which prompted us to extend our therapeutic toolbox 
to include chemotherapeutics. To demonstrate that drugs released from the interior were 
effective, we mixed loaded RBCs with human cells taken from cervical tissue (HeLa cells) and 
observed effects of dark and light conditions on HeLa characteristics. Figure 5.11 represents 
one of these experiments using microtubules as indicative markers. Microtubules are normal 
cell structures needed for cell support and the released drug causes them to collapse. In the 
dark, microtubules spread out like a fan. Only when we illuminated the cells with the appropriate 
light did we see microtubules that resembled crumbled paper, confirming both light-induced 





























Figure 5.11. Effect of drugs released from RBCs after antenna-B12-drug encapsulation. Left: 
We demonstrated that loaded RBCs in the dark have no effect on the microtubules of human 
cells. Right: When the cells were illuminated, we observed microtubule collapse, a known effect 
of the released drug. These results suggest that illumination releases the drug and that the 




The third generation of drug-loaded RBCs was the most challenging to design and test. 
The need to switch from human to small animal RBCs forced us to confront molecular 
differences in seemingly identical RBCs and provided us with a broader understanding of RBC 
biology. I redesigned the loading procedure so that it was gentler and applicable to more fragile 
rodent cells. Using the vascular damaging drug, docetaxel, and a red Cy5 antenna, I confirmed 
area-specific release at a blood vessel in a mouse ear. Furthermore, I demonstrated that blood 
vessel architecture in a tumor could be compromised by site-specific release (Figure 5.12).           
 The first experiment was performed by observing the treated area with a microscope. 
You can clearly see bright red Cy5 fluorescence overtaking the screen around 1 hour, pointing 
towards blood vessel damage. In the second experiment, a tumor was imaged using ultrasound 
instead of microscopy. Here, blood vessel damage is more difficult to see by eye, but 
quantitative analysis of blood vessel leakage demonstrated that the drug was indeed working. 
While we learned that we can release effective drugs with our light-activated system, we are still 
exploring whether vasculature damage is enough to shrink the tumor. It may be that an even 
more powerful drug or a combination of drugs is needed – we are still looking for the answers to 































Figure 5.12. Preclinical studies with Cy5-B12-docetaxel-loaded RBCs. a) Intravital imaging 
setup. Loaded RBCs are fluorescent, so they can be seen flowing through blood vessels. b) 
Microscopy images of blood vessels in a mouse ear during light treatment. Fluorescence 
escaping from vessels demonstrates that blood vessels were compromised in a healthy mouse 
ear around 1 hour. c) Ultrasound imaging setup. d) Ultrasound images of a mouse tumor. In this 
case, light treatment was completed before imaging. Images confirm the microscopy results in 
that enhanced contrast agent (shown as white in the images, a compound injected to stain the 








My work highlights the incredible teamwork and collaborations necessary to take an idea 
from the bench to preclinical studies. Often, multiple generations of an idea are necessary to 
arrive at a promising solution. I believe persistence and inquiry will teach us the most about the 
world and ultimately allow us to find ideal treatments for many horrible diseases. My graduate 
work resulted in the proof of concept for a new light-activated drug delivery system. The next 
steps will be to look more closely at disease models and determine whether this method has 
preventive or even curative properties more effective than our current drugs. I hope that the 
work in my dissertation will inspire both my lab’s research and the work of other scientists and 
will one day be useful in clinical therapy.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
